Identification of lipid binding sites in myosin VI and XXI and regulation by the cargo-binding domain by Ellrich, Heike
 
 
Aus dem Physiologischen Institut der Ludwig-Maximilians-Universität München, 
Lehrstuhl zelluläre Physiologie 
Vorstand: Frau Prof. Dr. Claudia Veigel 
 
 
Identification of lipid binding sites in 
myosin VI and XXI and regulation by 
the cargo-binding domain 
 
Dissertation 
zur Erlangung des Doktorgrades der Naturwissenschaften 
an der Medizinischen Fakultät 
der Ludwig-Maximilians-Universität München 
 
eingereicht von  
Heike Ellrich  
aus Mainz  
2014 
 
 
Gedruckt mit Genehmigung der Medizinischen Fakultät der Ludwig-Maximilians-
Universität München 
 
Betreuerin: Priv.-Doz. Dr. rer. nat. Beate Averbeck 
Zweitgutachter: Prof. Dr. Axel Imhof 
Dekan: Prof. Dr. med. Dr. h. c. Maximilian Reiser, FACR, FRCR 
Tag der mündlichen Prüfung: 17.03.2015 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I 
Abstract 
The cytoskeleton along with its motor proteins plays a central role in the realization of 
essential biological processes such as cell motility, muscle contraction, chromosome 
segregation, intracellular transport of organelles, and endo- and exocytosis. A vast array 
of motor proteins are utilised to achieve these highly specific tasks. 
Myosin VI, the subject of this study, is unique amongst myosins. Being ubiquitously 
expressed it is the only known minus-end directed myosin which is involved in a variety 
of tasks including autophagy, endo- and exocytosis and has the capability to directly 
interact with lipids, or bind cargo via binding partners. Its depletion results in hearing loss 
and secretory diarrhoea. It is overexpressed in certain human prostate and ovarian cancer 
types. Although containing the requirements for dimerisation, a coiled-coil region in the 
C-terminal tail, it is unable to dimerise, at least under all concentrations and conditions 
tested in this study. Under certain circumstances myosin VI is able to adopt a ‘folded 
back’ conformation which we hypothesise inactivates the motor and makes it incapable of 
binding to cargo. 
Myosin XXI is a newly described myosin from the parasite Leishmania sp.. Being the 
sole known expressed myosin motor in this organism it is possibly a very versatile motor, 
like myosin VI, since it has to reclusively perform all tasks in the cell that normally are 
performed by an array of myosins. Depletion of myosin XXI expression in Leishmania 
results in impairment of flagellar assembly and intracellular trafficking. 
The objective of this study is to increase our understanding of how myosins bind to lipids 
and lipid cargo. It is important to understand how and where different lipids bind to the 
tail region. The ability of myosins to selectively bind different cargoes is poorly 
understood but is integral to their specific function within cells. Myosins must bind cargo 
specifically to transport it to its cellular destination, navigating a complex and densely 
packed environment and thus relocate the cargo in a specific and timely fashion. 
Furthermore, cargo binding and mechanical regulations of the motor protein are linked to 
avoid futile and unnecessary ATP hydrolysis. Understanding how these two processes are 
connected is critical to understand how the protein is regulated. 
To investigate this, a variety of biochemical and biophysical techniques are employed 
including bulk protein experiments such as co-sedimentations, western-, far-western and 
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dot-blots. Motility assays, affinity titrations and ATPase assays explore the activity, lipid 
binding abilities and regulatory mechanisms of myosin VI. 
The back-folding of the tail of myosin VI is an interaction of the first 65 N-terminal 
amino acids of the cargo-binding domain with the calmodulin bound to the IQ-motifs, and 
not to the motor domain as previously thought. Calcium disrupts this interaction and 
provides a simple mechanism by which myosin can be activated by calcium fluctuations 
within the cell. Another remarkable new finding is that myosin VI not only binds to a 
particular phosphatidylinositolphosphate (PIP) with a formerly described special binding 
motif in the cargo-binding domain, but that it is capable of binding to a range of lipids 
along the entire tail. This interaction also seems to be regulated or rather co-regulated by 
calcium, which changes the affinity of the motor to certain lipids. Furthermore it was 
discovered that myosin VI and XXI are able to translocate actin filaments faster and with 
a higher affinity for binding to the surface when bound to lipid surfaces. Similar to 
myosin VI lipid binding in myosin XXI is shown to occur along the length of the entire 
tail, although with different affinities for different tested lipids. A PX domain, which 
specifically binds PI(3,5)P2, was found in the converter region of this myosin. This 
myosin is capable of dimerisation and here it is shown that lipid binding and dimerisation 
are mutually exclusive. 
Myosin VI has the ability to bind to various lipids along its entire tail and calcium seems 
to co-regulate this interaction by enhancing or disrupting the interaction. This gives the 
motor flexibility in cargo-transport through the cell and might enable it to quickly 
exchange and deposit different cargoes. Differences in PIP affinities revealed regulatory 
options for cargo-transport in cells as well. Since calcium disrupts the interaction of the 
back-folded C-terminal tail to the N-terminal calmodulin, it as well seems to play a role in 
activation and inactivation of myosin VI. The PX domain in the converter region of 
myosin XXI and its ability to switch between a dimeric motor that does not bind lipids 
and a monomeric motor which can bind lipids might give further insights towards the yet 
unknown set of tasks myosin XXI fulfils in Leishmania sp..  
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Zusammenfassung 
Die Filamente des Zytoskeletts eukaryotischer Zellen erfüllen vielseitige Aufgaben. Sie 
sind wichtig für die Formgebung und die Stabilität der Zellen, sowie für die 
Fortbewegung. Darüber hinaus dienen die Filamente als Transportwege für Motorproteine 
für den intrazellulären Transport. An der Ausführung zentraler biologischer Prozesse von 
der Muskelkontraktion über die Bewegung ganzer Zellen, Chromosomensegregation bis 
hin zum intrazellulären Transport ganzer Organellen oder Vesikel ist eine Vielzahl von 
Motorproteinen beteiligt. 
Die Motorproteine Myosin VI und XXI sind in vielerlei Hinsicht besondere Motoren. 
Myosin VI ist das einzige bislang bekannte Myosin, welches sich rückwärts in Richtung 
des Minus-Endes der Aktinfilamente bewegt. Ubiquitär exprimiert ist es an einer Vielzahl 
von Aufgaben in der Zelle beteiligt wie z.B. der Exo- und Endozytose sowie der 
Autophagozytose. Ein Mangel oder eine Fehlfunktion von Myosin VI können unter 
anderem zu Hörverlust und sekretorischer Diarrhoe führen, wohingegen bei bestimmten 
Prostata- und Ovarialkarzinomen eine Überexpression dieses Motors in betroffenen 
Zellen gemessen wurde. Myosin XXI ist ein in der Literatur neu beschriebenes Myosin, 
das soweit bekannt, das einzige exprimierte Myosin im Parasiten Leishmania sp. ist. Es 
erfüllt im Parasiten alle Aufgaben, die in anderen Zellen meist verschiedene 
Myosinklassen übernehmen. Folglich stellt es wahrscheinlich einen ebenso vielseitigen 
Motor wie Myosin VI dar. Wird die Expression von Myosin XXI unterdrückt, folgen 
daraus Schädigungen der Struktur des Flagellums und Beeinträchtigungen des 
intrazellulären Transports. Beide Myosine, VI und XXI, interagieren direkt mit Lipiden. 
Myosin VI bleibt, obwohl strukturell mittels einer coiled-coil (Doppelwendel) Region im 
C-terminalen Schwanz zur Dimerisierung befähigt, unter den bislang bekannten 
Bedingungen monomerisch. Unter bestimmten Voraussetzungen faltet sich der C-
terminale Schwanz auf den N-terminalen Schwanzanteil zurück und nimmt ihm die 
Möglichkeit an Lipide zu binden. 
Ziel dieser Arbeit ist es, ein tieferes Verständnis der Bindung von Myosinen an Lipide 
und Lipid-Vesikel (lipid cargo) zu erlangen. Es ist wichtig zu verstehen, wo und wie die 
verschiedenen Lipide in der Schwanzregion des Myosinmotors binden. Die Fähigkeit der 
Myosine selbst verschiedene Transportgüter zu binden, ist bislang kaum verstanden, sie 
stellt jedoch einen wesentlichen Bestandteil der spezifischen Funktion der Myosine in 
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Zellen dar. Die Myosinmotoren müssen, um ihre Aufgaben in der Zelle erfüllen zu 
können, spezifisch mit ihrem jeweiligen Transportgut interagieren, um es durch das 
dichte und komplexe Netzwerk der Zelle zum Bestimmungsort transportieren zu können. 
Die Bindung an Cargo ist mit den mechanischen Eigenschaften des Motors verknüpft, um 
einer sonst möglicherweise resultierenden Energieverschwendung (ATP-Hydrolyse) 
vorzubeugen. Das Erfassen, wie die beiden Prozesse Bindung und Motilität miteinander 
verknüpft sind, ist entscheidend für das Verständnis der Regulation der Motoren.  
Als Methoden zur Untersuchung der Bindung an Lipide und der Analyse der 
regulatorischen Mechanismen für die Lipidbindung werden Western-, Far-Western und 
Dot-Western-Blots sowie Gleitfilament-Versuche (motility assays), Ko-Sedimentationen 
und Affinitätstitrationen angewendet. ATPase-Versuche geben Aufschluss über die 
Aktivität der Motorproteine.  
Ein wesentliches Ergebnis dieser Arbeit ist, dass Myosin VI nicht ausschließlich über ein 
schon bekanntes Sequenzmotiv im C-terminalen Schwanz an ein bestimmtes 
Phosphatidylinositolphosphat (PIP) bindet, sondern das es, wie Myosin XXI auch, mit 
einer Reihe von Lipiden auf der gesamten Länge des Schwanzes interagieren kann. Die 
Lipidbindung ist nicht stereospezifisch, sondern beruht auf unspezifischen 
elektrostatischen Protein-Lipid-Wechselwirkungen. Calcium spielt dabei eine 
regulatorische bzw. co-regulatorische Rolle, indem es die Interaktion unterbricht oder 
verbessert. Die in vitro Gleitfilament-Versuche auf Lipidoberflächen zeigen für beide 
Myosine, VI und XXI, dass die Translokation von Aktinfilamenten schneller und mit 
einer höheren Bindungsaffinität zum Untergrund stattfindet als ohne Lipide. Ferner wird 
für Myosin VI gezeigt, dass die Rückfaltung des C-terminalen Teils des Schwanzes in 
Richtung Motor eine Interaktion der ersten 65 N-terminalen Aminosäuren mit der Cargo-
bindenden Domäne darstellt. Da Calcium diese Interaktion verändert, ist eine Beteiligung 
der in der Halsregion des Proteins gebundenen Calmoduline wahrscheinlich. Für Myosin 
XXI wurde eine phox homology (PX) Domäne in der Converter Region gefunden, die 
spezifisch an PI(3,5)P2 bindet. Myosin XXI kann entweder dimerisieren oder Lipide 
binden. 
Die Fähigkeit von Myosin VI verschiedene Lipide auf der gesamten Länge seines 
Schwanzes zu binden, erlaubt dem Motor die Aufgabe des Transports innerhalb der Zelle 
flexibel auszuführen und das Transportgut schnell austauschen oder abladen zu können. 
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Die Unterschiede in den Affinitäten und Bindungen von Myosin VI an PIP zeigen die 
Vielfältigkeit dieses Transporters auf. Da Calcium die Wechselwirkung zwischen dem N-
terminalen Calmodulin und dem darauf zurückgefalteten C-terminalen Schwanz 
unterbricht, spielt es eine Rolle bei der Aktivierung und Inaktivierung von Myosin VI. 
Die gefundene PX Domäne im Nackenbereich von Myosin XXI und dessen Fähigkeit 
zwischen der dimeren nicht lipid-bindenden Form und der monomeren lipid-bindenden  
Form umschalten zu können, verdeutlicht die Wandlungsfähigkeit dieses Motors und gibt 
einen Einblick in seine zahlreichen noch weitgehend unbekannten zellulären Aufgaben in 
Leishmanien. 
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1.1 The cytoskeleton and its motor proteins 
With progression past the single-cell state cellular motility becomes essential and is 
required for almost all the cellular processes that accomplish life itself. Wherever exact 
positioning is necessary, active motility is needed and outperforms diffusion. 
Accumulation of immune cells at sites of infection, active movements within a cell that 
provide nourishment of distal parts in nerve or plant cells or muscle contraction are only a 
few examples were active motility is indispensable. Intracellular cargoes are moved over 
short distances along actin filaments and over long distances along microtubules to reach 
their destinations. Most of these intracellular movements are accomplished by motor 
proteins, small nano-scale machines. These motor proteins convert chemical energy 
(ATP) into mechanical energy and take nanometre steps along their tracks to transport 
cargo from one location inside the cell to another. The motor proteins that move along 
actin filaments are known as myosins and transport along microtubules is mediated by 
kinesins and dyneins (Langford 1995). In addition, these molecular motors are specialized 
regarding their directional movement along their appropriate track. While the majority of 
kinesin motors move towards the plus end of microtubules, all dyneins exhibit minus end 
directed movements on the microtubule. With the exception of myosin VI, which moves 
toward the minus end, all myosins described to date perform plus end directed movement 
on actin filaments (Buss and Kendrick-Jones 2007). 
1.1.1 Actin 
The cytoskeleton is an interconnected network that resists deformation and is capable of 
transmitting mechanical forces and therefore provides support and organisation to cells. 
The three polymer classes are referred to as actin filaments, microtubules and 
intermediate filaments and are composed of specific protein subunits. In this thesis, actin 
filaments and associated transport proteins stand in focus and are therefore described here 
in more detail. Globular actin (G-actin) is the most abundant protein in eukaryotic cells 
(1-10% of all cellular protein) it has a size of 42 kDa and a diameter of approximately 
5 nm (Kabsch et al. 1990). In muscle cells about 10% of all protein is actin. The actin 
concentration in non-muscle cells is approximately 0.5 mM. Filamentous actin (F-actin; 
approx. 8 nm in diameter) consists of G-actin subunits polymerised to form polar, helical 
filaments in which subunits are connected by a 167° rotation and 2.7 nm axial rise 
(Holmes et al 1990). The pitch of the helical turn is approximately 36 nm long and 
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consists of 13 monomers. The G-Actin subunit consists of two lobes with an adenosine 
triphosphate (ATP) and Mg2+-binding cleft (see figure 1A) where the former is 
hydrolysed to ADP and phosphate. G-Actin is only functional with ATP or ADP bound, 
in cells the ATP-bound form is predominant. Ions (Mg2+, K+ or Na+) induce 
polymerisation. This process is reversible and F-actin is depolymerised as soon as the ion 
concentration in solution is reduced to a critical concentration. Filaments grow in both a 
minus- and a plus-direction but polymerisation in the plus direction happens faster due to 
the asymmetry of the monomers. The attachment and detachment rates of actin monomers 
to F-actin polymers are different at either end, giving rise to a process known as 
treadmilling (figure 1C) (Small 1995). The rate of treadmilling is 𝑟 = 𝑘+𝐵(𝐶𝑆𝑆 − 𝐶𝐶𝐵) =
𝑘+𝑃(𝐶𝐶𝑃 − 𝐶𝑆𝑆) where 𝑘+𝐵 and 𝑘+𝑃 forward rate constants for association of G-actin to the 
barbed (+) and pointed (-) end, and 𝐶𝐶𝐵 and 𝐶𝐶𝑃 the corresponding critical concentrations. 
For pure actin 𝐶𝑆𝑆 = 0.1 mM,  𝐶𝐶𝑃= 0.6 µM, 𝑘+𝐵= 10 µM 
-1 s-1, 𝑘+𝑃= 0.6 µM -1 s-1 and 
𝑟= 0.3 s-1. Within the cell F-actin does not exist in isolation, two kinds of proteins 
regulate treadmilling: actin depolymerising factor or cofilin and capping proteins such as 
gelsolin (Pantaloni et al. 2001, Schmoller et al. 2011). 
 
Figure 1: Actin structure and treadmilling. (A): Structure of the actin monomer (G-actin) (Holmes et al. 1990) with 
its two similar domains (grey and blue). And F-actin helix; each repeat contains 13 molecules so that the first molecule 
of each repeat is in identical orientation (arrows) (Holmes 2009). (B): Intrinsic treadmilling of actin filaments 
represents the energetic imbalance between the plus and the minus end. (C) shows the polymer state as a function of the 
concentration of protein present. In polymerising conditions no polymer is observed until the monomer concentration 
exceeds that of the critical concentration (Cc) of the plus end. However the filament formed would not be stable until 
after the point indicated above, where the off rate at the minus end equals that of the plus end (adapted from Pantaloni 
et al. (2001)). 
Introduction 
4 
F-actin is both flexible and strong with a persistence length of approximately 15 µm; it 
builds up a cytoskeletal transport as well as a motility system, which is present in all 
eukaryotes. A further function of actin was discovered in Listeria bacteria where plus 
ends of the actin are inserted in the leading edge of the lamellipodia where they are 
growing whilst the minus ends of the filaments are depolymerised at the rear in a 
treadmilling process (see figure 1C) (Loisel et al. 1999). During further studies it was 
revealed that the process of actin assembly and disassembly is the driving force for 
Listeria movements (Pantaloni et al. 2001). Studies support the thesis that in eukaryotes 
the plus ends of actin are inserted in or near the plasma membrane and at intracellular 
organelles such as the Golgi or the phagosome and that the minus ends reach into the 
cytosol (Geeves et al. 1980, Yengo and Sweeney 2004). The actin cytoskeleton 
complements and interacts physically with cytoskeletal structures composed of 
microtubules and intermediate filaments (Hartman and Spudich 2012).  
1.1.2 Myosin 
In this study the focus will be myosins which are a large superfamily of structurally 
diverse yet conserved actin based molecular motors. Myosins are actin-activated Mg2+-
ATPases that use the chemical energy derived from ATP hydrolysis to move along actin 
tracks (Lymn and Taylor 1971). There are known to be 47 myosin classes 
(Foth et al. 2006, Odronitz and Kollmar 2007, CyMoBase 2013) (see figure 2), whose 
classification is based on the amino-acid sequence of the globular motor domain. This 
motor domain remains highly conserved across the whole family with variations in 
velocity, direction of movement and processivity. Through the different kingdoms 
myosins perform a large variety of functions and are involved in a number of cellular 
pathways. They play fundamental roles in the cell, such as cell crawling, cytokinesis, 
maintenance of cell shape, phagocytosis, vesicle trafficking, growth cone extension, 
signal transduction and possibly even actin polymerization (Berg et al. 2001). The myosin 
superfamily is highly conserved and its members are defined by a collective structural 
design: a heavy chain with a conserved catalytic domain (~80 kDa) which is normally 
followed by an α-helical light-chain binding neck region which is capable of binding up 
to 6 calmodulins or calmodulin-like proteins; a C-terminal tail and/or N-terminal 
extension with class-specific properties such as binding-partner interactions, lipid binding 
or kinase-activity. The functions of the three conserved regions motor, neck and tail can 
be summarized as follows. The motor binds to F-actin filaments and is capable of 
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hydrolysing ATP to produce force and movement, the neck domain which acts as a lever 
arm that amplifies the movement generated by the motor domain. The lever arm is 
stabilised by different myosin light chains (or calmodulin) that also have regulatory 
functions and form part of the macromolecular complex. This neck domain typically 
consists of one or more IQ-motifs (consensus sequence IQxxxRGxxxR, ~24 amino acids 
(Cheney and Mooseker 1992)) that serve as binding sites for calmodulins. The tail is 
thought to have regulatory functions, and often binds different cargoes either directly or 
via binding partners. All myosins known to date move from the minus end of the actin 
filament towards the plus end. Myosin VI, on which this study focuses, is the only known 
minus end directed myosin and therefore serves in a different range of tasks in cells than 
plus end directed myosins (see section 1.4) (Buss and Kendrick-Jones 2007).  
Since muscle-myosin II was the first myosin to be described, it is known as 
‘conventional’, the subsequent discovery and description of different non-muscle myosins 
are therefore termed ‘unconventional’. 
The importance of unconventional myosins can be seen when looking at the genome of 
Drosophila melanogaster where 11 out of 13 myosin encoding genes are unconventional. 
Approximately two thirds of the myosin genes in humans encode for unconventional 
myosins (Berg et al. 2001). Additionally it can be seen as a general rule that the more 
complicated the organism the greater the number of myosin isoforms it contains. For 
example Saccharomyces cerevisiae contain three myosin families (I, II and V), whereas 
C. elegans encodes seven (I, II, V, VI, VII, IX and XII). Analysis of the human genome 
revealed 39 different genes coding for representatives from 12 different families (I, II, III, 
V, VI, VII, IX, X, XV, XVI, XVIII and an unclassified novel short-tailed myosin) 
(Berg  et al. 2001). 
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Figure 2: An unrooted phylogenetic tree of the myosin superfamily (Hodge and Cope 2000). Note that myosin VI is 
depicted as a dimer. 
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1.2 Skeletal muscle myosin II 
Muscle cells have evolved to perform a highly specialised task, contraction. The 
contractile unit of skeletal muscle is the sarcomere. Myosin II is one of the two main 
proteins in the sarcomere. It was named by Wilhelm Kühne (1864) who described a 
muscle protein (“myo”) he isolated by saline extraction. The second main type of protein 
in the sarcomere is actin (Straub 1943), which is described in more detail in chapter 1.1. 
Each sarcomere consists of interwoven myosin containing thick filaments and actin 
containing thin filaments. The plus ends of the actin filaments are anchored in the Z-
disc’s scaffold-like structure which forms the boundaries of the sarcomere in the middle 
of the sarcomere a zone of overlapping thick and thin filaments forms the AI zone 
(Hanson and Huxley 1953). Many other proteins are located in the sarcomere and are 
responsible for the structural integrity and the regulation of muscle contraction. Myosin II 
is a double-headed myosin with a molecular weight of 520 kDa which is susceptible to 
proteolysis that results in HMM and LMM fragments or a further HMM digestion to S1 
and S2 (figure 3D). In skeletal muscle, myosin II tails form a thick filament from which 
the myosin heads project at regular angles (3 per crown, in vertebrate muscle every 145 
Å, figure 3B and C). Therefore each thick filament can interact with the six thin filaments 
arranged around it. Figure 3A depicts how the thick filament is bipolar resulting in a bare 
zone in the middle of the filament devoid of myosin heads where the two bipolar 
filaments meet. This central zone is anchored to the centre of the sarcomere by proteins of 
the M-line. As described above, the thin actin filaments are fixed at both Z-discs and 
extend towards the middle of the sarcomere overlapping with the thick filaments as far as 
the central bare zone where the minus (“pointed”) end of the actin filament is capped and 
regulated by tropomodulin (Bagshaw 1993). 
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Figure 3: Striated muscle structure and myosin II thick filament. A: Electron micrograph of a longitudinal section 
of a skeletal muscle myofibril representing a single sarcomere. B: electron micrograph of a reconstituted thick filament 
showing the bare zone in the middle. C: schematic representation of (B).(modified after Berg et al. (2012)). D: 
representation of a single myosin II molecule and the different functional fragments it can be digested to. 
 
1.2.1 Sliding filament model 
The sliding filament model (figure 4) describes the process of muscle contraction in more 
detail. Activation of the interwoven thin and thick filaments produces muscle contraction. 
The thick filaments move towards the Z-disc which results in the thick filaments sliding 
past each other. While the length of the filaments remains the same the sarcomere 
shortens. This causes muscle contraction (Gordon et al. 1966). Muscles can only shorten 
actively, so that the relaxed muscle must be extended by the contraction of an 
antagonistic muscle.  
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Figure 4: Sliding filament model. The thin filaments (blue) move relative to the thick filaments (red) and thus create 
muscle contraction. (Berg et al. 2012) 
 
1.2.2 Swinging lever arm hypothesis 
The interaction of individual myosin heads with actin units creates the sliding force that 
gives rise to muscle contraction. 
The molecular mechanism of muscle contraction was for a long time seen as ‘cross bridge 
hypothesis’ (see figure 5A) in which the relative sliding of the thick and thin filaments in 
striated muscle is accomplished by the ‘cross bridges’, parts of the myosin molecules that 
protrude from the thick filaments and interact cyclically with the actin filaments, creating 
a rowing action that is powered by ATP-hydrolysis (Holmes 1997). This hypothesis gave 
a good insight into the whole muscle-contraction cycle but left out the molecular details 
of the actual movement of the cross bridge. This was largely based on electron 
microscopy (EM) studies by Hugh E. Huxley (1969). Today the swinging lever arm 
hypothesis has elucidated these missing aspects (figure 5B). It is a modification of the 
‘rocking cross bridge’-model which was put forward by Andrew F. Huxley and Robert 
Simmons (1971), and was based on mechanical experiments on muscle fibres. This again 
was a modification of the former model by Andrew F. Huxley (1957) which was entirely 
based on mechanical studies, still lacking the crystal structure of myosin.  
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Figure 5: Swinging cross bridge model versus swinging lever arm model. (A): The myosin cross bridges are shown 
in their conventional conformations at 90° and 45° to the actin filament. Initially the nucleotide-free cross bridge is 
bound to the actin filament in the 45° conformation (state 1, rigor). The binding of ATP brings about rapid release from 
actin of the cross bridge (state 2), still in the 45° position. The subsequent hydrolysis of ATP puts the cross bridge into 
the 90° conformation (state 3), whereupon it rebinds to actin (state 4). The binding to actin brings about the release of 
products of hydrolysis and the cross bridge returns to its initial state, thereby ‘rowing’ the actin past the myosin. (B): A 
myosin head (yellow) in the ADP form is bound to an actin filament (blue). The exchange of ADP for ATP results in 
(1) the release of myosin from actin and (2) substantial reorientation of the lever arm of myosin. Hydrolysis of ATP (3) 
allows the myosin head to rebind at a site displaced along the actin filament (4). The release of Pi (5) accompanying this 
binding increases the strength of interaction between myosin and actin and resets the orientation of the lever arm 
(Uyeda et al. 1996, Berg et al. 2012). 
The swinging lever arm model became more substantial with the obtained crystal 
structure of the myosin II molecule by Rayment et al. (1993). A key feature of myosin 
motors seems to be the lever arms ability to act as an amplifier of movement. The lever 
arm amplifies small structural changes at the nucleotide-binding site to accomplish the 
110-Å movement along the actin filament that takes place in each ATP hydrolysis cycle 
(for the detailed ATPase cycle see section 1.3). A prediction of the mechanism proposed 
for the movement of myosin along actin is that the length travelled per cycle should 
depend on the length of this lever arm. Therefore the length of the lever arm should have 
an influence on the overall rate at which actin moves relative to the myosin heads. To test 
this prediction mutations of S1 fragments with different lever arm lengths were used 
(Uyeda et al. 1996). The lever arm was lengthened or shortened by adding or subtracting 
the light-chain-binding regions. In vitro motility assays then revealed that the speed of 
actin transport was linearly related to the number of light-chain binding-sites in the neck 
region of the S1 molecules (Uyeda et al. 1996, Holmes 1997) (figure 6). These in vitro 
studies of isolated myosin motors interacting with actin filaments were developed in the 
1980s by Japanese and American laboratories (Yanagida et al. 1985, Umemoto and 
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Sellers 1990, Winkelmann et al. 1995), and revolutionised the studies of muscle 
mechanics and cell motility and paved the way for single molecule experiments. 
 
Figure 6: The speed of actin along a lawn of myosin heads as a function of the length of the S1 neck region. The 
observed speed is linearly related to the number of light-chain binding sites in the lever arm (Uyeda et al. 1996, Holmes 
1997) 
 
1.3 The myosin ATPase cycle 
1.3.1 Chemomechanical transduction 
There were 3 lines of evidence for the relation between biochemical, structural and 
mechanical states of the chemomechanical cross bridge cycle: (1) biochemical studies 
using solution kinetics, (2) structural studies using EM and crystallography and (3) 
mechanical studies using fibres and single molecule experiments. In landmark 
experiments these lines of evidence were pursued and helped complete the view of the 
chemomechanical coupling in myosins (Holmes 2005). Rayment et al. (1993) were able 
to investigate crystal structures of myosin in different nucleotide states albeit only in the 
absence of actin. With high-resolution cryo-electron microscopy it was possible to 
investigate myosin bound to actin (Milligan and Flicker 1986, Jontes et al. 1995, 
Whittaker et al. 1995) although only in rigor and ADP bound state. Finally fibre studies 
and single-molecule experiments allowed further insight into the mechanics of single 
molecules. Experiments with optical tweezers revealed a two-step working-stroke where 
two mechanical steps of the working stroke were linked to the transition between three 
biochemical states (Veigel et al. 1999, Veigel et al. 2002, Sellers and Veigel 2010) These 
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studies and the formerly mentioned EM studies proved and further developed the 
swinging lever arm hypothesis. 
Myosin converts the chemical energy stored in ATP into directional movement on the 
actin filament by hydrolysation. In order to understand how this chemomechanical 
transduction works the following features need to be highlighted: (1) binding of different 
ligands (ATP or the products of ATP hydrolysis) induces different conformations in the 
nucleotide binding pocket of the myosin head, (2) a small conformational transition in the 
nucleotide pocket is amplified through rigid structural elements and appears as a large 
swinging movement of the head relative to the tail and (3) myosin exhibits different 
affinities for actin in different nucleotide states because the actin and nucleotide binding 
sites communicate with each other. Based on these principles, figure 7 represents a 
simplified flowchart of the motor cycle (Fischer et al. 2005). This model is an updated 
version of the chemomechanical model proposed by Lymn and Taylor (Lymn and Taylor 
1971) and based on structural studies, i.e. EM, biochemical and mechanical studies 
(Huxley 1957, Huxley 1969, Huxley and Simmons 1971). The present diagram shows 
only the main flux pathway of the intricate mechanism. 
 
Figure 7: The actomyosin contraction cycle (Fischer et al. 2005) The myosin head fragment is represented in colors. 
Red: motor domain, Green: hinge, Yellow: lever arm or neck. 
The upper left corner of figure 7 shows a “rigor” (nucleotide-free) actomyosin complex. 
Upon ATP binding the actin affinity of the myosin head decreases dramatically and the 
myosin rapidly releases actin (I-II). A reversible conformational transition follows (II-III). 
This is the “cocking” of the myosin. The resulting conformation (III) hydrolyses the 
bound ATP. After hydrolysis, the residual myosin-ADP+ Pi complex rebinds to actin (III-
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IV). Finally, the products (Pi and then ADP) sequentially dissociate from the nucleotide 
binding site. Product dissociation is linked to the power-stroke, the directional pull on the 
actin filament. Although detailed biochemical data on the ATPase cycle and crystal 
structures of several conformational states are available the assignment of biochemical 
steps to the structural changes is ambiguous (Trentham et al. 1976, Murphy et al. 2001, 
Kovács et al. 2004, Paavilainen et al. 2008). For instance, one of the important points 
under debate is the relationship between the re-formation of the strong actin binding 
interaction, product release and the power stroke (Llinas et al. 2012). 
Depending on the configuration of the motor (myosin) and the track (actin), the above 
demonstrated motor cycle leads to either contraction or transport. If the myosin is 
anchored by its tail it is the actin filament which is translocated upon movement of the 
myosin head. This is what happens in the muscle where thousands of anchored myosin 
molecules pull on each actin filament generating muscle contraction (see section 1.2.1). 
In another scenario actin is anchored (to the cytoskeleton) and the myosin power-stroke 
will displace the centre of mass of the myosin itself. This is the basis of intra-cellular 
transport.  
1.3.2 Kinetics-processivity-duty ratio 
A more detailed view on the biochemical scheme of myosin working reveals that every 
step is thermodynamically reversible. However, ATP-binding to the myosin head and Pi 
release afterwards, in the absence of external forces, keeps the cycle going predominantly 
in one direction. Although actin is an enzyme itself, it is traditionally considered as an 
activator or track throughout the actomyosin cycle since myosins can only interact with 
filamentous actin. Therefore, when characterizing a myosin actin is treated as a ligand. 
Binding of ATP to myosin is observed as a two-step process whereby a diffusion limited 
collision step is followed by a rapid isomerisation of the myosin head. ATP hydrolysis 
occurs mainly in the detached state and is reversible as measured with isotope labelled 
ATP or H2O (Geeves et al. 1980). ATP binding to actomyosin at physiological ATP 
concentrations (2-5 mM) and the following, actin-detached hydrolysis step are both faster 
than the steady-state ATPase in all known myosins. Therefore the rate limiting step in the 
enzymatic cycle must be one of the product release steps. Whether this is the dissociation 
of Pi or ADP will determine the stepping behaviour of the motor. If the release of Pi is 
slow, the myosin head will spend most of its cycle time with the hydrolysis products 
bound (AM.ADP.Pi) in which state the myosin has a low affinity for actin (a so-called 
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“weak actin binding state”). This happens in low duty ratio myosins (duty ratio = strong 
actin attachment / lifetime of total cycle time). Fast Pi and slow ADP dissociation, 
however, will result in a relatively long-lived actomyosin-ADP state (a strong actin 
binding state). Myosins that have their kinetic bottle neck at the ADP release step are high 
duty ratio myosins that spend most of their cycle time strongly bound to actin (figure 8) 
(De La Cruz and Ostap 2004). Several examples of these myosins have been discovered 
(myosins V, VI, VII) and it became clear that their cellular role requires the kinetic 
feature of slow ADP release (Mehta et al. 1999, Rock et al. 2001, Yang et al. 2005). With 
two high duty ratio heads a myosin can “walk” a large number of steps on actin, without 
dissociating from the track. This property is called processivity. In the light of the kinetic 
features of duty ratio and processivity we can identify two major types of functional 
adaptation in myosins. The low duty ratio enables a large complex of motors to work 
together because the short actin attachment of each head imposes little drag on the others. 
Most conventional type II myosins belong to this category. Low duty ratio is a property of 
ensemble contractile systems such as muscles or the cytokinetic contractile ring. 
 
 
Figure 8: The actomyosin enzymatic cycle with focus on the rate-limiting step and its consequences (De La Cruz 
and Ostap 2004). Note the weak and strong actin binding states. Low duty ratio results from the fact that myosin dwells 
in the weak actin binding states whereas in high duty ratio myosins the cycle time is spent mostly in a strongly bound 
AM.ADP state. 
 
High duty ratio, processive myosins on the other hand can typically perform intracellular 
transport with high efficiency as a double-headed molecule. They are able to carry their 
cargo long distances upon one diffusional encounter with an actin filament. Another 
cellular task often performed by high duty ratio myosins is tension bearing. Non-muscle 
myosin IIB performs this task within stress fibers by having a high duty ratio and a very 
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slow ATPase rate that leads to long lifetimes of the actin-attached states and efficient 
tension maintenance instead of contractility (Wang, Kovacs et al. 2003). Long lifetimes 
of the force-bearing intermediates are not a direct consequence of the high duty ratio but 
that of slow ADP release from actomyosin. A low duty ratio myosin with a very long 
ATPase cycle (slow motor) may assume long attachment periods and therefore is also 
suitable for tension maintenance. Myosin Ib belongs to this category and is a membrane 
motor that may be responsible for maintaining the structure and/or shape of different 
organelles. Finally, it is important to point out that processivity is an inherent property of 
every functional unit of molecular motors. Whether the unit consists of one, two, or 
hundreds of motors it is defined by the above discussed structural and kinetic parameters. 
A very important aspect of processivity is mechanical gating. In a double-headed 
molecule, the fraction of the time spent strongly bound to actin must be above 0.5 for a 
single head as a prerequisite for processivity. Vertebrate myosin V satisfies this condition 
(Rosenfeld and Sweeney 2004). Additionally to the inherent kinetics of one head, 
communication (‘gating’) between the two heads of myosin V can increase duty ratio and 
processivity (Veigel et al. 2002, Veigel et al. 2005, Sellers and Veigel 2010). 
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1.4 Myosin VI  
Myosin VI is a ubiquitously expressed unconventional myosin that has the unique ability 
to translocate towards the minus end of the actin filament. Structurally, like all myosins it 
consists of an N-terminal motor domain, which binds and hydrolyses ATP and can bind 
filamentous actin. The conversion of chemical energy (ATP hydrolysis) into mechanical 
energy is accomplished by conformational changes in the motor domain and then 
transmission through the converter region into a large movement of the lever arm. The 
unique insert of myosin VI between the converter region and the lever arm is the ‘reverse 
gear’ that enables it to move backwards. Stabilised by a calmodulin this reverse gear 
swings in the opposite direction to all other known myosins. The reverse movement of 
myosin VI is made possible by the rotation of the converter which is attached to the lever 
arm (made up of variable numbers of IQ-motifs) (Hasson and Mooseker 1994) that then 
amplifies the movements of the converter (Geeves and Holmes 1999, Houdusse and 
Sweeney 2001, Bahloul et al. 2004). The unique insert (see figure 9), which is located 
between the conventional IQ-motif and the converter, seems to be involved in altering the 
converter to reposition the lever arm and allowing therefore a minus end directed 
movement (Wells et al. 1999). A second calmodulin is reversibly bound to a more 
canonical IQ-motif in the neck region adjacent to the first IQ (Bahloul et al. 2004). 
Additionally myosin VI exhibits an intriguingly large working stroke (18 nm) as 
monomer (Lister et al. 2004) and step size of 30-36 nm length (as enforced dimer) similar 
in size to those of myosin V (Rock et al. 2001, Veigel et al. 2002, Rock et al. 2005, 
Veigel et al. 2005) despite the lever arm was expected to be shorter than that of myosin V 
which binds six calmodulins to its neck region in contrast to two in myosin VI, as 
proposed by Bahloul et al. (2004). Therefore other structures might contribute to the 
effective lever (Lister et al. 2004). The region immediately following the IQ-motif 
(proximal tail) was proposed as candidate for being the flexible element responsible for 
the large step size (Rock et al. 2005). Recent findings suggest that in the C-terminal tail a 
central single α-helix (SAH) domain exists (Peckham 2011) which is followed by the 
globular cargo-binding domain that exhibits lipid binding as well as interactions with 
different binding and interaction partners. This single α-helix was suggested to give 
mechanical stability to extend the lever arm and thus helping to explain how the large 
working stroke is made possible. Another theory was that the myosin VI lever arm was 
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achieving the relatively large step size not by extending the lever arm but by changing the 
angular swing to 180° (Lister et al. 2004). 
Despite there being many studies presenting data for description of an artificial myosin 
VI dimer (Rock et al. 2001, Sweeney and Houdusse 2007, Ali et al. 2011, Bond, Arden et 
al. 2012), so far it has not been shown whether myosin VI acts as a monomer or dimer in 
cells or if it possibly switches between both states depending on the cell’s requirements. It 
seems likely, given myosin VI’s diverse roles in cells, that it is a ‘flexible’ motor protein 
(Buss and Kendrick-Jones 2007) that could function either as non-processive monomer or 
processive dimer depending on its localisation or target. Non-processive monomers 
would be sufficient for tethering vesicles to actin filaments or maintaining membrane 
tension. Processive dimers on the other hand would be more suitable for vesicle transport 
to diverse cellular compartments. A predicted coiled-coil α-helical region in the myosin 
VI tail (see figure 9) was long seen as an indication of myosin VI being dimeric (Rock et 
al. 2005). Lister et al. (2004) showed that endogenous myosin VI is almost entirely 
monomeric (< 1% dimeric) upon purification. As said above it was then suggested that 
the formerly predicted coiled-coil region more likely forms a single α-helix domain 
(Peckham 2011), i.e. a single α-helical domain that is stable in solution on its own 
without the necessity of stabilising calmodulins as in the lever arm of myosin II or 
myosin V. Nevertheless myosin VI might have the ability to function either as a monomer 
or a dimer. Binding to cargo or other ligands may induce and regulate dimerization 
(Spudich et al. 2007). Indeed it has been shown that binding to optineurin and Dab2 can 
induce dimerization (Phichith et al. 2009, Yu et al. 2009). It was discussed whether there 
is a dynamic transition between the inactive, folded, monomer state and as active, 
unfolded dimeric state when bound to clathrin-coated vesicles via Dab2 (Buss et al. 2004, 
Lister et al. 2004, Spink et al. 2008). 
As mentioned in chapter 1.1.1 the plus ends of actin filaments are inserted in or near the 
plasma membrane and at intracellular organelles such as the Golgi or the phagosome 
while the minus ends reach into the cytosol (Geeves et al. 1980, Yengo and Sweeney 
2004). This and the fact that myosin VI is a minus end directed motor gives an indication 
for a completely different set of tasks in the cell. Myosin VI performs various roles in the 
cell: it clusters and transports transmembrane receptors in the area of a clathrin-coated pit, 
transports internalised vesicles away from the cell surface during endocytosis, stabilizes 
actin during spermatid individualisation (Tumbarello et al. 2013), facilitates movement of 
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vesicles through the peripheral actin cytoskeleton towards the early endosome and/or 
regulates a signalling platform for newly endocytosed receptors (Aschenbrenner et al. 
2003). Additionally myosin VI functions in the exocytic pathway as well and helps to 
maintain Golgi morphology and facilitates the fusion of secretory vesicles at the plasma 
membrane (Sahlender et al. 2005, Bond et al. 2011). The role of myosin VI as a short-
range transporter is supported by its relatively slow speed (ca. 30-60 nm/s) as measured in 
the in vitro motility assay.  
 
Figure 9: Myosin VI full-length protein. Myosin VI Chicken full-length protein with motor domain, Calmodulin 
binding unique insert, IQ-motif, lever arm extension, predicted coiled coil region with Single-α-helix (SAH) and the 
globular cargo-binding domain. Numbers denominate amino acids (taken from sequence of chicken full-length 
sequence, large-insert splice-variant). MIU: Motif Interacting with Ubiquitin, RRL: binding motif for binding partners 
such as NDP52, optineurin and GIPC; WWY: binding motif for binding partners as Dab2, Tom1 and LMTK1. PIP2-
binding: binding site for binding of PI(4,5)P2 (Spudich et al. 2007). 
 
1.4.1 Myosin VI and endocytosis 
Myosin VI is expressed as a number of different splice variants, as first described in 
Drosophila (Millar and Geeves 1983). Cremo and Geeves (1998) identified myosin VI 
isoforms containing either a large 13 or 17 amino acid (aa) insert or a small 9 aa insert in 
the C-terminal tail in the striped bass (Morone saxatilis). In human and other 
mammalian tissues a tissue-specific expression of splice variants of myosin VI containing 
a large, a small or no insert in their tails can be found (Buss et al. 2001). 
The isoforms containing the large insert (LI) and no insert (NI) provide the faculty for 
function in at least two different stages of the endocytic pathway because the isoforms 
target at different intracellular interfaces (Tumbarello et al. 2013). Myosin VI LI is linked 
to clathrin-mediated receptor endocytosis and degradation, whereas the NI splice variant 
is coupled with a subpopulation of early endosomes under the plasma membrane. This 
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process is mediated through binding to GIPC and Tom1. GIPC promotes backwards 
movement of endosomes through the peripheral actin cytoskeleton to the early endosome 
(Aschenbrenner et al. 2003). According to Arden et al. (2007), myosin VI and GIPC are 
recruited to the cleavage furrow in dividing cells and are required during cytokinesis.  
1.4.2 Myosin VI and exocytosis 
Exocytosis can be divided into two different pathways: constitutive secretion and 
regulated secretion. During constitutive secretion proteins synthesised on ribosomes of 
the ER are transported in carriers to the Golgi complex where they are processed and 
sorted for further transport to the plasma membrane for immediate release from the cell. 
The proteins on the regulated secretion pathway are transported on the same route from 
ER to Golgi to plasma membrane but are then stored in either neuronal synaptic vesicles 
or secretory granules. Instead of releasing their contents immediately, these carriers 
remain near the plasma membrane until the release is triggered by a specific intracellular 
signal or ligand (e.g. change in Ca2+ ion concentration) (Zucker 1996). 
By targeting proteins to one pathway or the other, the cell can carefully control rates and 
levels of secretion into the extracellular environment. 
The final steps of the secretory pathway can be divided into four stages: (1) approach of 
vesicles/granules to plasma membrane, (2) docking of these vesicles/granules to the 
plasma membrane, (3) priming for the fusion process and (4) fusion with the plasma 
membrane to release contents from the cell (Bond et al. 2011). Throughout these stages 
constant remodelling and reshaping of the cortical actin network plays a key role. To let 
secretory vesicles through this dense barrier during regulated secretion, a constant 
reorganisation and partial disassembly of the cross-linked actin network underneath the 
plasma membrane is important. In many cell types complete depolymerisation of actin 
filaments inhibits secretion (Bond et al. 2011). Therefore actin filaments seem to provide 
the tracks for transport of secretory carriers through the network. 
Myosin VI interacts with its binding partner optineurin and seems to be a control point for 
regulation of the dynamics of the fusion pore formation at the plasma membrane (Bond et 
al. 2011). It has been suggested that myosin VI might provide the tension/force that is 
necessary to stabilize or open the fusion pore by moving towards the minus end of the 
actin filament (Bond et al. 2011) and the small-insert splice variant tethers secretory 
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granules to the cortical actin (Tomatis et al. 2013). Another recent discovery highlights a 
similar role for myosin VI in the regulated secretion where it interacts with otoferlin, an 
endocytic calcium sensor which directly regulates SNARE-mediated membrane fusion in 
auditory hair cells (Dulon et al. 2009, Roux et al. 2009).  
1.4.3 Myosin VI and autophagy 
Autophagy is the basic lysosomal degradation pathway that involves all deterioration of 
unnecessary or dysfunctional cellular components through fusion of double-membrane 
autophagosomes which deliver their contents to lysosomes for decomposition. The 
membranes needed for autophagosome expansion and maturation may be derived from 
the plasma membrane, ER, Golgi complex, mitochondria and endosomes (Razi et al. 
2009, Ravikumar et al. 2010). Through binding to the autophagy related partners NDP52, 
optineurin, Tom1 and T6BP myosin VI is involved in targeting of ubiquitylated cargo and 
autophagy-related degradation (Morriswood et al. 2007, Tumbarello et al. 2012, 
Tumbarello et al. 2013).  
1.4.4 Myosin VI pathogenies 
Since myosin VI is involved in so many aspects of the endo- and exocytic pathways as 
well as autophagy, it is quite obvious that a loss of function or changes in expression 
patterns must result in more or less severe changes in cell health and maintenance. 
Studies on the Snell’s waltzer mice provided evidence for myosin VI’s role in hearing. 
These mice have a mutation in the myo 6 gene and are deaf, other symptoms are 
hyperactivity, head-tossing and circling (Avraham et al. 1995). Histopathology of hair 
cells of the mutant mice showed a great dysmorphism: they do not contain stereocilia and 
degenerate about six weeks after birth (Avraham et al. 1995). The cuticular plate of the 
hair cells is an area with high membrane transporting activity, crucial for continuous 
stereocilia rebuilding, it is probable that a lack of functional myosin VI leads to the 
impairment of intracellular transport of vesicles and in consequence to the collapse of 
stereocilia and dysmorphology of hair cells (Redowicz 2002). In this mouse model it was 
revealed as well that myosin VI is essential for cystic fibrosis transmembrane 
conductance regulator endocytosis in enterocytes (Mehta et al. 1999). Defects of myosin 
VI in this pathway lead to secretory diarrhoea. 
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Myosin VI is an early marker of prostate and ovarian cancer development. It is required 
in border cell migration during Drosophila ovary development (Geisbrecht and Montell 
2002). Yoshida et al. (2004) found that there is a functional link between myosin VI 
expression and aggressiveness of ovarian cancers. Myosin VI is abundantly expressed in 
high-grade ovarian carcinomas but not in indolently behaving ovary and ovarian 
carcinomas. Inhibiting myosin VI expression in high-grade ovarian carcinoma cells 
impedes cell spreading and migration in vitro. In prostate cancer similar overexpression 
levels have been reported but a correlation between aggressiveness of the cancer and 
myosin VI expression was not found (Dunn et al. 2006). 
Myosin VI has also been linked to hypertrophic cardiomyopathy and neurodegeneration 
through reduction in endocytic uptake of AMPA receptors in hippocampal neurons 
(Osterweil et al. 2005, Yang et al. 2005)). 
Little is known about the role of Myosin VI in the nervous system. It has already been 
established that the physiological loss-of-function of myosin VI is associated with 
astrogliosis in the brain, hypertrophic cardiomyopathy, defects in endocytosis in neuronal 
and epithelial tissues, disruption in the integrity of the intestinal brush border and various 
metabolic dysfunctions (Osterweil et al. 2005). Myosin VI is highly expressed throughout 
the brain, localized to synapses, and enriched at the postsynaptic density. Myosin VI 
deficient (Snell’s waltzer; sv/sv) hippocampus exhibits a decrease in synapse number, 
abnormally short dendritic spines, and profound astrogliosis (Osterweil et al. 2005). 
Myosin VI contributes to synaptic transmission and development at the Drosophila 
neuromuscular junction (Kisiel et al. 2011). This study concludes that Myosin VI is 
important for proper synaptic function and morphology. Myosin VI may be functioning 
as an anchor to tether vesicles to the bouton periphery and, thereby, participating in the 
regulation of synaptic vesicle mobilization during synaptic transmission. It has recently 
been shown that myosin VI maintains exocytosis by tethering secretory granules (SG) to 
the cortical actin (Tomatis et al. 2013). The precise mechanism is unkown. Tomatis et al. 
(2013) have shown, using a secretory granule pull-down assay and mass spectrometry, 
that myosin VI is recruited to SGs in a Ca2+ dependent manner.  
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1.4.5 Myosin VI binding partners 
Several binding partners are interacting with myosin VI, targeting it to different cellular 
destinations (figure 10). 
 NDP52 (Nuclear dot protein 52 kDa) 1.4.5.1
NDP52 (52 kDa) is a mainly cytosolic protein, which is highly similar to T6BP (see 
1.4.6.3) in terms of structure and binding to myosin VI. Like T6BP it consists of an N-
terminal SKICH domain, a coiled-coil region and a C-terminal zinc-finger arrangement 
(Morriswood et al. 2007). The zinc-finger domain interacts with ubiquitin and the SKICH 
domain with Nap1 (Ivanov and Roy 2009). The interaction with ubiquitin points at the 
involvement of NDP52 in the autophagy pathway. It binds to the RRL motif of myosin VI 
via its C-terminal zinc-finger like structure (Morriswood et al. 2007) and together they 
are localised on cytoplasmatic vesicles at the trans side of the Golgi. Interestingly NDP52 
and T6BP can interact with each other and with myosin VI. These complexes may play a 
role in coordinating membrane transport pathways and cytokine signalling with actin 
filament organisation and cell adhesion (Morriswood et al. 2007). 
 Dab2 (Disabled homolog-2 / DOC-2) 1.4.5.2
Dab2 is a 96 kDa protein that contains various known signalling domains and motifs and 
is thought to be a specific adaptor for members of the Low Density Lipoprotein receptor 
(LDLR) family. With its N-terminal phosphotyrosine (PTB) domain it interacts not only 
with the LDLR receptor but as well with phosphoinositides such as PIP2 (Mishra et al. 
2002). Different interaction patterns are located in the central and C-terminal regions of 
Dab2. It binds to clathrin via the amino acid motif DPW, endocytic accessory proteins 
such as Eps15 (NPF) and myosin VI (SYF) (Morris and Cooper 2001, Morris et al. 
2002). By acting as a cargo-specific adaptor protein Dab2 plays a key role in clathrin-
mediated endocytosis, where it sorts and links membrane receptors to the endocytic 
machinery at the plasma membrane (Buss and Kendrick-Jones 2007). Spudich et al. 
(2007) revealed by alanine scanning mutagenesis that residues 1184 to 1186 (WWY) in 
the globular tail of myosin VI are the Dab2 binding site, whereas the amino acids SYF 
(682-684) in the C-terminal region of Dab2 are the myosin VI binding site (Morris et al. 
2002). Since Dab2 and myosin VI colocalise in clathrin-coated pits and vesicles in the 
apical domain of polarised cells they seem potentially to be involved in the early stages of 
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clathrin-mediated endocytosis (Morris et al. 2002, Aschenbrenner et al. 2003, Spudich et 
al. 2007). 
 T6BP (Traf6-binding protein) 1.4.5.3
This 82 kDa protein is very similar to NDP52. It binds the RRL motif on the myosin VI 
cargo-binding tail via the two zinc-fingers (Morriswood et al. 2007). 
 GIPC (G-Alpha interacting protein C) 1.4.5.4
GIPC is a myosin VI interacting protein (Bunn et al. 1999) with a size of 36 kDa that 
binds to the RRL motif in the globular tail of myosin VI  via its C-terminal domain (Reed 
et al. 2005, Spudich et al. 2007). Since GIPC interacts with a number of transmembrane 
receptors, it is possible that myosin VI and GIPC are involved in the endocytosis of these 
receptors (Gotthardt et al. 2000, Hu et al. 2003, Naccache et al. 2006). This theory is 
supported by the findings that myosin VI isoforms with no insert or small insert co-
localise with GIPC in uncoated endocytic vesicles and seem to be involved in the 
movement through the actin filament network below the plasma membrane 
(Aschenbrenner et al. 2003, Dance et al. 2004). 
 SAP97 (synapse-associated protein 97) 1.4.5.5
SAP97 is a mammalian member of the MAGUK (membrane associated guanylate kinase) 
protein family that is expressed throughout the body in epithelial cells and in neurons. 
With its three PDZ domains, a SH3 domain and a region with a guanylate kinase like 
sequence (Fujita and Kurachi 2000), it interacts with diverse proteins. Interaction with 
myosin VI was shown as well by Wu et al. (2002), as it immunoprecipitates as a complex 
from neuronal cells with myosin VI and GluR1 (subunit of the α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor (AMPA)). In the Snell’s waltzer mouse the 
number of synapses and dendritic spines is reduced as well as the internalisation of 
AMPA receptors (Osterweil et al. 2005, Nash et al. 2010). This led to the conclusion that 
myosin VI together with SAP97 appears to be involved in the clathrin-mediated 
recycling, endocytosis of AMPA receptors or in the exocytic transport of them to the cell 
surface. Furthermore myosin VI may link cell adhesion molecules such as E-cadherin and 
β-cadherin and SAP97 to the actin cytoskeleton at cell contact sites and may therefore 
have a role in membrane protrusion and cell adhesion (Buss and Kendrick-Jones 2007). 
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 Optineurin 1.4.5.6
Optineurin is a 67 kDa protein with four predicted coiled-coil regions, two leucine zipper 
domains and a putative zinc-finger (Buss and Kendrick-Jones 2007). Optineurin binds to 
the myosin VI globular tail via the RRL motif (Sahlender et al. 2005). Interestingly 
phosphorylation of two threonine residues upstream of this site (T1089 and T1092) 
regulates the interaction between optineurin and myosin VI (Sahlender et al. 2005). In 
unpolarised cells optineurin and myosin VI co-localise at the trans-side of the Golgi 
complex and in vesicles right below the plasma membrane. In polarised cells on the other 
hand myosin VI and optineurin are both found on recycling endosomes where they are 
involved in cargo-sorting to the basolateral membrane (Au et al. 2007). Depletion of 
optineurin in unpolarised cells resulted in loss of myosin VI from the Golgi complex and 
the Golgi itself was fragmented and a reduction of secretion to the plasma membrane 
could be observed (Sahlender et al. 2005). Therefore optineurin and myosin VI, possibly 
together with Rab8 (Ras-related protein 8), are responsible for maintaining the Golgi 
structure and secretion from the Golgi to the plasma membrane. 
 LMTK2 (Lemur tyrosine kinase 2) 1.4.5.7
The transmembrane protein LMTK2 is a Ser/Thr specific protein kinase with a predicted 
N-terminal transmembrane sequence and a long C-terminal cytoplasmic tail domain. 
Several binding partners and potential substrates have been identified (Wang and 
Brautigan 2002) including myosin VI (Chibalina et al. 2007). LMTK2 is the first kinase 
and transmembrane protein known to bind directly to myosin VI. Chibalina et al. (2007) 
show not only that LMTK2 binds to myosin VI’s WWY motif but also that both proteins 
are required for delivery of cargo such as transferrin from the early endosome to the 
endocytic recycling compartment. However, further roles of LMTK2 in the cell remain to 
be elucidated. 
 DOCK7 (dedicator of cytokinesis 7) 1.4.5.8
DOCK7, expressed mainly in neuronal cells, is a guanine nucleotide exchange factor 
(GEF) for small GTPases (Rac1 and Cdc42), which are major regulators of the actin 
cytoskeleton. Majewski et al. (2012) show that Myosin VI and DOCK7 co-localize in 
neuronal PC12 cells at different cellular locations and during the whole cell cycle. It was 
shown that depletion of Myosin VI in neuronal PC12 cells caused significant changes in 
actin cytoskeleton organisation (Majewski et al. 2011).  
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 Phospholipase Cδ3 1.4.5.9
Phospholipase Cδ3 (PLCδ3) is a key enzyme in the phosphoinositide metabolism, but its 
physiological functions remain mostly unknown. PLCδ3 binds myosin VI via a PH and a 
C2 domain. Myosin VI and PLCδ3 are limitedly co-expressed in the inner and outer hair 
cells of the cochlea, but although a myosin VI knock-out will cause deafness, a PLCδ3 
knockout did not prove to do so (Sakurai et al. 2011). But since Sakurai et al. (2011) 
found a massive decrease of expression of myosin VI in PLCδ3-KO mice in intestines, 
where microvilli structure is well developed show that PLCδ3 might play a role in 
stability of microvilli structure via regulation and anchoring of myosin VI to the plasma 
membrane. 
 Tom1  1.4.5.10
Tom1 binds to myosin VI via the WWY motif, which also binds to Dab2 and LMTK2. 
Myosin VI and Tom1 co-localise on vesicles along the cell periphery. With Tom1 absent 
in cells, myosin VI is lost from endosomes (Tumbarello et al. 2012). Myosin VI is 
targeted by Tom1 to endocytic structures in mammalian cells and they function together 
in the final stages of autophagy. 
 
Figure 10: Cellular functions of myosin VI are directed by its distinct cargo adaptors. Myosin VI functions in 
various membrane trafficking pathways, such as clathrin-dependent endocytosis through interaction with Dab2, sorting 
at the early endosome, through interaction with Tom1, GIPC and LMTK2 and, in autophagy, through interactions with 
T6BP, NDP52, optineurin and Tom1. Myosin VI has multiple other functions in the secretory pathway as well as 
maintaining Golgi morphology, facilitation of vesicle fusion at the plasma membrane and regulation of basolateral 
sorting through interactions with optineurin. Modified after Tumbarello et al. (2013). 
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Binding 
Partner 
Interaction 
motif 
Function Protein domains Localization References 
NDP52 RRL 
Exocytosis, 
Autophagy 
receptor, 
signalling 
SKICH, coiled-coil, 
UBD, zinc-finger 
Golgi 
Morriswood et al. 
(2007) 
Dab2 WWY 
Endocytic 
adaptor, clathrin-
mediated 
endocytosis 
Phsophotyrosine-
binding motif, AP-2 
clathrin-binding 
endocytic 
vesicles 
Bond et al. (2012), 
Morris et  al. (2002) 
T6BP RRL 
Exocytosis, 
Autophagy 
receptor, 
signalling 
SKICH, coiled-coil, 
UBD, zinc-finger 
Golgi 
Morriswood et al. 
(2007) 
GIPC RRL 
Endocytosis, 
cargo sorting 
PDZ Vesicles 
Aschenbrenner et al. 
(2003), Spudich et al. 
(2007) 
SAP97  Endocytosis  
endocytic 
vesicles 
Osterweil et al. 
(2005) 
Optineurin RRL 
Exocytosis, 
secretion, 
signalling, 
autophagy 
receptor 
coiled-coil, UBD, zinc-
finger 
Golgi/ 
Endosomes 
Buss and Kendrick-
Jones (2011), 
Sahlender et al. 
(2005) 
LMTK2 WWY 
Endocytosis , 
cargo sorting 
Transmembrane, 
serine/threonine kinase 
Endosomes 
Chibalina et al. 
(2007) 
TLS  RNA-binding   Takarada et al. (2009) 
DOCK7  
intracellular 
signalling 
  
Majewski et al. 
(2012) 
phospholipase 
Cδ3 
 
anchoring MVI to 
cell membrane 
C2, PH, EF-hand 
cell 
membrane 
Sakurai et al. (2011) 
Tom1 WWY 
autophagy, 
endocytosis, cargo 
sorting 
VHS; GAT  
Tumbarello et al. 
(2012) 
Table 1: Binding partners of myosin VI. Modified after: Tumbarello et al. (2013) 
Optineurin, T6BP, NDP52 and GIPC share the RRL motif as interaction site on the 
myosin VI CBD whereas Tom1, LMTK2 and Dab2 interact with the WWY motif (table 
1). For a number of interaction partners no interacting motif is defined yet. 
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1.5 Myosin XXI  
Most eukaryotes express diverse isoforms of myosin, which perform manifold cellular 
tasks. The genome of Leishmania encodes for two different myosin isoforms: namely a 
myosin class IB and a class XXI. It has been reported that only myosin XXI is expressed 
(Foth et al. 2006, Katta et al. 2009). Being possibly the only myosin motor in these cells 
it must be a multifunctional motor that is capable of performing multiple tasks in the cell 
(Batters et al. 2012), similar to myosin VI with its scope of duties. Although the 
associated tasks in the cell are different between these myosins there are structural 
similarities. A basic-hydrophobic (BH) plot of myosin VI revealed a possible lipid-
binding domain around the IQ-motif (see 3.3.1.1) which is potentially not functional since 
calmodulin binds to it and additionally it is able to bind to lipids along its tail (see 
3.3.1.1). Myosin XXI shows a lipid binding domain at the converter domain and lipid 
binding propensity along the tail too (see 3.4.1). Therefore myosin XXI was used in this 
study as a second model system for a multifunctional cellular motor. 
Myosin XXI is a plus end directed motor, which preferentially localizes at the proximal 
region of the flagellum (Katta et al. 2009). The depletion of the encoding gene Myo21 
results in impairment of flagellar assembly and intracellular trafficking (Katta et al. 
2010). This shows that myosin XXI is essential for assembly of the Leishmania flagellum 
and that there must be other mechanisms than expression level control that allow myosin 
XXI to perform its tasks in the cell. Myosin XXI is expressed in both the pro- and 
amastigote stage of the parasite but expression is reduced ~20 fold in the non-motile 
amastigote stage (Katta et al. 2009). Two subpopulations of XXI can be found in the 
cells, one that is fixed to the flagellar proximal region and one that can be found in the 
cell with a low abundance (Katta et al. 2010). Under the conditions used, this myosin is a 
monomeric, mechanically functional molecular motor that binds a single calmodulin and 
moves actin filaments at a very low speed. It can therefore act as an anchor during 
endocytic processes within the flagellar pocket and possibly as well in the formation of 
the paraflagellar rod structure (Katta et al. 2009). One of the most intriguing facts about 
this myosin is that it contains two ubiquitin-associated domains (UBA) in the tail  and has 
no structural or functional relationship with the myosin proteins in other ciliates or 
flagellates (Batters et al. 2012, Katta et al. 2010). Several coiled-coil regions in the tail 
(figure 11) could point towards the possibility that myosin XXI is capable of dimerisation 
or even oligomerisation (Batters et al. 2012). In a very recent study connected to this 
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thesis, we were able to show that myosin XXI is indeed able to dimerise under certain 
conditions (Batters et al. 2014). We were as well able to show that it has, besides the N-
terminal extension SH3-like domain and its unique UBAs, the ability to bind lipids along 
its tail (Batters et al. 2012, Batters et al. 2014). 
. 
Figure 11: Myosin XXI full-length protein. Domain structure of L. donovani myosin XXI comprising the SH3-like 
domain from amino acids (aa) 11 to 37, the motor (aa 65-747), the converter domain (aa 662-747) and directly 
following the IQ-motif (744-759). From aa 744 to 961 three consecutive predicted coiled-coil regions. The last 
predicted coiled-coil region from aa 1016-1046 is with a very high probability a Ubiquitin associated domain (UBA). 
The total length of the protein is 1050 amino acids. 
Myosin XXI has been reassigned to a kinetoplastide-specific class of myosin by Odronitz 
and Kollmar (2007), class XIII; but throughout this work will be further called XXI 
according to the cited publications and to maintain consistency. 
 
1.5.1 Pathogenies 
Since myosin XXI is a myosin in Leishmania it is relevant to discuss the role of this 
inparasite pathophysiology. Leishmania are a group of trypanosomatid parasites that can 
be grouped into four species complexes- L. tropica, L. donovani, L. mexicana and L. 
brasiliensis. Each can give rise to a variety of diseases (Wakelin 1996). The best known 
ones are oriental sore, a cutaneous lesion caused by L. tropica and L. major, kala-azar, a 
predominantly visceral form caused by L. donovani and espundia (Uta) a mucocutaneous 
form caused by L. brasiliensis (Hiepe 2006). The life cycles of leishmanias follow a 
consistent pattern; all species are using blood-feeding sandflies (phlebotomines) as 
vectors (Figure 12). Human infections are mostly transmitted through various animal 
reservoir hosts, but direct human-human transmission occurs as well (Hiepe 2006). The 
parasites go through two life-stages: (1) the non-motile amastigote which exists within the 
mammalian macrophages, and (2) the highly motile promastigote with anterior flagellum 
which resides in the alimentary tract of the sandfly host (Katta et al. 2010). Sandflies 
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acquire infection when they take up infected cells as they feed. The amastigote stage is 
released into the insect’s intestine, transforms into promastigotes, divides and moves 
towards the pharyngeal valve (Figure 12). 
 
Figure 12: Life cycle of Leishmania parasite. Shown are the different stages in the sandfly vector and human. 
Leishmania parasites go through different developmental stages during their life cyle and change between the non-
motile amastigote state and the motile promastigote. From: National Institute of Allergy and Infectious Diseases, U.S. 
Department of Health and Human Services. 
In cutaneous and mucocutaneous leishmaniases infections remain restricted to the skin 
and superficial tissues. In visceral form, as transmitted by L. donovani, infection spreads 
to invade visceral organs (Wakelin 1996). From here the parasites spread from the initial 
site of infection and can become widely distributed throughout the body. A characteristic 
enlargement of spleen and liver accompanies the infection. 
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1.6 Calmodulin 
Calcium (Ca2+) is a major secondary messenger in cells. Changes in cytosolic Ca2+ 
concentration regulate and control a variety of cellular processes such as muscle 
contraction, molecular motor activity, cytoskeletal organisation, apoptosis, cell 
proliferation, mitosis, long-term potentiation, and many others (Tidow and Nissen 2013). 
For several of these cellular effects a calcium sensor that translates the Ca2+ signal into a 
cellular process is needed. Calmodulin (CaM), a 17 kDa protein is a highly conserved 
eukaryotic calcium sensor. Its crystal structure reveals two globular domains (N-lobe and 
C-lobe) with two EF-hand type Ca2+-binding sites in each. The two lobes are connected 
by a linker helix that shows some conformational flexibility (Park et al. 2008). Each CaM 
can bind 4 Ca2+ ions and then forms the Ca2+/CaM complex (see figure 13). Upon binding 
Ca2+ CaM undergoes a conformational change that enables it to bind to its target proteins. 
Target proteins are amongst others: myosins, protein kinases, phosphatases, synthases, 
ATPases and ion channels.  
 
Figure 13: Calmodulin binding to Calcium and structural changes in the Ca2+/CaM complex. (A): Calmodulin 
bound to 4 Ca2+, (B): Function of Ca2+-Calmodulin complex, (C): structural changes of Calmodulin molecule between 
unbound and Ca2+-bound state. (D): depiction of EF-Hand motif (modified after: Berg J.M. et al. (2012)) 
Although the protein sequence of CaM is highly conserved and identical among 
vertebrates, Ca2+/CaM-binding regions of target proteins display low homology and little 
sequence dependence. Typically CaM is Ca2+ activated and binds to short peptides and 
proteins. But it can as well bind in its apo (Ca2+-free) form to some target sites or in both 
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binding states with different affinities (Tidow and Nissen 2013). With these abilities a 
resourceful system linking Ca2+ concentration to the regulation of CaM target proteins is 
generated. 
1.6.1 IQ-motifs 
CaM can interact with proteins in a Ca2+-independent manner; one of these interacting 
motifs is the so called IQ-motif, a ~ 24 amino acid domain that serves as a binding site for 
one CaM light chain or any other calmodulin family member (Cheney and Mooseker 
1992). These motifs share the consensus sequence IQxxxRGxxxR (Cheney and 
Mooseker 1992), although Bähler and Rhoads (2002) suggest [I,L,V]QxxxRxxxx[R,K] as 
a more generalized IQ-motif. But on the whole there are different classes of IQ-motifs 
and IQ-like motifs. They are classified upon the number of residues that space the bulky 
residues in the respective motif. And each motif class includes several subclasses that 
show minor variations of the particular motif spacing. In the 1-14 motif for example the 
key bulky residues are spaced 12 residues apart. The other classes are the 1-10 and 1-16 
motifs (Calmodulin Target Database, Webb and Corrie 2001).  
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1.7 Calmodulin and myosins 
Nearly all myosins contain between one and seven IQ-motifs, not all of them binding 
CaM but CaM-related proteins like conventional myosin II, myosin X and myosin Ic 
(Acanthamoeba castellanii) (Rogers and Strehler 2001). As already discussed the neck 
domain serves as a lever arm and thereby contributes to the step size of a given myosin. 
When light chains are bound to the α-helical neck, they mechanically stabilise this 
structure so it can form a lever arm to amplify the conformational change generated in the 
catalytic domain. As soon as 4 Ca2+-ions bind to one CaM the conformation is changed 
which activates the target protein (see figure 13 B). Table 2 gives a summary of IQ-motif 
distribution among myosin classes. 
Myosin class Number of IQ-motifs/ Calmodulin/  
CaM binding sites 
References 
I 3-6 light chains Cheney and Mooseker (1992) 
II 4 light chains Cremo and Hartshorne (2007) 
III (ninaC) 2 splice variants: 
2 IQ-motifs 
1 IQ-motif 
Montell (2012) 
IV 1 IQ-motif Horowitz and Hammer (1990),  
V 6 IQ-motifs Espindola et al. (1992),  
Reck-Peterson et al. (2000) 
VI 1 IQ-motif 
1 Calmodulin binding unique insert 
Kellerman and Miller (1992), Wells et al. 
(1999), Bahloul, et al. (2004) 
VII 5 IQ-motifs Hasson (1997), Liu et al. (1997) 
IX 4-6 IQ-motifs Reinhard et al. (1995), Post et al. (1998) 
X 3 IQ-motifs Cheney and Baker (1999) 
XIV No classic IQ-motif Hasegawa and Araki (2002) 
XV 2 IQ-motifs Liang et al. (1999) 
Table 2: Distribution of IQ-motifs in different myosin classes. 
 
 
 
 
 
Introduction 
33 
1.8 Cell plasma membrane 
Myosin VI shows lipid-binding capabilities (Spudich et al. 2007) in its cargo-binding 
domain. Since no deeper understanding about further binding sites and interactions with 
the plasma membrane have been obtained yet, it will be one of the main aspects of this 
thesis to expand the insights into myosin VI’s interaction with membrane components. 
The cell membrane is a biological membrane that surrounds the cytoplasm of living cells, 
physically separating the intracellular components from the extracellular environment. It 
is selectively permeable and thus able to regulate transport in- and out of cells. Membrane 
formation is a consequence of the amphipathic nature of the phospholipids. The polar 
head groups favour contact with water, whereas their hydrocarbon tails interact with one 
another in preference to water (Tokumasu et al. 2002). A micelle is one option to arrange 
these molecules in the presence of water. Here the polar head groups form the outside 
surface whilst the hydrocarbon tails are sequestered inside, interacting with one another. 
Alternatively, the strongly opposed hydrophobic and hydrophilic moieties can be satisfied 
by forming a lipid bilayer (figure 14). A bilayer is then always composed of two lipid 
sheets and can therefore as well be called bimolecular sheet or a two-dimensional liquid 
(Singer and Nicolson 1972). The hydrophobic interior of the bilayer forms a permeability 
barrier whilst the hydrophilic head groups interact with the aqueous medium on each side 
of the bilayer. Lipid bilayers form spontaneously by a self-assembly process. The growth 
of lipid bilayers from phospholipids is spontaneous and rapid in water. These membranes 
have a very low permeability for ions and most polar molecules with an exception of 
water, which easily traverses these membranes because of its low molecular weight, high 
concentration and lack of a complete charge. In general one can say that the permeability 
of small molecules is correlated with their solubility in a nonpolar solvent relative to their 
solubility in water (Chakrabarti 1994).  
The cell plasma membrane which surrounds the cell and cell organelles embeds several 
proteins in different fashions. There are integral membrane proteins that interact 
extensively with the hydrocarbon region of the bilayer. There are proteins that traverse 
the bilayer completely, peripheral proteins interact with the polar head groups of the 
lipids or bind to the surfaces of integral proteins (McIntosh et al. 2006). Other proteins 
are tightly anchored to the membrane by a covalently attached lipid molecule (Nagle and 
Tristram-Nagle 2000). 
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Figure 14: Model of membrane structure. This model of the plasma membrane of a eukaryotic cell is an adaptation 
of the original model proposed by Singer and Nicholson (1972). The phospholipid bilayer is shown with integral 
membrane proteins largely containing helical transmembrane domains. Peripheral membrane proteins associate either 
with the lipid surface or with other membrane proteins. Lipid rafts (dark grey head groups) are enriched in cholesterol 
and contain a phosphatidylinositol glycan-linked (GPI) protein. The light grey head groups depict lipids in close 
association with protein. The irregular surface and wavy acyl chains denote the fluid nature of the bilayer. 
Through these integral proteins the bilayers are also involved in signal transduction. And 
in addition to these protein- and solution-mediated processes it is as well possible for lipid 
bilayers to perform direct signalling (Escribá et al. 2007). A good example is the 
phosphatidylserine (PS) -triggered phagocytosis (Greenberg and Grinstein 2002). During 
this process the normally asymmetrically distributed PS is mustered by scramblase during 
programmed cell death. The presence of PS then triggers phagocytosis. 
1.8.1 Lipid vesicles 
A vesicle is a small organelle mostly within a cell (figure 15 B). It consists of fluid 
enclosed by a lipid bilayer membrane. Vesicles can form naturally during exo- and 
endocytosis as well as phagocytosis. They are either produced by pinching off part of 
membrane of the Golgi complex, the endoplasmic reticulum or the cell membrane or by 
surrounding an object outside the cell (Deatherage and Cookson 2012). Since the inside 
of a vesicle differs from the cytosol they are not only used as transport ‘wrapping’ to 
move materials between locations in the cell (e.g. from rough endoplasmic reticulum to 
Golgi apparatus) but can as well act as chemical reaction chambers. There are different 
types of vesicles such as lysosomes which are membrane-bound organelles that contain 
hydrolytic enzymes which have the capability to break down almost all kinds of 
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biomolecules such as carbohydrates, proteins, nucleic acids, lipids and cellular debris 
(Settembre et al. 2013). And there are secretory vesicles which contain materials to be 
excreted from cells, such as synaptic vesicles which are located at presynaptic terminals 
in neurons and store neurotransmitters. Upon a signal that travels down the axon they fuse 
with the pre-synaptic membrane and release the stored neurotransmitter which can 
subsequently be detected by receptors. Other secretory vesicles are released from 
endocrine tissues and can transport and release hormones. Vesicle formation and release 
in cells is always connected with complex coating and docking in which different surface 
markers and coating proteins are involved. Examples for surface markers that identify the 
vesicle's cargo are SNAREs (Chen et al. 2001). Complementary SNAREs on the target 
membrane act to cause fusion of the vesicle and target membrane. As for coatings there 
are three types of vesicle coats: COPI, clathrin and COPII. Clathrin coated vesicles are 
found trafficking between the Golgi and plasma membrane, the Golgi and endosomes, 
and the plasma membrane and endosomes (Mousavi et al. 2004). The COPI coated 
vesicles are responsible for transport from the Golgi to the ER, whilst COPII coated 
vesicles are responsible for the transport from the ER to the Golgi (Popoff et al. 2011). 
If vesicles are produced artificially they are called liposomes. One way is to crush the 
living tissue into suspension and let the membranes build tiny closed bubbles. Another 
possibility is to use a homogeneous phospholipid vesicle suspension which can be 
prepared by sonication (Barenholz et al. 1977) or extrusion (Hope et al. 1985, Mayer et 
al. 1986). In this way aqueous vesicle solutions can be prepared of different phospholipid 
composition, as well as different sizes of vesicles. 
 
Figure 15: (A) Micelle, (B) vesicle and bilayer (C). Different conformations of lipids in aqueous buffer. 
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1.8.2 Lipids 
Fatty acids are aliphatic, usually straight chain, monocarboxylic acids. Natural fatty acid 
structures reflect their common biosynthesis- the chain is built in two-carbon units and cis 
double bonds are inserted at specific positions relative to the carboxyl carbon. Over 1000 
fatty acids are known but only around 20 fatty acids occur widely in nature (Scrimgeour 
and Harwood 2007). The fact that lipids differ in shape makes not only lipid phases 
possible but allow lipid monolayers to acquire spontaneous curvature (Dopico and Tigyi 
2007). In the cell lipids fulfil three general functions: first, they are used as energy storage 
in lipid droplets. These function primarily as storage of caloric reserves and as 
repositories of fatty acid and sterol components, which are needed for membrane 
biogenesis (Scrimgeour and Harwood 2007). Second, they form the matrix of cellular 
membranes which consists of polar lipids that consist of a hydrophobic “tail” and a 
hydrophilic “head” portion. It is the physical basis of spontaneous formation of 
membranes that the hydrophobic parts show a propensity to self-associate (driven by 
water) and the hydrophilic moieties interact with the aquatic environment and with each 
other. Finally lipids can act as primary and secondary messengers in signal transduction 
and molecular recognition processes (van Meer et al. 2008). In the following chapter only 
the lipids with relevance to the assays used in this thesis will be discussed. 
 Phospholipids  1.8.2.1
Phospholipids can be divided into two main classes depending on whether they contain a 
glycerol or a sphingosyl backbone into glycerophospholipids and spingophospholipids. 
The compounds of the former contain and are named after structures that are based on 
phosphatidic acid (3-sn-phosphatidic acid). The X moiety attached to the phosphate 
includes amino alcohols (nitrogenous bases) or polyols: 
 
note: R1 and R2 are long-chain alkyl groups 
Figure 16 presents the main structure and its derivates in more detail. 
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Figure 16: Structure of glycerophosphate-based lipids. The complete lipid structure shown is 1,2-distearoyl-sn 
glycerol-3-phosphocholine or phosphatidylcholine (PC). Substitution of choline (box) with the head groups listed below 
results in the other phospholipid structures. Phosphatidic acid (PA) has a hydroxyl group in place of choline (not 
shown). Cardiolipin (CL) is also referred to as diphosphatidylglycerol since it contains two PAs joined by a glycerol. 
Adapted after: Dowhan and Bogdanov (2002) 
In eubacteria and eukaryotes the diacylglycerol backbone sn-3-glycerol is esterified at 
positions 1 and 2 with long-chain fatty acids (figure 16). Eukaryotic lipids contain fatty 
acid chains up to 26 carbons in length with multiple or no double bonds (Dowhan and 
Bogdanov 2002). The most common phospholipids and their properties are listed in 
table 3. 
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Substituent (X) Phospholipid Remarks 
-H Phosphatidic acid (PA) Negatively charged lipid, occurring only in 
trace amounts. Important metabolic 
intermediate. 
-CH2CH(NH3)+COO- Phosphatidylserine (PS) Widespread but minor negatively charged lipid 
in eukaryotes. 
-CH2CH2NH3+ Phosphatidylethanolamine (PE) Widespread and major lipid. Partly methylated 
derivatives are metabolic intermediates in the 
conversion of phosphatidylethanolamine to 
phosphatidylcholine. 
-CH2CH2N+(CH3)3 Phosphatidylcholine (PC) Neutral net carge. The major animal 
phospholipid and main component of 
nonchloroplast membranes of plants. 
-C47H83O13P Phosphatidylinositol Negatively charged lipid. Widespread and 
usually minor lipid. Phosphorylations can take 
place in different positions Important for 
signalling. 
-Phosphatidylglycerol Diphosphatidylglycerol (DPG) 
(Cardiolipin) 
Common in bacteria and localized in the inner 
leaflet of mitochondrial membranes. Negatively 
charged. 
Table 3: Most common phospholipids and their characteristic properties. Modified after: Scrimgeour and Harwood 
(2007) 
 
1.8.2.1.1 Sphingolipids 
Sphingolipids contain sphingosine or a related amino alcohol. The most common is N-
acylsphingosine that is commonly called sphingomyelin. Although sphingomyelin is a 
major lipid of certain membranes in animal tissues (particularly nervous tissues), even in 
animals the nonphosphorous sphingolipids (glycosphingolipids) are more widely 
distributed. Sphingolipids are a minor group of membrane lipids (10-20 mol% of plasma 
membrane). They consist of a phosphorycholine and ceramide or a phosphoethanolamine 
headgroup. Sphingomyelin is usually found in animal cell membranes, especially in the 
myelin sheath that surrounds some nerve cell axons. Its functions range from insulating 
nerve fibres over cell signalling to apoptosis. It was found to be associated with lipid 
microdomains in the plasma membrane, known as lipid rafts. In these rafts, lipid 
molecules are in the lipid ordered phase, offering more rigidity and structure than the rest 
of the plasma membrane. Due to the specific types of lipids in these rafts they can 
accumulate certain types of proteins associated with them and thus increasing the special 
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functions they possess. There are speculations that lipid rafts are involved in the apoptosis 
cascade (Kolesnick 1994, Scrimgeour and Harwood 2007).  
Sulfatides are Glycosphingolipids (ceramides) carrying a sulphate esther group attached 
to the carbohydrate moiety. Although sulfatides tend to be minor components of tissues, 
3-sulfogalactosylceramide (Sulfatide) is one of the more abundant glycolipid constituents 
of brain myelin and is also present in other organs but only encountered at trace levels in 
tissues. Sulfatide is located exclusively in the extracellular leaflet of the membrane of the 
myelin sheath. In the pancreas it is located in the islet of Langerhans and is involved in 
insulin processing and secretion through activation of ion channels.  
1.8.2.1.2 Cholesterol 
Cholesterol is a primary steroid in membranes of plants and animals. The cell membrane 
is abundant in cholesterol (15-50% of total lipid) whilst scarce in internal organelles 
(≥ 5% in mitochondrial membranes) (Sackmann 1995, Dopico and Tigyi 2007). In 
eukaryotic membranes it is largely up to cholesterol to regulate membrane fluidity and 
permeability. Increasing cholesterol in animal membranes changes the physicochemical 
properties in terms of increased bending rigidity and compressibility (Bloom et al. 1991). 
But exactly these two features of bilayers need to be regulated and controlled since they 
are needed to perform distinct physiological tasks within the cell membrane. A ‘soft’ 
membrane is easier to permeate by for example red blood cells (Evans 1989). 
Additionally cholesterol serves as a precursor for biosynthesis of steroid hormones, 
Vitamin D and bile acids (McCabe and Green 1977). 
1.8.2.1.3 Phosphoinsoitides 
Phosphoinositides (PIs) are a family of eight minor components of cellular membranes, 
with the parent lipid phosphatidylinositol (PtdIns) representing only 8% of the total 
phospholipid content in a typical mammalian cell but accounting for more than 80% of 
total PIs (Vanhaesebroeck et al. 2001). Nevertheless the role of PIs in the cellular 
machinery is fundamental. PIs perform multiple and highly specialised roles in regulation 
of cell homeostasis, membrane trafficking and signal transduction (figure 17).  
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Figure 17: Cartoon showing intracellular membranes in the endocytic and biosynthetic pathways and their 
hypothesized phosphoinositide content . Trafficking pathways given by letters. A, internalization from the plasma 
membrane; B, degradative sorting to the lysosome; C, recycling from endosomes back to the trans-Golgi network 
(TGN), delivery of cargo from the TGN to endosomes; F, secretion of cargo from the TGN to the plasma membrane 
(Carlton and Cullen 2005). 
Structurally PtdIns consists of a D-myo-inositol 1-phosphate moiety that is linked via its 
phosphate group to diacylglycerol (DAG). The inositol ring has the unique property of 
undergoing sequential and reversible phosphorylation at one or more of the 3-, 4-, or 5-
OH positions. Accordingly, PtdIns serves as the precursor of the seven functionally 
distinct stereoisomers (figure 18). 
 
Figure 18: Mammalian phosphoinositide cycle. Illustration of the phosphoinositide species that can be naturally 
generated by the phosphorylation of PtdIns at positions 3, 4 and 5 of the inositol ring. Only the reactions catalysed by 
mammalian lipid kinases are shown. Double arrows indicate reversibility by phosphoinositide phosphatases. Modified 
after Halet (2005). 
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PI(3)P is predominantly found in early and multivesicular endosomes through association 
with FYVE (Fab 1, YOTB, Vac 1 and EEA1) domains involved in endocytic trafficking 
(Janmey and Stossel 1987). It is phosphorylated to PI(3,5)P2 by Fab1p, a FYVE domain 
containing protein. The actual target of this PI is unknown. PI(4)P is the most abundant 
Phosphoinositide, a direct precursor of PI(4,5)P2 and is prevalently found in the Golgi 
apparatus where it maintains structural and functional organisation of the Golgi complex. 
At the plasma membrane it is bound to proteins by PH (pleckstrin-homology) domains 
(Mayer et al. 1993). Most of its interacting proteins are involved in membrane trafficking 
such as exo- and endocytosis. 
PI(5)P is synthesised by Phosphatases and constitutively present in many cell types but 
100-fold less abundant than PI(4)P, it binds PHD (plant homeodomain) domains. 
Nevertheless its metabolic pathway and role remain unknown. Its mass level has been 
shown to increase with cell activation which implies a regulatory role in the nucleus 
(Payrastre et al. 2001). 
PI(3,4)P2 is a minor lipid of which only traces in unstimulated cells can be detected. It is 
mostly found at the plasma membrane and in early endocytic pathway. Interacting 
proteins are bound to via PH domain. Additionally the PX (phox homology) domain of 
p47phox is specific for PI(3,4)P2 binding (Teasdale and Collins 2012). 
PI(3,5)P2 is concentrated mainly in late compartments of the endosomal pathway and 
plays important functions in multivesicular body sorting, endosomal dynamics and 
autophagy (Payrastre et al. 2001). 
PI(4,5)P2 (PIP2) is the major polyphosphoinositide in the mammalian cell. It is enriched in 
the plasma membrane, at the Golgi and the nuclear envelope but in total distributed in 
various cellular compartments (Carlton and Cullen 2005). It is the precursor of the two 
important secondary messengers DAG and inositol 1,4,5-trisphosphate (IP3). It is a 
signalling molecule on its own (Hinchliffe 2000). Its importance for the attachment of the 
cytoskeleton to the plasma membrane was shown by Lassing and Lindberg (1985) where 
they found a first indication for the influence on the cytoskeleton organisation through 
dissociation of profiling-actin complexes and thus regulating the free actin monomers 
concentration in the cell. Moreover PIP2 can uncap actin filaments from CapZ-related 
proteins and gelsolin allowing elongation of pre-existing filaments. Since gelsolin is a 
Ca2+ dependent severing protein, PIP2 can regulate the breaking of actin filaments. Once 
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gelsolin binds to PIP2 its severing function is inhibited. This interaction is modulated by 
Ca2+ and pH (Iida et al. 1987). Furthermore PIP2 is involved in exocytosis, endocytosis, 
membrane trafficking and activation of enzymes (Carlton and Cullen 2005). 
Another minor polyphosphoinositide is PI(3,4,5)P3.It accounts for only <10% of PIP in 
the cells and is mainly localized at the cell membrane (Payrastre et al. 2001) and has a 
variety of targets and functions in the cell (Toker and Cantley 1997). It is noteworthy that 
PI(3,4,5)P3 cannot only interact with PH domains but binds to hydrophobic and basic 
protein sequences as well. Recent studies imply that PI(3,4,5)P3 may also regulate the 
restructuring of focal adhesions through interaction with α-actinin (Greenwood et al. 
2000). 
 
1.9 Aim of the study 
The ability of myosins to selectively bind different cargoes is poorly understood but is 
integral to their specific function within cells. The aim of this study was to increase our 
understanding of how myosins bind to lipid cargo. It is important to understand how and 
where different lipids bind to the tail region. Myosins must bind specifically to their load 
and transport it to its cellular destination, navigating a complex and densely packed 
environment and thus relocate the cargo in a specific and timely fashion. Myosin VI and 
XXI are two very versatile molecular motors. The aim of this thesis is to discover more 
about their capabilities to bind to various cellular lipid components and to map the lipid 
binding sites on their tails. Furthermore, cargo binding and mechanical regulations of 
motor proteins are linked, thus it is an objective of this study to ascertain how these two 
processes are connected to understand how the two addressed motor proteins are 
regulated.  
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2.1 Molecular Biology Methods 
2.1.1 Used organisms and culture 
DH5α (Library efficiency® DH5 α) competent cells (Invitrogen) 
These competent cells are used for general cloning and vector reproduction. The yield and 
quality of isolated DNA as well as the transformation efficiency is enhanced within this 
strain because of the lack of ability for homologous recombination and a mutation in 
DNA specific endonuclease I. 
BL21 (BL21 Star™ DE3 Combo and BL21 AI™ one shot chemically competent E. coli, 
Invitrogen) 
Bl21 Star™ (DE3) chemically competent E. coli are used for high-level expression of 
non-toxic recombinant proteins from low copy number T7 promoter-based expression 
systems. The promoter has to be induced by the lactose-analogue Isopropyl-β-D-1-
thiogalactopyranoside (IPTG). This compound mimics allolactose which triggers 
transcription of the lac operon via binding to the lac repressor and release of the same 
from the lac operon and thereby allowing the transcription of genes in the lac operon.  
BL21 AI™ cells are chemically competent cells that are used for protein expressions 
which require tighter regulation and strong expression of toxic proteins from a T7 
promoter-based expression system. These cells contain a chromosomal insertion of the 
gene encoding T7-RNA polymerase into the araB locus of the araBAD operon, placing 
regulation under control of the arabinose-induced araBAD promoter. 
MAX Efficiency® DH10Bac™ competent cells (Invitrogen) 
DH10Bac™ competent cells are used for production of recombinant bacmids used in the 
Bac-to-Bac® Baculovirus Expression System (Invitrogen). The DH10Bac™ E. coli strain 
contains a baculovirus shuttle vector (bacmid) that can recombine with a donor plasmid, 
in this case pFastBac™, to create an expression bacmid containing the cloned gene of 
interest. An additional plasmid in these cells encodes for the enzyme transposase that 
catalyses the transposition. Insertion of the target gene interrupts the lacZ α-peptide in a 
way that colonies bearing the recombinant bacmid show white and wild type colonies 
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blue colour. Insertion of this recombinant bacmid into insect cells (see 2.2.5) results in 
formation of infectious baculoviruses and target protein. 
Spodoptera frugiperda (Sf21)-cells (IPLB-Sf21AE) 
Sf21 is a continuous cell line derived from pupal ovarial tissue of the fall army worm 
Spodoptera frugiperda, a moth species. It was developed at the United States Department 
of Agriculture (USDA) Insect Pathology Laboratory. They are commonly used to isolate 
and propagate baculoviral stocks and to produce recombinant proteins expressed in a 
baculoviral system. 
2.1.2 Expression systems 
Strains were cultivated on 2YT plates or in 2YT liquid media at 37 °C. For the Bac-to-
Bac system LB media was used. To select for antibiotic resistant plasmids, after 
autoclaving following sterile antibiotics were added: 
antibiotic stock concentration end concentration in media 
Kanamycin 25 mg/ml 25 µg/ml 
Ampicillin 50 mg/ml 50 µg/ml 
Gentamycin 50 mg/ml 7 µg/ml 
Tetracyclin 10 mg/ml 5 µg/ml 
 
When agar plates were used, bacterial agar was added to liquid medium before 
autoclaving and antibiotics were added after the medium cooled down (< 50 °C). 
Since Sf21 cells are not dependent on adherent growth, cultivation of cells was done in 
suspension culture at 27 °C in Grace’s insect media supplemented with FBS (Invitrogen, 
GIBCO), Normocin (Invivogen) and Pluronic (Invitrogen). Every day cell density was 
measured using a BioRad TC 10 automated cell counter and cells were maintained at a 
concentration of 106 cells/ml. 
 Media 2.1.2.1
If not stated differently Milli Q water was used for preparation of media (Millipore). 
Media for E. coli: Luria Bertani Medium (LB) 1 l: 10 g Tryptone, 5 g Yeast extract, 10 g 
NaCl, pH 7.00; 2 YT 1 l: 16 g Tryptone, 10 g Yeast extract, 5 g NaCl pH 7.5 
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SOC 1 l: 20 g Tryptone, 5 g Yeast extract, 0.5 g NaCl, 0.2 g KCl, 20 mM Glucose pH 7.0 
2.1.3 Plasmids 
pET-28a (Novagen) 
This 5369 base pair vector carries an N-terminal His-tag and an optional C-terminal His-
tag sequence. It is a T7-promoter system based vector and expression is induced by 
providing a source of T7 RNA polymerase in the host cell. It carries a kanamycin 
resistance. 
pGex 6P-1 (GE healthcare) 
The glutathione S-transferase fusion vector (4900 bp) encodes the recognition sequence 
for site-specific cleavage by PreScission Protease between the GST domain and the 
multiple cloning site. It carries an ampicillin resitance. 
pFastBac HTB (Invitrogen) 
This 4857 base pairs vector is part of the Bac-to-Bac baculovirus expression system. The 
donor plasmid has a bacterial replication origin, an ampicillin resistance gene and an 
expression cassette. This cassette contains the polyhedron promoter of the Autographa 
californica nuclear polyhedrosis virus (AcNPV), a multiple cloning site, a SV40 poly(A) 
signal, a gentamycin resistance gene as well as an N-terminal His-tag sequence. 
Additionally it carries a TEV Protease cleavage site to cleave off the His-tag sequence 
after purification. 
pFastBac 1 (Invitrogen) 
This 4775 base pairs vector resembles the pFastBac HTB vector and is part of the Bac-to-
Bac baculovirus expression system. The main difference lies in the lack of any tag in this 
vector. 
pColaDuet™-1 (Novagen) 
The pColaDuet™-1 vector with its 3719 base pairs is designed for coexpression of two 
target genes from a single plasmid. The vector encodes two multiple cloning sites (MCS) 
which is each preceded by a T7 promoter, lac operon and a ribosome binding site. MCS-1 
encodes for the N-terminal polyhistidine tag, whilst MCS-2 encodes the 15 amino acid S-
Tag™ peptide for C-terminal fusion if desired. The vector is kanamycin resistant. 
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pAC4 (Avidity) 
This 4216 bp vector is used to express C-terminal AviTag-protein fusions. Expression of 
the AviTagged gene is under the control of the tightly repressed Trc promoter and is 
IPTG-inducible. The vector is ampicillin resistant. 
Champion™ pET SUMO (life technologies) 
The pET SUMO vector (5600 bp, kanamycin resistant) utilizes a small ubiquitin-related 
modifier (SUMO) fusion, belonging to the growing family of ubiquitin-related proteins, 
to enhance the solubility of expressed fusion proteins. In contrast to ubiquitin, SUMO is 
involved in the stabilization and localization of proteins in vivo. After expression, the 
11 kD SUMO moiety can be cleaved by the highly specific and active SUMO protease at 
the carboxyl terminal, producing a native protein. Additionally expression is controlled 
by the lac operon and a 6x His-tag preceding the SUMO site simplifies purification. An 
overview over vector maps can be found in the appendix. 
2.1.4 Polymerase chain reaction (PCR) 
Amplification of DNA fragments and generation of site-directed mutagenesis was carried 
out by polymerase chain reactions (PCR). Hot Start Phusion polymerase (Thermo 
Scientific), the provided Taq buffer and dNTPs were used according to manufacturer 
(PCR Kit, Thermo Scientific). The reaction was performed on a thermocycler (eppendorf 
Mastercycler personal) in a 50 µl reaction. Plasmid DNA was used as template. To 
facilitate optimal primer-annealing a touchdown programme was used. 
Reaction conditions:  
Denaturing at 98 °C for 45 s  
Denaturing at 98 °C for 15 s 
Annealing at 68 °C for 30 s 
Elongation at 72 °C for 1 min 
Denaturing at 98 °C for 15 s 
Annealing at 60 °C for 30 s 
Elongation at 72 °C for 1 min 
Final extension at 72 °C for 1 min 
Temperature decline 1 °C per cycle,  
8 cycles 
 
28 cycles 
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2.1.5 Agarose Gel electrophoresis 
Electrophoretic separation of DNA was carried out using 0.8%-1.2% (w/v) agarose gels 
prepared in 1x Tris Borate EDTA (TBE) buffer including 20 µl/l Ethidiumbromide at 
80 mA with the run length depending on product size. The gels were cast in BioRad Mini 
Sub Cell GT chambers, the DNA to be separated was mixed with 0.1 volume of 6x DNA 
loading buffer and loaded onto the gels. Subsequently the gels could be observed under 
UV light at 302 nm and photos taken with the ChemiDoc XRS+ system (BioRad). 
20x TBE buffer: 1.76 M Boric acid, 1.78 M Trizma base, 80 mM EDTA pH 8.3, 20 µl 
10 mg/ml Ethidiumbromide solution (1 g Ethidium bromide solved in 100 ml H2Odd) 
6x DNA loading buffer: 0.25% (w/v) Bromphenol blue, 0.25% (w/v) Xylene cyanole ff, 
30% Glycerol (99%) 
2.1.6 Isolation of DNA fragments from agarose gels 
Extraction and purification of DNA from agarose gels were performed using PureLink ® 
Quick Gel extraction and PCR Purification COMBO Kit (both Invitrogen) according to 
manufacturer’s instructions. 
2.1.7 Purification of PCR products 
For cloning purposes the PCR products were purified using the same kit as for the 
isolation of DNA fragments from agarose gels according to manufacturer’s protocol. 
2.1.8 DNA cleavage with restriction enzymes 
Usually 1 µg of DNA (plasmid or PCR product) was digested in a 40 µl reaction with at 
least 5 U of each enzyme. The buffer suitable for the restriction enzyme(s) was added and 
the volume adjusted with H2Odd. The tube was incubated for at least 1 h at 37 °C. The 
digestion of the vector was monitored on an agarose gel.  
2.1.9 Ligation of DNA into a plasmid vector 
Ligation of vector and insert was carried out using the Rapid Ligation Kit (Thermo 
Scientific) at room temperature. Vector and insert were usually mixed in a ratio 1:5, but 
this ratio was adjusted when needed. 
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2.1.10 Transformation of E. coli 
For transformation, chemically competent E. coli cells were thawed on ice and incubated 
with the ligation mix on ice for 15 min followed by a heat shock at 42 °C for 45 s. The 
cells were immediately placed back on ice and revived with 2YT medium. Cells were 
kept at 37 °C with agitation for 30-60 min (depending on the antibiotic resistance) and 
plated on 2YT plates containing the appropriate antibiotic. Plates were incubated at 37 °C 
overnight to obtain E. coli colonies harbouring the transformed plasmid. Single colonies 
were inoculated into tubes containing 5 ml 2YT with antibiotics. Cells were grown in a 
37 °C shaker overnight. The positive transformants were detected by restriction enzyme 
mapping and confirmed by DNA sequencing. 
In the case of transformation into BL21 E. coli the procedure was exactly the same, 
despite an upscaling step after picking the colonies from the agar plates. Colonies were 
picked and an over day culture followed by a bigger volume overnight culture (200- 
400 ml) with appropriate antibiotics was set up and then used for bacterial expression 
purposes. 
2.1.11 Mini preparation of plasmid DNA 
The plasmid DNA from E. coli was isolated with the PureLink Quick Plasmid Miniprep 
Kit (Invitrogen) according to manufacturer’s instructions. The principle here is binding 
the plasmid DNA to spin columns and to finally elute it with the provided buffer. DNA 
was verified on agarose gels and the seemingly appropriate samples sent for sequencing 
(GATC). 
2.1.12 Whole plasmid Site-directed mutagenesis (SDM) 
For the closer investigation of certain binding sites on the target proteins, site-directed 
mutagenesis was performed to make intentional and specific changes to the target DNA 
sequence. For the initial PCR a primer containing the desired mutation (in our case a 
point mutation) which was complementary to the template DNA around the mutation site 
was used. This was followed by an overnight digest with the enzyme DpnI which only 
cleaves at methylated sites and therefore digests the template plasmid but not the PCR 
product. After a heat-inactivating step of the DpnI at 80 °C the mutated PCR DNA was 
transformed into DH5α-cells. After plating and incubation overnight at 37 °C, colonies 
were picked, transferred to a liquid culture, and after incubation overnight subsequently 
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miniprepped and sent for sequencing. The resulting DNA was, in case of several point 
mutations used as a template for another round of mutagenesis. 
2.1.13 Protein expression using the baculovirus expression system 
Over the past decade the use of baculoviruses has become an important tool for over-
expressing recombinant proteins in eukaryotic cells (King and Possee 1992). Unlike the 
bacterial expression systems, this eukaryotic system uses most of the protein 
modification, processing, folding and transport machinery that is present also in higher 
eukaryotes. Thus, with this system, most of the over-expressed proteins exhibit proper 
biological activity and function (King and Possee 1992). 
For the purpose of this thesis, the expression of the different protein constructs 
comprising the motor domain and parts of the tail or the full-length protein was carried 
out with the Bac-to-Bac® baculovirus expression system (Invitrogen) in the Sf21 insect 
cell line described before (see 2.1.1). One of two major components of the Bac-to-Bac®-
system is the vector into which the gene or genes of interest are cloned. For this work 
vectors containing one promoter, and thus one expression cassette, were used.  
The second major component of the Bac-to-Bac® system is represented by an E. coli 
strain (DH10Bac® Competent E. coli) that is used as host for the before generated 
plasmid, consisting of transfer vector and gene(s) of interest. 
DH10Bac™ Competent E. coli cells contain a baculovirus shuttle vector, referred to as 
bacmid. After transformation into these cells, transposition between transposons of the 
vector and the bacmid occurs. This recombinant bacmid is the basis to then generate the 
recombinant baculovirus. An overview of the key steps for baculovirus protein expression 
is given in figure 19. 
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Figure 19: Protein expression via the Baculovirus Bac-to-Bac® system-overview. The flowchart illustrates the 
required steps for the successful protein expression in the baculovirus expression system. (modified after: Invitrogen 
Bac-to-Bac® handbook)
 
2.1.14 Generation of the recombinant bacmid 
Once the recombinant vector was generated, for transposition into the baculovirus shuttle 
vector (bacmid) the amplified and purified DNA was transformed into DH10Bac ™ E. 
coli cells (figure 20). This strain of E. coli cells contains the bacmid with a mini-attTn7 
attachment site, which is inserted in a segment of DNA encoding the LacZα peptide, and 
a helper plasmid. Generation of the recombinant bacmid is achieved via site-specific 
transposition between the mini-Tn7 element of the donor vector and the mini-attTn7 
attachment site on the bacmid. For transformation, chemically competent DH10Bac® 
E. coli cells (aliquots of 50 μl) were thawed on ice and incubated with 1 ng DNA for 30 
min on ice. The heat shock was performed for 45 s at 42 °C, followed by immediate 
incubation on ice. Subsequently, 900 µl of SOC medium was added and the suspension 
was incubated in a shaker device at 225 rpm, for 4 h at 37 °C. The Tn7 transposition 
functions are provided by a helper plasmid, which encodes for the transposase and 
confers resistance to tetracycline. Thus, successful recombination leads to the disruption 
of the LacZ gene on the bacmid, which in turn allows for blue-white screening in the 
presence of the chromogenic substrate 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-gal) and the inducer IPTG. Therefore, 100 µl of dilutions 1:10, 
1:100 and 1:1000 in SOC medium were plated on LB plates supplemented with 
(50 µg/ml) X-Gal, (40 µg/ml) IPTG, (50 µg/ml) kanamycin, (7 µg/ml) gentamicin and 
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(10 µg/ml) tetracycline. The plates were incubated for 48 h at 37 °C to grow single 
colonies. Four white colonies with the thereby confirmed (i.e., recombined bacmid) 
phenotype were picked and added to 3 ml of LB media ( see section 2.1.2.1) 
supplemented with gentamycin (7 µg/ml), tetracyclin (10 µg/ml) and kanamycin (50 
µg/ml) and incubated on a shaker device overnight at 250 rpm at 37 °C. After this final 
step a mini preparation of the DNA was done following the manufacturer’s instructions 
for the PureLink™ HiPurePlasmid DNA Miniprep Kit (Invitrogen) and a test PCR to 
verify the correct size was performed. 
 
Figure 20: Generation of recombinant bacmid by site-specific transposition. Left: before transformation of transfer 
vector into DH10Bac™ cells; middle: transposition of the gene of interest and the gene encoding for gentamycin 
resistance into the bacmid (black arrow); right recombinant bacmid with Tn7-element of transfer vector. LacZ gene and 
genes encoding resitance for indicated antibiotics are colour-coded. (modified after: Invitrogen Bac-to-Bac® handbook)
 
2.2 Biochemical Methods 
2.2.1 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Protein mixtures were separated by discontinuous SDS-PAGE on 10 and 15% SDS – 
PAGE gels (table 4) according to Laemmli (1970) using the BioRad Mini protean Tetra 
system. The stacking gel deposits the polypeptides to the same starting level at the surface 
of the resolving gel, and subsequently the SDS-polypeptide complexes are separated in 
the resolving gel according to size under uniform voltage and pH. Prior to SDS-PAGE, 
2 x SDS gel loading buffer was added to the protein samples to be separated. The mixture 
was boiled for 3-5 min at 98 °C. Electrophoresis was carried out at a constant voltage of 
120 V for 10 min and 170 V for about 60 min (depending on the size of the protein). As 
standard, a mixture of proteins of defined molecular masses was electrophoresed (Pre-
stained protein ladder 10-245 kDa, Applichem). 
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10% Separating gel 1.7 ml 30% acrylamide, 1.25 ml 1.5M Tris-HCl pH 8.8, 2 ml 
H2Odd, 50 µl 10% (w/v) SDS, 20 µl 10% (w/v) Ammonium 
persulphate (APS), 2 µl Tetramethyl-ethyl-diamine (TEMED) 
15% Separating gel 2.5 ml 30% acrylamide, 3.75 ml 1.5 M Tris-HCl pH 8.8, 
1.2 ml H2Odd, 50µl 10% (w/v) SDS, 20 µl 10% (w/v) APS, 
2 µl TEMED 
Stacking gel  
 
0.28 ml 30% acrylamide, 0.2 ml 0.5 M Tris-HCl pH 6.8, 
1.13 ml H2Odd, 16.7µl 10% (w/v) SDS, 16.7 µl 10% (w/v) 
APS, 1,7 µl TEMED 
SDS sample buffer (25ml) 
 
2.5 ml 1 M Tris-HCl pH 6.8, 1 g SDS, 354 µl 2-
mercaptoethanol, 5 ml glycerol, 50 µg bromophenol blue 
SDS running buffer (1 litre) 
 
18.77 g glycine, 3 g Tris, 1 g SDS (final pH 8.3) 
 
Molecular weight markers                Pre-stained protein ladder, 10-245 kDa (Applichem)                 
Table 4: SDS-PAGE gel preparation. 
Following SDS-PAGE, gels were stained in Coomassie Blue solution by shaking for 15-
30 min, and subsequently destained for direct observation of the protein bands. 
Coomassie Blue solution: 0.1% (w/v) Coomassie Brillant Blue, 10% acetic acid, 
45% (v/v) methanol, 45% (v/v) H2Odd 
Destain solution: same as Coomassie Blue solution without Coomassie Brilliant Blue. 
2.2.2 Silver staining 
For silver staining the Pierce® Silver Stain Kit (Thermo Scientific) was used according to 
manufacturer’s protocol. The acrylamide gels were fixed in a solution containing 
30% methanol and 10% acetic acid for 30 min at room temperature. The fixative was 
removed and washed 3 times 5 min with 10% ethanol. The gels were treated with the 
sensitizer working solution from the kit for 1 min and then stained in stain working 
solution which was as well provided with the kit. After brief washes in water the gels 
were developed using the developer solution and the reaction was stopped with 5% acetic 
acid. 
2.2.3 Western blotting 
Following separation of protein by SDS-PAGE, the proteins were transferred from gels 
onto nitrocellulose membranes (Hybond C-extra, Amersham Biosciences) according to a 
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modified protocol of Towbin et al. (1979) by the means of the Mini-Trans Blot module 
(Mini Protean tetra system component, BioRad). In this wet blotting method, the gel and 
its attached nitrocellulose membrane were sandwiched between several pieces of 
Whatman® 3 mm filter paper which had been soaked in blotting buffer, and protein 
transfer was carried out at room temperature at 100 V for 60 min. After this the 
nitrocellulose filter was blocked for at least 15 min at room temperature in 5% (w/v) milk 
powder in PBS-T buffer (blocking buffer). The membrane was then washed three to five 
times with PBS-T. The membrane was then incubated with primary antibody diluted in 
blocking buffer for at least 45 min or overnight. After washing 3 times with PBS-T 
buffer, the membrane was incubated with a secondary antibody conjugated with horse 
radish peroxidase (HRP) (diluted 1:2000 in blocking buffer) for at least 1 h. The 
membrane was washed 5 times with PBS-T. Finally, the protein bands were detected by 
using the Clarity Western ECL Kit (BioRad) and visualised on a ChemiDoc XRS+ 
(BioRad). If only one antibody, HRP conjugated, was used, the detection step could 
follow the washing step directly. Antibody dilutions varied from 1:5000 (e.g. anti-GST 
HRP) to 1:10000 (anti-6x His HRP). 
Blotting buffer: 25 mM Tris- HCl, 192 mM glycine, 20% (v/v) Methanol 
Blocking buffer: 1x PBS, 0.1% Tween 20 and 5% (w/v) skim milk 
PBS-T buffer: 1x PBS, 0.1% Tween 20 
2.2.4 Bacterial expression 
Bacterial expressions were started with 15-30 ml of starter culture in 420 ml 2YT. 
Depending on the construct temperatures and expression durations differed. Initially 
culture in flasks were shaken at 37 °C until the optical density at 600 nm (OD600) reached 
0.5 to 0.8 and then were induced with the appropriate reagent (IPTG or Arabinose). After 
induction temperature was dropped to the desired degree and expression took at least 4 h. 
A 20 min centrifugation step at 4000 rpm followed to pellet the bacteria and after 
redissolving the pellet in Buffer B and protease Inhibitor (Roche) they were frozen and 
stored at -80 °C. 
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 Standard protocol 2.2.4.1
4 h expression time from induction on, 37 °C until induction, 27 °C from induction to end 
Buffer B: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM DTT, 20% (w/v) Sucrose, 
40 mM Imidazole 
2.2.5 Transfection of Sf21 cells 
For transfection cells are kept in a monolayer in Grace’s insect medium with added 
Pluronic (5 ml on 500ml medium), heat-inactivated FBS (50 ml on 500 ml medium) and 
Normocin (Invivogen) (0.1 mg/ml on 500 ml medium). After leaving them to adhere to 
the well’s bottom plating medium (Grace supplemented + FBS without Normocin) is 
added and the cells are mixed with the mix of the target bacmid and Cellfectin® 
(Invitrogen) to introduce the bacmid into the cells (figure 21). Cellfectin is a cationic-lipid 
formulation that forms spontaneously lipid-DNA complexes which fuse with the plasma 
membrane resulting in uptake and expression of the DNA within these cells (figure 22).  
 
Figure 21: Preparing the bacmid for transfection into insect cells via Cellfectin® reagent. The cationic lipid 
(Cellfectin® reagent) coats the bacmid DNA for the subsequent chemical transfection into insect cells. 
After mixing the three components together the medium is exchanged against Grace’s 
medium with FBS and Normocin and the cells are left to incubate at 27 °C for 3-7 days. 
Transfected cells are taken off the well and centrifuged, the supernatant is kept and in 
Grace’s medium with FBS, Normocin and Pluronic the cells are scaled up to passage 
number 4 (P4). Here 500 ml 0.8x106 cells/ml and 40 ml of the target P3 are combined 
with a Calmodulin P3 and shaken for 3 days. After a final centrifugation step the pellet is 
resuspended in Myosin extraction buffer with Protease Inhibitor and frozen at -80 °C.  
Myosin extraction buffer: 90 mM KH2PO4, 60 mM K2HPO4, 300 mM KCl, pH 6.8 
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Figure 22: Representation of the time course from cell transfection until harvesting of released virus. Top left: 
Cellfectin-mediated transfection of insect cells with bacmid DNA; top right: following transfection, within approx. 48 
to 60 h cells produce viral proteins, that eventually assemble into intact lytic viral particles; free virus is eventually 
harvested and used for further virus amplification. 
 
2.2.6 Protein purification 
Pellets from bacterial expression and from insect cell culture were treated equally. An 
exceptional case was full length (FL) myosin VI (see 2.2.6.1). After thawing the pellets at 
25 °C in a water bath, a brief sonication on ice (5 min, 5 s cycles, power 50%) followed. 
The lysed mixture was then centrifuged at 20000 rpm (Beckman Coulter JA25.50 rotor) 
for 20 min 4 °C. After passage through a 0.45 µm sterile syringe filter the sample was 
loaded onto a suitable resin column, depending on the tag of the protein. Polyhistidine-
tagged proteins (His-tag) bind with micromolar affinity to resins that contain bound 
bivalent nickel ions (HiTrap ff, bed volume 5 ml, GE). After loading onto the column, the 
column was washed with HIS low buffer to remove nonspecifically bound proteins and 
the target protein was then washed off in a stepwise manner using HIS high buffer (figure 
23). When proteins were expresses in the pGex 6P-1 vector, the purification was carried 
out with Glutathione Sepharose columns (GSTTrap ff, bed volume 1 or 5 ml, GE). GST-
tagged proteins bind to the offered glutathione ligand and impurities were washed away 
by washing with PBS. Tagged protein was then eluted from the column by washing with 
Reduced Gluthathione Tris-buffer (RGT) in a single step. 
RGT buffer: 50 mM Tris-HCl pH 8.0, 10 mM L-Gluthatione reduced 
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Figure 23: Typical result of a protein purification using an Äkta® (GE lifesciences) FPLC system: A: UV/Vis 
absorbance curve shows the purification result as it was while the protein passed the absorbance detector and B shows 
the collected fractions on a SDS-PAGE; indicated in red are the fractions containing the target protein. 
 
 Myosin VI full length purification 2.2.6.1
Cells were thawed in a water bath at 25 °C. After adding 1 mM DTT, 1 mM ATP and 
5 mM MgCl2 as well as 100 µl of purified calmodulin (approx. 1 mM), cells were 
sonicated on ice with 10x 15 s bursts at 50%. Incubation on rotator in the cold room 
(10 °C) for 30-60 min was followed by the aforementioned centrifugation at 20000 rpm at 
4 °C for 20 min. After these additional steps the purification followed standard protocol. 
HIS low: 50 mM Tris-HCl pH 7.5, 40 mM Imidazole, 500 mM NaCl, 1 mM DTT 
HIS high: 50 mM Tris-HCl pH 7.5, 400 mM Imidazole, 500 mM NaCl, 1 mM DTT 
RGT buffer: 50 mM Tris-HCl pH 8.0, 10 mM L-Glutathione reduced, pH 8.0
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2.2.7 Dialysis of proteins 
Proteins were dialysed into different buffer conditions to rid them of contaminants such 
as ADP or free phosphate. Different dialysis devices were used for different applications 
and sample or protein sizes. Usually dialysis was performed in the cold room in a large 
volume (2 l) overnight with continual stirring to ensure complete dialysis. 
2.2.8 Cleavage of the GST tag 
If pGEX-6P vectors were used for expression, the GST tag could be removed by 
PreScission Protease (GE healthcare). Following elution of the GST fusion protein from 
Glutathione Sepharose, the eluate was dialysed extensively against PBS containing 1 mM 
EDTA and 1 mM DTT in order to remove reduced glutathione and protease inhibitors 
from the sample. 10 μg of enzyme were used to cleave 1 mg of GST fusion protein. 
Cleavage was carried out at 4 °C overnight on a rotatory shaker. Once digestion was 
complete, the sample was passed through a washed and equilibrated Glutathione 
Sepharose to remove free GST and the PreScission Protease from the protein of interest. 
2.2.9 Biotinylation of BRS (biotin recognition site) proteins 
For the covalent attachment of biotin to a protein to create a different type of tag, firstly 
target proteins had to be expressed with a C- or N-terminal BRS site. Enzymatic 
biotinylation was carried out by incubating the tagged protein with biotin ligase (BirA) in 
the presence of biotin and ATP. This biotin-protein ligase activates biotin to form 
biotinyl-5’-adenylate and transfers the biotin to biotin-accepting proteins. Following a 
protocol from the manufacturer Avidity, each Biomix, additional biotin and BirA enzyme 
were mixed in a ratio of 1:1:1:0.5 with the target protein. Then this mix was incubated for 
at least 1 h at 4 °C and a western blot was performed to confirm successful biotinylation. 
For higher yield the whole reaction was scaled up depending on the needed amount of 
biotinylated protein. Purification of the biotinylated proteins was performed over a 
Monomeric Avidin column® (Thermo Scientific) following manufacturer’s instructions 
and checking the result with western blot (figure 24). The protein was loaded in 
Potassium free PBS and incubated on the column for 1 h. Then the column was subjected 
to washing steps with PBS whilst the absorbance at 280 nm was checked for unbound 
protein. When the absorbance approached the PBS-baseline elution, was started by 
washing with Biotin Blocking and Elution Buffer. Again absorbance at 280 nm was 
checked and the fractions with the eluted biotinylated protein were kept and concentrated 
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using a spin column concentrator. The column was regenerated afterwards with 
Regenerating buffer.  
 
Figure 24: Biotinylation of myosin VI full-length BRS (VI BRS) construct with BirA. (A):one-step HIS-affinity 
purification of myosin VI BRS. (B): western blot after purification of VI BRS over Monomeric Avidin® column with 
Streptavidin detection. Lane 1: molecular weight marker, A3 and A4 (red): elution fractions from HIS column, 1: 
combination of both eluted fractions, (tested for motility); 2: flow-through of Avidin column, 3-8: wash fractions of 
Avidin column, 9-14: elution of Avidin column, Reg. buffer: sample of wash step with Regenerating buffer, end 
product: concentrated final biotinylated VI FL BRS. 
 
For the biotinylation of myosin VI FL protein the His-tag affinity purification and 
biotinylation had to be performed during one day to keep the protein active. Biomixes, 
biotin and BirA were added to the slurry after sonication of the cells and incubated on a 
rotator at 4 °C for 1 h before the centrifugation and subsequent His-tag affinity 
purification (see 2.2.6). Loading of protein was performed in PBS, followed by a one-step 
elution at 50% HIS high 500.  
Biomix A: 10 mM Tris-HCl pH 8 
Biomix B: 100 mM ATP, 100 mM Mg-acetate, 500 µM d-Biotin 
Biotin: 500 µM d-Biotin 
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Potassium free PBS: 100 mM Na3PO4, 150 mM NaCl 
Biotin Blocking & Elution buffer: 2 mM d-Biotin in 500ml Potassium free PBS 
Regenerating buffer: 100 mM glycine pH 2.8
 
2.2.10 Determination of protein concentration 
For the determination of protein concentrations at least two different methods were 
deployed on the same sample for accuracy reasons. 
 Bradford assay 2.2.10.1
This assay is based on the observation that the absorbance maximum for an acidic 
solution of Coomassie Brilliant Blue G-250 shifts from 465 nm to 595 nm when binding 
to protein occurs (Bradford 1976). Both hydrophobic and ionic interactions stabilize the 
anionic form of the dye, causing a visible colour change from red/brown to blue. 
With every Bradford assay a standard BSA-curve was performed with known 
concentrations of BSA (bovine serum albumin) ranging from 0-0.9 mg/ml. After a linear 
fit to the standard curve has given a linear equation, the measured data of at least 3 data 
points of differing dilutions of the target protein was taken into the equation and the 
protein concentration was calculated by:  
(𝑚𝑚𝑚𝑚𝑚𝑟𝑚𝑚 𝑚𝑎𝑚𝑎𝑟𝑎𝑚𝑎𝑎𝑚 − 𝑦/𝑥) ∗ 𝑚𝑑𝑑𝑚𝑑𝑑𝑎𝑎 𝑓𝑚𝑎𝑑𝑎𝑟 =  𝑎𝑎𝑎𝑎𝑚𝑎𝑑𝑟𝑚𝑑𝑑𝑎𝑎 𝑚𝑚/𝑚𝑑 
Equation 1 
 Warburg-Christian 2.2.10.2
The Warburg-Christian method was developed to correct for nucleic acids contamination, 
leaving only the absorbance due to protein (Warburg and Christian 1942). Since nucleic 
acids absorb strongly at 260 nm while proteins do not, the method uses a correction factor 
calculated from the ratio of the absorbance at 280 nm to that at 260 nm. The Warburg-
Christian uses the A280 and A260 values to calculate protein concentrations (see table 5). 
The purpose of using both values is to correct for nucleic acid contamination in protein 
samples. The sample was measured in the UV-spectrophotometer and the values at 280 
and 260 nm were taken.  
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The ratio of these two values was determined (A280/A260), and a correction factor taken 
from the table below. The concentration of protein equals:  
(𝐴280)  ∗ (𝑎𝑎𝑟𝑟𝑚𝑎𝑑𝑑𝑎𝑎 𝑓𝑚𝑎𝑑𝑎𝑟)  =  𝑚𝑚/𝑚𝑑 𝑝𝑟𝑎𝑑𝑚𝑑𝑎 
Equation 2 
 
Table 5: Warburg-Christian correction table. 
 
 280 nm method 2.2.10.3
The A280 method takes advantage of the absorbance of light at 280 nm by the amino acids 
tyrosine and tryptophan (Stoscheck 1990). A sample of the protein was taken and 
transferred to a UV-spectrophotometer (Varian Cary) the A280 was the output value for 
the concentration of the protein in mg/ml. 
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2.2.11 Purification of Myosin II from rabbit skeletal muscle 
Myosin II was prepared following the method of Margossian and Lowey (1973). 
Extracted muscle from fast twitch fibres of the dorsal lateral and hind leg muscles of 
rabbits were minced and Guba-Straub solution added (300 mg/100 g of minced muscle). 
Minced muscle was stirred in Guba-Straub solution for 15 min at 4 °C to solubilize the 
myosin. The mixture was then centrifuged for 30 min at 9000 rpm. The supernatant is the 
myosin fraction and the pellet the Actin fraction (see 2.2.12). The supernatant was filtered 
and stirred into 10 volumes cold H2Odd. After 1 h the supernatant was siphoned off and 
the myosin slurry centrifuged at 9k rpm for 15 min. The myosin pellet was further 
purified by another round of solubilization by addition of a minimal volume of 3 M KCl 
and precipitation (10 volumes H2Odd), before a final solubilization in Myosin prep 
solution. After addition of the myosin preparation solution to the pellet the concentration 
was determined by measuring the optical density:  
 
𝐴𝑎𝑚𝑎𝑟𝑎𝑚𝑎𝑎𝑚280 − 340 𝑎𝑚 =  0.533 ≡  1 𝑚𝑚/𝑚𝑑 
Equation 3 
Purified myosin was stored at -20 °C in 50% (v/v) glycerol. 
 
Guba-Straub solution: 0.3 M KCl, 0.1 M KH2PO4, 0.05 M K2HPO4, 1 mM ATP, 5 mM 
MgCl2, pH 6.5 
Myosin prep solution: 50 mM Phosphate buffer, 5 mM DTT, 5 mM EDTA, 3 M KCl, 
pH 7.0
 
2.2.12 Purification of Actin from rabbit skeletal muscle 
Buffers: see Purification of Myosin II from rabbit skeletal muscle 
 
Rabbit actin was prepared by the method of Pardee and Spudich (1982). Actin was 
extracted from the insoluble muscle mince left over from the myosin preparation above. 
The insoluble fraction of the minced muscle was mixed with 2 l of actin extraction buffer 
(0.4% w/v NaHCO3) and stirred for 10 min. The mixture was filtered through 
cheesecloth, and the residue scraped from the cheesecloth and mixed with 1 l of 
1 mM EDTA (pH 7.0). After stirring the mixture for 10 min the slurry was again filtered 
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through cheesecloth. The residue was further extracted with 2 l of H2Odd (the slurry was 
filtered through cheesecloth after each extraction). Two volumes of cold acetone were 
added to the residue and stirred for 30 min; the resulting slurry was filtered through 
cheesecloth. This step was repeated four times with 1 volume of acetone. The residue was 
then allowed to dry in the fume hood overnight. The actin containing acetone powder was 
stored at -20 °C. 
 
2.2.13 Purification of Actin from acetone powder 
6 grams of acetone-dried powder were stirred into 120 ml ACEX (actin extraction) 
solution following the method of Pardee and Spudich (1982). The resulting slurry was 
filtered thoroughly through cheesecloth and the filtrate was stored on ice while the 
residue was again stirred with a further 80 ml of ACEX for 10 min. The slurry was again 
filtered through cheesecloth and the filtrate was combined with that from the first 
extraction and centrifuged at 20k rpm for 15 min. The supernatant was removed and Tris-
HCl (2 M, pH 8.0), KCl (3 M) MgCl2 (1 M) and ATP (100 mM) were used to make up 
the concentration in the supernatant to 5 mM, 50 mM, 2 mM and 1 mM respectively. The 
Actin was then allowed to polymerise for 2 h at 4 °C. To remove tropomyosin and other 
regulatory proteins from the polymerised actin, a “high salt cut” had to be deployed by 
adding solid KCl to the supernatant to make up the concentration up to 0.8 M, whilst the 
pH was adjusted to 8.3-8.5 with 1 M KOH. The F-actin was then pelleted by 
centrifugation at 70k rpm for 40 min. After removal of the supernatant the pellet was 
gently homogenised in 8 ml of ACEX for 30 min on ice. The homogenised actin pellet 
was then dialysed against ACEX overnight. The resulting G-Actin was clarified by 
spinning at 13k rpm for 15 min (figure 25). The concentration was determined by 
measuring the optical density:  
𝐴𝑎𝑚𝑎𝑟𝑎𝑚𝑎𝑎𝑚290 − 310 𝑎𝑚 =  0.62 ≡ 1 𝑚𝑚/𝑚𝑑. 
G-actin was aliquoted before being drop frozen in liquid nitrogen and stored at -80 °C or 
in liquid nitrogen.  
 
ACEX solution: 2 mM Tris-HCl pH 8.0, 0.2 mM ATP, 0.2 mM CaCl2, 1 mM DTT 
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Figure 25: A 10% SDS-PAGE gel showing samples from actin purification. Lane 1: Molecular weight markers 
(kDa). Lane 2: before high salt cut, lane 3: before dialysis, lane 4: purified G-actin after dialysis. 
 
2.2.14 Myosin II HMM Preparation 
5 ml of a Myosin II Glycerol-stock solution (stored at a concentration of about 10 mg/ml) 
were pipetted together with 40 ml of ice cold H20dd into centrifuge tubes. The mixture 
was centrifuged for 15 min at 20k rpm and 4 °C. The pellet was resuspended in 5 ml 
2x High Salt Buffer and 50 µl Chymotrypsin were added and the mixture was thoroughly 
vortexed. After exactly 10 min at RT the digest was stopped by mixing with 50 µl of the 
Bowman-Birk-Inhibitor. After an overnight dialysis in 3 l of Low-Salt-Buffer the solution 
was then centrifuged at 20k rpm for 30 min at 4 °C to remove all undigested Myosin and 
LMM. The supernatant was taken and frozen at -80 °C. 
Low Salt buffer: 40 mM KCl, 20 mM K-Phosphate buffer (pH 6.5), 2 mM MgCl2, 2 mM 
DTT 
2x High-Salt buffer: 1M KCl, 40 mM K-Phosphate buffer (pH 6.5), 4 mM MgCl2, 2 mM 
DTT 
α-Chymotrypsin: 5 mg/ml in Tris HCl pH 7.5 
2.2.15 Myosin II S1 Preparation using Papain 
Rabbit Mg2+ papain-S1 was prepared by Papain (Sigma) digestion of myosin under 
conditions of low salt and high free magnesium. The presence of magnesium is essential 
to ensure papain cleavage occurs between S1 and S2. In the absence of magnesium the 
RLC may become unfolded and dissociate from its IQ-motif on the myosin neck, 
enabling papain digestion to occur within the exposed RLC binding region. The resulting 
S1 has a short neck with no RLC (figure 26). 
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Myosin II (glycerol stock) was exchanged into low salt buffer by precipitation with cold 
H2Odd and centrifugation (4 °C, 15k rpm), followed by redissolving of the myosin pellet 
in low salt buffer. Activated Papain stock solution (0.5 mg/ml papain in 5 mM cysteine, 2 
mM EDTA pH 6.0) was added to the redissolved myosin to a final Papain concentration 
of 0.03 mg/ml. Digestion was allowed to proceed at 23 °C for 15 min. Digestion was 
stopped by the addition of a 2x molar excess of E64 inhibitor. Digestion products were 
dialysed against a low salt buffer (+2 mM DTT) and insoluble products were removed by 
centrifugation (20k rpm, 30 min). The soluble S1 was purified on an anion exchange 
column (Mono Q, GE) by deploying a linear salt gradient (0-1 M NaCl) over 
approximately five column volumes. The 2 ml fractions were collected and concentrated 
on spin concentrator columns. Concentration was determined by measuring the Optical 
density:  
𝐴𝑎𝑚𝑎𝑟𝑎𝑚𝑎𝑎𝑚280 − 340 𝑎𝑚 =  0.83 ≡  1 𝑚𝑚/𝑚𝑑 
as well as with a Bradford assay (see 2.2.10.1). 
The aliquots were stored at -80 °C in the presence of 30% (w/v) sucrose. 
 
Figure 26: SDS PAGE of HMM preparation using Papain. Lane 1: molecular weight markers (kDa); Lane 2: HMM 
(2 µg) (220 kDa) after digestion of myosin II with papain. 
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2.3 Methods for functional protein analysis 
2.3.1 In vitro-motility assay (gliding filament assay)  
For studying the translocation of actin filaments by myosin, rhodamine phalloidin-
labelled actin was exposed to immobilized myosin in a flow cell (figure 27). The flow cell 
was filled with myosin at different concentrations (diluted in AB--buffer) and the myosin 
allowed to adhere to the nitrocellulose or nitrocellulose and antibody treated surface of 
the cell by incubating for 2 to 3 min. After this step the flow cell was washed with 2-3 
volumes of 1 mg/ml BSA in AB--buffer. The last volume was allowed to incubate for at 
least 2 min to block unspecific binding. The flow cell was then washed with diluted 
rhodamine phalloidin-actin in AB-/BSA which was allowed to bind for 1 to 2 min. Before 
the motility assay was started, AB--scavenger solution was added and the cell was placed 
on the microscope stage and observed using either a 60x or 100x TIRF objective. To start 
the actual motility assay AB+-scavenger solution was added and if motility was observed 
movies were recorded using a CCD camera system on the microscope (Sellers 2001) 
(figure 27 B). 
 
Figure 27: Schematic picture of a motility assay using myosin VI, (A): note that myosin VI does not move on 
nitrocellulose but needs to be bound to an antibody, (B): typical field of view with Rh/Phalloidin labelled actin 
filaments bound to myosin VI; scale bar: 20µm 
The AB- and AB+ solutions were degassed prior to use in order to reduce the 
concentration of dissolved oxygen and thus additional bleaching effects on the 
fluorophores. Following degassing, solutions were stored in 10 ml syringes to slow down 
the diffusion of oxygen. Smaller volumes (1 ml) of oxygen scavenger solutions were 
made using the degassed AB- and AB+ stock solutions; these were also stored in syringes. 
All solutions were kept on ice. 
The oxygen-scavenging system was included to keep photo-bleaching low. In this system, 
glucose-oxidase catalyses the oxidation of D-glucose to form D-glucono-1,5-lactone and 
hydrogen peroxide. Hydrogen peroxide would severely damage the motor proteins, so 
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that catalase is used to decompose the hydrogen peroxide to water and oxygen (figure 
28). 
 
Figure 28: Reaction of the oxygen-scavenging system used in in vitro motility assays. To avoid photo-bleaching of 
the sample during acquisition, an oxygen-scavenging system containing glucose, glucose-oxidase and catalase was 
used. 
Data was obtained with time-lapse movies where one picture was taken every 10 s for at 
least 2 min, under TIRF illumination using a 543 nm laser. Data was analysed using the 
GMimPro package (see chapter 2.4) and filaments where tracked by hand. Motility assays 
were performed with protein from at least three different preparations and at least four 
flowcells per setting. 
Myosin VI has shown no movement in normal assay buffer and therefore all myosin VI 
motility assays were performed using Myosin VI motility buffer and at 32 °C. 
AB+: 25 mM Imidazole, 25 mM KCl, 4 mM MgCl2, 1 mM EGTA, 2 mM ATP 
AB-: 25 mM Imidazole, 25 mM KCl, 4 mM MgCl2, 1 mM EGTA 
AB--scavenger: As for AB+, including 0.02 mg/ml catalase, 0.1 mg/ml glucose oxidase, 
3 mg/ml glucose, 20 mM DTT 
AB+-scavenger: As for AB--scavenger including 2 mM ATP. 
Myosin-VI-motility buffer: 20 mM Tris-HCl (pH 7.5), 20 mM Imidazole, 25 mM NaCl, 
5 mM MgCl2, 1 mM EGTA, 10 mM DTT, (+5 mM ATP for AB+-scavenger ) 
 Removal of dead heads 2.3.1.1
Dead heads, which only bound actin but did not show the ability to hydrolyse ATP and 
thus stayed in the rigor state on actin, could be removed from the stock solutions before 
use. This can greatly improve the quality of the motility. The motor protein was mixed in 
a 5:1 molar ratio with F-actin in 1x AB+ solution (total volume 200 µl). An ultracentrifuge 
spin at 100k rpm for 15 min at 4 °C followed. The dead heads would remain bound to 
actin and therefore pellet, whilst the functional heads remained in the supernatant. 
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AB+: 25 mM Imidazole, 25 mM KCl, 4 mM MgCl2, 1 mM EGTA, 2 mM ATP 
 N-Ethylmaleimide myosin (NEM-myosin) 2.3.1.2
NEM myosin is chemically inactivated muscle myosin II that still binds to actin and was 
produced for tethering and immobilisation purposes in gliding-filament assays. Already 
extracted myosin II (in glycerol) was pipetted into an adequate tube and H2Odd. After 
centrifugation at 13k rpm for 6 min the supernatant was discarded and 2x High Salt buffer 
was added. To this mixture n-Ethylmaleimide was combined and the mixture was left to 
incubate for 75 min at room temperature (RT). Addition of 1 M DTT and fresh H2Odd 
was followed by a centrifugation step at 13k rpm for 6 min. The pellet was washed with 
2x High Salt buffer and after a final centrifugation, the supernatant, containing the NEM 
myosin was kept on ice until used. 
2.3.2 ATPase 
 NADH-coupled assay  2.3.2.1
ATPase activity was determined in a coupled enzymatic assay (De La Cruz and Ostap 
2009) (figure 29). In this assay, ATP hydrolysis is linked to the oxidation of NADH, 
which is measured spectroscopically at 340 nm by its decrease in concentration. The 
coupling takes place via phosphoenol pyruvic acid (PEP), pyruvic acid kinase (PK) and 
lactate dehydrogenase (LDH), which is referred to as ATP regenerating system.  
 
Figure 29: Schematic of the coupled enzymatic steady-state ATPase assay. Myosin hydrolyses ATP to ADP and 
inorganic phosphate, while simultaneously the regenerating system recycles the generated ADP back into ATP. 
Therefore, the system maintains a steady-state ATPase of myosin. Via the enzymatic action of pyruvate kinase (PK), 
for each ATP molecule generated, one NADH molecule is oxidized by lactate-dehydrogenase (LDH) to NAD+. The 
resulting decrease in absorption can be measured at 340 nm.  
To study the filament-stimulated ATPase activity of the assayed motor protein, 
measurements at different F-actin concentrations were carried out. With the output value 
of absorption (A) in OD (optical density) per second, the molar absorptivity (ε) of NADH 
Material and Methods 
69 
at 340 nm and the diameter of the well, the NADH concentration in the activated ATPase 
assay can be determined by applying the law of Lambert-Beer (see Equation 4). 
𝐴𝜆 = 𝜀𝜆 ∗ 𝑚 ∗ 𝑎 
Equation 4: (Haid, Lehmann et al. 1975) 
Where ε (NADH at 340nm) = 6.22 Mol-1*cm-1 and d = 0.3125 cm. The amount of NADH 
that is oxidised per second corresponds to the amount of hydrolysed ATP per second, 
which in turn reflects the maximal rate of ATP hydrolysis (Vmax). Km expresses the motor 
concentration that yields the halfmaximal reaction rate.  
kcat or the catalytic constant expresses the number of hydrolysed ATP molecules per 
motor head (or motor dimer) per second, and was calculated according to Equation 5. 
𝑘𝑐𝑐𝑐 =
𝑎𝐴𝐴𝑃 ∗ 𝑚−1
𝑎𝑚𝑚𝑚𝑚𝑚𝑚
 
Equation 5 
The standard mixture consisted of 10 µl PEP (600 µM), 6 µl NADH (360 µM), 3 µl ATP 
(3.78 mM) and 3 µl of PK/LDH, following the protocol from De La Cruz and Ostap 
(2009). Then 100 nM myosin was added as well as a defined amount of F-actin, ranging 
from 0-25 µM in concentration. 
 HPLC based assay 2.3.2.2
Since ATPase forms ADP from ATP through Pi release, measurement of ADP can be 
used as an alternative for the assay of ATPase activity. On the basis of this consideration, 
high-performance liquid chromatography (HPLC) was used to measure ADP derived 
from ATP by the enzymatic reaction of the ATPase myosin (figure 30). 
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Figure 30: HPLC data curves from ATPase measurement of myosin II S1 fragment. ATP peak appears after 4 min 
elution and corresponding ADP peak at 3.6 min. Brown curve indicates the starting ATP concentration at 0 min 
reaction time, grey: 5 min, light blue: 10 min, green: 15 min, pink: 20 min and dark blue: 30 min.  
The components ATP (2 mM), myosin (100 nM) and actin (varying concentrations from 
0-25 µM) were mixed together with buffer to make up a final volume of 200 µl, then 
20 µl were removed at different time points, mixed with 2µl 1 N HCl and 378 µl of the 
HPLC buffer, to stop the reaction and precipitate the protein. To remove the precipitant, 
the tubes were centrifuged at 10k rpm for 10 min in a table top centrifuge at RT. The 
samples were loaded on the HPLC and assayed with a flow rate of 0.2 ml/min for 10 min 
over a PL-SAX column (1000 Å, 8 µm). PL-SAX columns are ideal for the anion-
exchange HPLC separations of proteins and deprotected synthetic oligonucleotides under 
denaturing conditions. In addition, the anion exchange capacity is mostly independent of 
pH. 
HPLC buffer: 0.2 M (NH4)2HPO4 pH 4.0 
Assay buffer for myosin VI ATPase assays (KMg50): 50 mM KCl, 1 mM MgCl2, 1 mM 
EGTA, 1 mM DTT, 10 mM Imidazole, pH 7.0 
Assay buffer for myosin II S1 ATPase assays (PIPES): 10 mM PIPES, 2 mM MgCl2, 
pH 7.0 
2.3.3 Dot Far-Western Blot 
Dot Far western blots are a form of western blot to detect protein:protein interactions 
(Ohba et al. 1998, Mahlknecht et al. 2001). The “prey” protein was spotted directly onto 
a nitrocellulose membrane (Amersham Biosciences) and left to dry up to 30 min. After an 
incubation step of 1 h in blocking buffer, the membranes were submitted to a 1 h wash 
Material and Methods 
71 
with the “bait”-protein in a dilution of 1:2000. During this time the tagged protein could 
bind to the proteins spotted on the nitrocellulose surface. After several washing steps with 
TBST buffer, the adequate antibody for the “bait”-tag was added to fresh blocking buffer 
for an additional hour. Washing of the membrane in TBST for 3-5 times was then 
followed by final detection using an ECL detection kit (BioRad). 
TBST buffer: 50mM Tris-HCl , pH 7.5, 150mM NaCl, 0,1 vol% Tween20 
2.3.4 Liposome preparation 
For liposome production a range of natural lipids were used: Phosphatidylcholine (PC), 
Phosphatidylethanolamine (PE), Cholesterol, Phosphatidylinositol (4,5)-bisphosphate 
(PIP2), Phosphatidylinositol (3,5)-bisphosphate (PI(3,5)P2) and Phosphatidyl-4-phosphate 
(PI(4)P) (figure 31). 
 
Figure 31: Structures of main lipid components. (A): Phosphatidylethanolamine (PE), (B): Phosphatidylcholine 
(PC), (C): Cholesterol, (D): Phosphatidylinositol (4,5)-bisphosphate (PI(4,5)P2, PIP2), (E): Phosphatidylinositol (3,5)-
bisphosphate (PI(3,5)P2), (F): Phosphatidyl-4-phosphate (PI(4)P). All structures originate from Avanti Lipids® website. 
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 Liposome preparation by extrusion 2.3.4.1
Stock solutions of lipids were stored at -20 °C in chloroform. Every mixture of lipids was 
treated equally, despite slight changes in thawing temperature. As a first step to produce 
liposomes (figure 32) the chloroform was evaporated using a Bachhofer® vacuum-
concentrator system. After evaporation the lipid cake was redissolved in aqueous buffer 
(e.g. Lipidbuffer) and subjected to a minimum of 5 freeze/ thaw cycles in liquid nitrogen 
and a water bath at 50 °C. After a brief sonication step in the sonicator bath, the emulsion 
was extruded through a 100 nm pore filter in an Avanti Lipid Mini Extruder for 11 to 21 
cycles. 
Lipidbuffer (Spudich et al. 2007): 20 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM DTT 
 Liposome preparation by sonication 2.3.4.2
Lipids and lipid mixtures were generally treated as before, with the difference, that 
instead of extruding them, they were subjected a 10-15 min long sonication in the 
sonicator bath. This method was preferred since no defined size of liposomes was crucial 
for the used assays (e.g. co-sedimentations). 
 Composition of lipids in liposomes 2.3.4.3
Following the protocol of Spudich et al. (2007), Phosphatidylinositol containing 
liposomes were made from 40% PE, 40% PC, 10% Cholesterol and 10% of a variable 
phosphoinositol, treated as above (2.3.4.1) before resuspension by sonication in 
Lipidbuffer to a final concentration of 1 mg/ml. This amounts to a total of 0.02 mg/ml 
PIP. These mixes were treated as for extrusion or sonication but with a higher thaw 
temperature of 60 °C due to the fact that Cholesterol did not go into solution below this 
temperature but formed white flakes. 
2.3.5 Protein-Lipid-Overlay Assay (PLO) 
Lyophilized lipids (in this case PC, PE and folch I (folch)) were reconstituted to 1 mM 
stocks in chloroform (despite the folch, which, as a mixture, was dissolved at 1 mg in 
1.5 ml) and stored at -20 °C until usage. According to Dowler et al. (2000) and Dowler et 
al. (2002) the lipids were diluted to three different concentrations (500, 350 and 200 µM). 
1µl drops of the dilutions, which contained 200 to 500 pmol of lipid, were spotted on a 
nitrocellulose membrane (Hybond-C extra, Amersham Biosciences) and allowed to dry 
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for 1 h at RT. Additionally 0.5 µl of the protein was spotted on the membrane as a 
control. The membrane was then incubated with gentle rocking for 1 h in Blocking Buffer 
at RT. Subsequently the membrane was incubated overnight at 4 °C with gentle rocking 
in fresh Blocking Buffer containing the target His-tag protein that was diluted to 5-
10 nM. On the next morning the membrane was washed 10 times over 50 min in TBST. 
Afterwards the membrane was incubated for another hour at RT with gentle agitation 
with a 1:2000 dilution of the appropriate antibody (e.g. Anti-6X His-tag® antibody (HRP) 
#1187, abcam) in fresh Blocking Buffer (figure 32). The washing step with TBST was 
repeated. The lipid binding protein bound to the membrane was detected by utilising a 
standard ECL detection kit (e.g. Novex® ECL Chemiluminescent Substrate Reagent Kit) 
following manufacturer’s instructions. 
 
Figure 32: Protein-lipid overlay assay (PLO). (A): overview over the method of preparing a (PLO) by spotting serial 
dilutions of lipids in chloroform onto the nitrocellulose membrane. After drying, the membrane is washed with the 
target protein which is subsequently detected by antibody binding and chemiluminescence detection. (B): layout of 
typical blot with serial dilutions of the target lipids of 500 pmol, 350 pmol and 200 pmol per spot. 
 
2.3.6 PIP Strips/Membrane Lipid Strips® (echelon inc.) 
These nitrocellulose strips are prespotted with a range of different phosphatidylinositols 
and/or the most important membrane lipids (figure 33). The principle follows the Protein-
overlay-assay but is much shorter, due to a higher sensitivity. The membrane was gently 
agitated throughout the process. The membrane was blocked with 5 to 10 ml Blocking 
Buffer for 1 h at RT. After discarding the Blocking Buffer, a standard dilution of 1:1000 
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of the sample protein was added in 5 ml of fresh Blocking Buffer and again the 
membrane is incubated for 1 h. The membrane then was washed thrice with TBST for 
5 to 10 min each. The wash solution was discarded and replaced by fresh Blocking Buffer 
with appropriate antibody (see 2.3.5) in a 1:2000 dilution. In this solution the strip was 
again incubated for 1 h. The washing step with TBST was repeated. The lipid binding 
protein bound to the membrane was detected by utilising a standard ECL detection kit 
(e.g. Novex® ECL Chemiluminescent Substrate Reagent Kit) following manufacturer’s 
instructions. 
Blocking Buffer: 50 mM Tris HCl (pH 7.5), 150 mM NaCl, 0,1% (v/v) Tween 20, 
2 mg/ml Fatty-acid free BSA 
TBST: 50 mM Tris HCl (pH 7.5), 150 mM NaCl, 0,1% (v/v) Tween 20  
 
Figure 33: Pre-spotted Membrane- and PIP strips. Membrane Strips comprise the most abundant and important 
membrane lipids whereas PIP Strips show the seven different species of phosphatidylinositolphosphates and seven 
other biologically important lipids (echelon™). 
 
2.3.7 Lipid-affinity co-sedimentation 
Protein (varying concentrations) and 0.2 mg/ml liposomes were mixed in a total reaction 
volume of 125 µl. This resulted in a total PIP concentration of 18.21 µM per reaction tube 
where phosphatidylinositolphosphates were used. After adding buffer and target protein 
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to the ultracentrifugation tube, the lipid mixture was added and the solution left to stand 
on the bench for 10 min. The centrifugation step, to pellet the liposomes and possibly 
bound protein, was carried out in a MAX-XP table top ultracentrifuge (Beckman-
Coulter ®) at 160k x g for 20 min at 4 °C. After centrifugation the supernatant was 
removed and collected in a reaction tube. The pellet was dissolved in 125 µl Lipidbuffer 
and collected in a separate tube. After denaturing the samples with SDS buffer at 98 °C 
for 5 min, a SDS-PAGE was performed to see if the protein fraction could be found in the 
pellet and therefore was bound to the formerly added lipid (figure 34). 
 
Figure 34: SDS-PAGE a co-sedimentation experiment utilizing liposomes as pull-down “weight”. Lane 1: 
molecular markers (kDa), lane 2: Supernatant fraction of myosin VI spun down only with buffer, lane 3: pellet fraction 
corresponding to lane 2; lane 4: Supernatant fraction of myosin VI spun down together with folch fraction I (folch) 
liposomes; lane 5: pellet fraction corresponding to lane 4, lane 6: Supernatant of myosin VI spun down with folch and 
additional 50 µM CaCl
2
, lane 7: pellet fraction corresponding to lane 6. 
 
2.3.8 Gliding-filament assay on lipid surfaces 
For a deeper insight into the protein:lipid interactions a variation of the abovementioned 
motility assay was performed. The nitrocellulose-covered surface was washed with one 
flow-cell volume of 1:20 diluted lipid suspension and left to incubate for 10 min at RT so 
the lipid molecules could adhere to the surface. Afterwards the surface was blocked with 
a 3-4 flow-cell volume wash of AB-/BSA to inhibit unspecific binding to the surface. 
Following this step myosin was flushed through the cell and the motility assay was 
performed as mentioned above (figure 35). 
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Figure 35: Gliding filament assay on nitrocellulose-bound lipid surface, due to the nitrocellulose the lipids do not 
form a fluid lipid bilayer but an unordered monolayer on which the protein can move actin filaments. 
 
2.3.9 Fluorescence Recovery after Photobleaching (FRAP) 
To quantify the absence two-dimensional lateral diffusion of the lipid surface used in the 
motility assays, a FRAP check was performed. For this purpose fluorescently labelled PE 
was incorporated into the lipid mixture (Lissamine®-PE) and the flowcell was prepared as 
described in 2.3.8. Then a region of interest (ROI) was defined on the confocal 
microscope and a laser pulse of 10 sec with a 405 nm laser was applied to this area. After 
this the recovery was recorded with a 554 nm laser for 2-5 min (figure 36). 
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Figure 36: FRAP experiments for quantification of lateral diffusion in lipid surfaces. (A) Typical bilayer surface 
before and after photobleaching with the corresponding FRAP answer (B). Inset shows surface without fluorescence 
recovery. 
 
2.3.10 Actin-affinity Co-sedimentation 
The procedure for co-sedimentations with actin followed the same protocol as with lipids 
(see 2.3.7), but using actin as the pulldown ‘weight’. Typically 5 µM actin was added to a 
total reaction volume of 125 µl and varying concentrations of myosin constructs. For the 
actin pellet was very sticky, it had to be carefully scraped off the sides of the 
centrifugation tube with the tip of a pipette.  
2.3.11 Co-sedimentation with ligand-coupled magnetic beads 
 His-tagged protein co-sedimentation with Dynabeads®  2.3.11.1
For detection of protein:protein interactions without the need of actin or liposomes as 
pull-down reagent, superparamagnetic beads (Dynabeads®, novex life technologies) were 
used as one alternative system. They are coated with a cobalt-based surface and allow fast 
binding of the His-tagged protein. The protocol was followed according to manufacturer’s 
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instructions. In short, the 6x His-tagged target protein was added to the previously 
washed beads in Binding/Wash buffer and incubated for 10 min at RT on a rotating 
platform. Then, after thorough washing were the beads were held down with a magnet 
and the supernatant was removed and fresh buffer added, the differently tagged protein 
was added to the protein: beads complex in Pull-down buffer and incubated at RT on a 
rotating platform for 30 min. After four washing steps with Binding/Wash buffer, 100 µl 
His Elution buffer were added and the suspension was subjected to a further incubation of 
5 min on the rotary shaker. The beads were now collected at the tube wall and the 
supernatant contained the eluted histidine-tagged protein and its interacting protein. A 
SDS-PAGE and if necessary a western blot were run for detection of proteins. 
Binding/ Wash buffer: 50 mM Sodium Phosphate pH 8.0, 300 mM NaCl, 
0.01% Tween 20 
His Elution buffer: 300 mM Imidazole, 50 mM Sodium Phosphate pH 8.0, 300 mM NaCl 
Pull-down buffer: 3.25 mM Sodium Phosphate pH 7.4, 70 mM NaCl, 0.01% Tween 20 
 
  GST-tagged protein co-sedimentation with MagneGST® 2.3.11.2
Detection of interactions between a GST-tagged construct and a non-tagged or His-tagged 
protein was performed with the MagneGST® (Promega) bead system. The system works 
in general similar to the Dynabeads® pull-down system but with a high affinity to GST. In 
short, after washing the beads in PBS the GST-tagged protein was added with an addition 
of 1% BSA to reduce unspecific binding and then incubated for 30 min at RT on a 
rotating platform. Then the suspension was subjected to several washes in PBS before the 
HIS-or differently tagged sample and 10% BSA were added. Another incubation step of 
1 h on a rotating platform was followed by a vigorous vortexing step to remove non-
specific adherent protein. Several washes in PBS followed and finally 20 µl of 
2x SDS buffer were added directly onto the sample containing bead-bound and 
interacting proteins. After the sample was boiled for 5 min at 98 °C the beads were 
removed and a SDS-PAGE or, if necessary a western blot was performed. 
2.3.12 Densitometry  
For further characterisation of binding in co-sedimentation assays, supernatant and pellet 
fractions were analysed on SDS–PAGE (10 or 15% acrylamide) gels using prestained 
broad-range standards (Applichem) for calibration. Gels were analysed using the 
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ImageLab® software and the ChemiDoc XRS+ (BioRad). The intensity of the tail or full-
length band in the pellet was divided by the total intensity (pellet + supernatant) for each 
sample to determine the percent of protein in the pellet. Background subtraction was 
automatically performed by the software. 
2.3.13 Calmodulin affinity titrations 
Titrations of target peptide sequences with Calmodulin or Calmodulin-like proteins were 
performed at 20 °C in titration buffer, using a Varian Cary Eclipse fluorescence 
spectrophotometer with the excitation wavelength λex = 290 nm and emission wavelength 
λem = 323 nm.The dissociation constants Kd for the tryptophane (Trp)-containing peptides 
were determined by direct titration, and the data was analysed as described in Martin and 
Bayley (2004). For titrations 2 µM peptide was used. Calmodulin was purified over His-
tag affinity columns (see section 2.2.6) and then dialysed into either the calcium buffer or 
EDTA buffer (see below). Titrations were carried out by adding approximately 0.1 µM 
Calmodulin per injection for more than 20 injections. The proportion of the signal 
attributed to Calmodulin alone was determined by continuing the titration to much higher 
ratios to a large excess of Calmodulin. This was taken into account by the analysis (see 
2.4.1.1).  
Titration buffers: 25 mM Tris (pH 8), 100 mM KCl, and 1 mM DTT with 1 mM CaCl2 or 
0.2 mM EDTA 
 
2.3.14 Size-exclusion chromatography (SEC) 
SEC is a good means to separate molecules according to differences in size as they pass 
through a gel filtration medium (porous matrix) packed in a column. Unlike ion exchange 
or affinity chromatography, molecules do not bind to the chromatography medium so 
buffer composition does not directly affect the degree of separation between peaks. 
Purified proteins (∼30–50 μM) were loaded onto a Superdex-200 prep-grade (10/300 GL) 
analytical column (GE Healthcare) or a Superose-6 column (10/300 GL). They were 
pumped through with a flow rate of 0.5 ml/min. The native molecular weight of the 
proteins was calculated from their Stokes radius (Dutta et al. 2001) measured by SEC 
(figure 37). The partition coefficient Kav for standard proteins was calculated as follows 
(Ohno et al. 1986): 
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𝐾𝑐𝑎 =
𝑉𝑒 − 𝑉𝑚
𝑉𝑐 − 𝑉𝑚
 
Equation 6: calculation of partition coefficient for standard proteins on size exclusion chromatography columns.  
Were Ve is the elution volume of the protein, Vo the void volume and Vc the total volume 
of the column. 
SEC buffers: 
GF150: 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM DTT 
GF500: 50 mM Tris-HCl (pH 7.5), 500 mM NaCl, 1 mM DTT 
 
Figure 37: Calibration curves for Superdex-200 (Prep-grade) and Superose-6 columns. Thyroglobulin, ferritin, 
aldolase, ovalbumin and myosin II were used as calibration proteins. Kav stands for the partition coefficient which takes 
retention time and void volume into account and serves as normalisation. The Einstein-Stokes radius gives the effective 
hydrated radius of a protein in solution. 
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2.4 Data analysis  
1. Quantitation of data obtained from lipid- and actin-affinity co-sedimentation 
Band intensities and the respective supernatant and pellet fractions were determined with 
the digital gel-analysis software ImageLab (Version 5.0, BioRad). The obtained intensity 
of the tail band in the pellet was divided by the total intensity (pellet + supernatant) for 
each sample to determine the percent of protein in the pellet) (Spudich et al. 2007). 
2.  Fluorescence microscopy data analysis: Gliding-filament motility measurements 
Only those filament-gliding events where the transport of an individual filament lasted for 
longer than ≥ 3 frames and remained uninterrupted during that time period were taken 
into account. The gliding velocity of individual actin filaments was recorded using the 
NIS Elements AR software package (Nikon) and determined using ImageJ (NIH, 
Bethesda, USA) and the GMimPro software (Dr Gregory Mashanov, MRC NIMR, 
London, UK). 
3. Protein purification and gel-filtration 
All FPLC data was obtained and analysed using the Unicorn software package by GE 
healthcare.  
4. Analysis of data obtained from ATPase assays on actin 
Actin-activated ATPase activity of myosin VI and myosin II was determined in a 
coupled-enzymatic assay and an HPLC based assay (chapter 3). The data were analysed 
using Microsoft® Excel and SigmaPlot® packages. Preliminary data analysis of the HPKC 
obtained data was carried out with the supplied Galaxie Software pack (Version 1.9, 
Varian) and then with Microsoft® Excel and SigmaPlot® packages. 
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2.4.1 Fitting routines and statistics 
 CaM-Titrations 2.4.1.1
The direct fluorometric titrations of the tryptophan-containing peptides (IQ1 and IQ2) 
with a calmodulin (C) were fit to the following equation:  
Fluorescence signal = F (C) [C] + F (W) [W] + F (CW) [CW] 
Equation 7 
where the F values are the molar fluorescence intensities and C and W the contributions 
of calmodulin (C) and the IQ motifs (W) to the fluorescence signal. A value for the 
dissociation constant (Kd(W)) was obtained from a nonlinear least squares fit to this 
equation with concentrations calculated by solving: 
[CW] 2 − (Kd (W) + CT+WT)[CW] + CTWT = 0 
Equation 8 
where the subscript T denotes total concentrations. We also included a factor (X(W)) in 
the fitting equation to correct for errors in the peptide concentration (i.e., actual 
concentration WTX(W)). Titrations with X(W) < 1.1 or with X(W) < 0.9 were rejected 
(Martin and Bayley 2004). 
 ATPase assay 2.4.1.2
As biocatalysts enzymes A form with the substrate B a complex AB which reacts to form 
the product P:  
A+B ⇌ [AB] ⇌ [AP] ⇌ P+A 
 
k1 and k-1 are the rate constants for association of A to B and for the dissociation of the 
AB complex respectively. k2 and k-2 are the constants for the reaction to form a product 
and the back reaction to the substrate respectively. k3 and k-3 describe the association and 
dissociation of an enzyme-product complex. Since this reaction does not happen directly 
after mixing the enzyme with the substrate k-3 = 0. Additionally the turnover from AB to 
AP is measured and not the release of P. Therefore the whole reaction can be simplified 
further and the following equations (9 and 10) can be applied.  
k1 
k-1 
 k2 
k-2 
k3 
k-3 
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The experimental conditions in the ATPase experiments are altered to pseudo-first order, 
where one reactant (A) is used in large excess (min. 5-fold) over the concentration of the 
second reactant (B). This ensures that the concentration of the first reactant remains 
virtually constant over the time of the reaction. In these reactions one step of the reaction 
needs to be faster than the other step in order to be able to determine between the two 
steps (ATP binding and ATP hydrolysis). Under these conditions the observed rate 
constant v shows hyperbolic dependence on the concentration of the second reaction 
partner B and a plot of v as a function of the concentration of B can be fitted to a 
hyperbola (Geeves et  al. 1992). 
𝑣 =  
𝑣𝑚𝑐𝑚[𝐵]
𝐾𝑀 [𝐵]
+ 𝑘𝑚𝑜𝑜  
Equation 9: Hyperbolic fit for ATPase reactions 
Where the equilibrium constant Ki for each (reverse) step is defined as kforward/kbackward 
constant: Ki = k+i/k-i. 
With vmax defined as the maximal rate constant (=𝑘+2 + 𝑘−2, however since 𝑘−2 is very 
small, vmax can be simplified to =𝑘+2) and 𝐾𝑀, the Michaelis constant, gives the 
concentration of B required to reach the half maximal of vmax (= 1/k1) and koff (=k-2) is the 
overall dissociation rate constant. The initial linear part of the hyperbola is defined by the 
slope which is equal to 1
𝐾𝑀
𝑣𝑚𝑐𝑚 . 
A direct measure of the catalytic production of product under optimum conditions 
(saturated enzyme) is measured with the turnover number kcat: 
𝑘𝑐𝑐𝑐 =
𝑣𝑚𝑐𝑚
[𝐴] + [𝐴𝐵]
 
Equation 10: Equation for the calculation of kcat 
 
 Statistical tests 2.4.1.3
For evaluation of statistical significance two-tailed t-tests were performed. Where 
significant differences below the significance level of p = 0.05 were calculated, they are 
given as p-values in the text.  
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3.1 Determination of the basal ATPase activity in 
myosin VI 
This chapter investigates the basal kinetics of myosin VI ATPase as a quality-check of the 
protein preparations used throughout the study with myosin II S1 as control. Two 
different methods for measuring the ATPase rates of the myosins are introduced. 
3.1.1 Generating myosin II S1 constructs for standard measurements 
The head or motor domain of myosin is a highly specialised ATPase which converts the 
energy derived from the hydrolysis of ATP into mechanical work. Since myosin II and its 
ATPase activity are well described, it was used in this thesis as a standard for verifying 
and validating measurements. Myosin II S1 constructs were produced by papain digestion 
of myosin II HMM (see 2.2.15). Figure 38 summarises the digestion process and shows 
corresponding SDS-PAGE pictures of the resulting constructs. 
 
Figure 38: Enzymatic digestion of myosin II to HMM and S1 fragments. Essential (ELC) and regulatory (RLC) 
light chains are depicted in red and yellow respectively. Gel pictures show examples of correspondent constructs. 
Modified after Lodish (2001). 
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3.1.2 Generation and purification of myosin VI full-length construct 
For ATPase measurements of myosin VI a full length construct (VI FL) was expressed 
using the Sf21 baculoviral expression system (see 2.1.12). The VI FL splice variant from 
chicken used in this thesis contains the large insert (LI) with no small insert (see 1.4). 
 
Figure 39: Generation and purification of myosin VI FL protein. (A): schematic of myosin VI FL, (B): SDS-PAGE 
of elution fractions corresponding to C (C): elution curve from FPLC (Äkta, GE). Number gives percentage of His-high 
buffer in the elution mix (see 2.2.6 for further information). 
Figure 39 shows a typical purification profile of VI FL protein with a SDS-PAGE of the 
eluted fractions. The protein preparations of myosin VI used in this study were checked 
for their stability and monomeric state using size exclusion chromatography (SEC). As 
figure 40 shows myosin VI ran as a single peak. Myosin II HMM (350 kDa) which is a 
dimer consisting of two motor domains, four IQ domains with four light chains and a 
short tail elutes at ~ 9 ml elution volume whereas myosin II S1 (106 kDa) with its single 
motor domain and one IQ with one light chain bound elutes at 12 ml elution volume. This 
proved that myosin VI was indeed a monomeric protein and never showed a shift in 
elution. The Stokes radius or Stokes-Einstein radius of a solute is the radius of a hard 
sphere that diffuses at the same rate as that solute. It is closely related to solute mobility, 
factoring in not only size but also solvent effects. A smaller ion with stronger hydration, 
for example, may have a greater Stokes radius than a larger but weaker ion. The Stokes 
radius of myosin VI is 6 nm, as figure 40 shows. 
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Figure 40: FPLC Superdex-200 prep grade gel filtration of myosin VI. (A) Typical elution profile of myosin VI on 
a Superdex 200 column. (B) Calibration curve of the Superdex 200 gel filtration column using standard proteins of 
known Stokes radii: (Ch) chymotrypsinogen A, 2.1 nm; (O) ovalbumin, 3.1 nm; (B) BSA, 3.6 nm; (A) aldolase, 4.8 nm, 
(C) catalse, 5.2 nm; (F) ferritin, 6.1 nm; (T) thyroglobulin, 8.5 nm. The elution position of myosin VI is shown, giving 
it a Stokes radius of 6 nm (modified after: Lister et al. (2004)). 
 
3.1.3 ATPase activity of myosin II S1 and myosin VI 
Actin-activated ATPase activity of both myosin VI and S1 was determined with 100 nM 
motor protein (different preparations, in KMg50 buffer for myosin VI and PIPES buffer 
for myosin II S1) using 0 to 30 µM F-Actin and 2 mM Mg∙ATP in a HPLC based assay 
as well as a NADH-coupled assay (for further details, see 2.3.2).  
 
Figure 41: Representation and schematic of the (A): principle of NADH-coupled assay and (B): example of HPLC 
based assay. The two peaks represent the elution peaks for ADP and ATP respectively. 
The NADH-coupled assay measures the ATP hydrolysis as a linked process. The ATP 
hydrolysis is linked to the oxidation of NADH, which is measured spectroscopically at 
340 nm by its decrease in concentration. The coupling takes place via phosphoenol 
pyruvic acid (PEP), pyruvic acid kinase (PK) and lactate dehydrogenase (LDH) (figure 
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41, A). The HPLC based ATPase assay (figure 41, B) only requires ATP, actin and 
myosin and is therefore a more direct way of measuring the ATPase activity compared to 
the NADH-coupled assay. In this assay myosin VI was mixed with actin and very pure 
ATP. The reaction was then stopped at different points in time of incubation with HCl 
acid. These samples were then centrifuged to rid the samples of the precipitated protein 
and measured on the HPLC where the ADP derived from ATP hydrolysis through myosin 
ATPase activity could be measured. 
 
3.1.4 Actin-dependent activation of myosin II S1 
The actin-dependent ATPase rate is an essential value to assess the activity of myosins. In 
figure 42 a clear actin-activation of the myosin II S1 fragment could be seen for both 
assays. The ATPase rate increased with higher actin concentration. kcat measures the 
number of substrate molecules turned over by enzyme molecule per second. It is therefore 
called the turnover number. The basal rate without actin was 0.1 s-1. The measured 
maximum kcat was 4.2 s-1 (±0.7) in the NADH-coupled assay and 6.7 s-1 (± 0.5) with the 
HPLC method. 
 
Figure 42: Actin-activated ATPase rate of myosin II S1. Filled circles represent average of 6 measurements with the 
NADH-coupled assay whereas empty circles represent average of 4 HPLC measurements. Both were performed with at 
least two different preps. 
For the NADH-coupled assay that equalled a 50-fold increase and for the HPLC based 
assay even an 84-fold increase of ATPase rate. After fitting the curves with kinetic 
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hyperbola fits, the actin filament concentration at half-maximal activation of the steady-
state ATPase was determined with KM-values of 29 µM (NADH-coupled) and 20.3 µM 
(HPLC based). Additionally vmax values of 8 and 13 s-1 were calculated respectively. 
Although values for vmax were not reached in the experiments, the rates above 20 µM 
actin levelled off and higher concentrations did not change the maximal measured rates. 
Due to the actin preparations available no higher concentrations than 30 µM could be 
tested. 
 
3.1.5 Actin-dependent activation of myosin VI 
The actin-dependent ATPase rates of myosin VI were used to measure the quality of 
myosin VI preparations. Figure 43 shows that the ATPase activity of myosin VI is actin-
activated. A basal rate of 0.45 s-1 and maximum rates of 3.6 s-1 (± 0.04) (NADH-coupled) 
and 2.5 s-1 (± 0.4) (HPLC) respectively were measured which equalled an 8-fold increase 
for the NADH-coupled and a 5-fold increase for HPLC based measurements of ATPase 
rate. 
 
Figure 43: Actin-activated ATPase rate of myosin VI. Filled circles represent average of 4 measurements with the 
NADH-coupled assay whereas empty circles represent average of 3 HPLC measurements. Both were performed with at 
least two different preps.  
KM values of 25 (NADH coupled) and 29 µM (HPLC) were calculated as well as 
maximum velocities vmax of 6 s-1 for both assays. Again the rates levelled off at 
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concentrations higher than 20 µM actin and even higher concentrations did not change the 
maximal measured rates. 
 
3.1.6 Discussion 
The rates measured with the myosin-II S1 in this study are lower compared to the 
published rates, which show considerable variation  ranging from 7.8 s-1 (Webb and 
Corrie 2001) over 18 s-1 (Kovács et al. 2004) to 29 s-1 (Trentham et al. 1976, Millar and 
Geeves 1983, Cremo and Hartshorne 2007). There are possible explanations to why the 
numbers show such variability: 1. used muscle types in preparations, 2. buffer conditions 
and 3. temperature. In previous publications the fast-twitch muscle (type II) m. psoas was 
used or a mixture of it and slow-twitch (type I) muscle m. soleus. We used a mixture of 
diverse muscles (e.g. m. quadriceps femoris, m. bizeps femoris, m. latissimus dorsae, m. 
glutaeus maximus, m. longissimus, m. splenicus, m. trapezius), leaving out the above 
mentioned m.psoas and m. soleus. All muscle-types used are more or less a mixture of 
type I and type II fibres. Our muscle material came from an old male breeder in contrast 
to 1 year old males used in ATPase based studies in the literature which as well may have 
an influence on ATPase performance.       
 All assays were performed at room temperature, which had an influence on the ATPase 
rate as well. However, similar ATPase rates (kcat = 6 s-1) as Webb and Corrie (2001) 
(kcat= 7.8 s-1) when using their buffer conditions (PIPES buffer) were obtained. This 
showed that differences in salt conditions and buffer substances as well as temperature 
have an influence on the obtainable maximum ATPase rates.    
 Calculated KM values of 20 µM to 29 µM were in the same range as published by 
Kovács et al. (2004) with 24 µM. Published ATPase rates for myosin VI range from 6 s-1 
(De la Cruz, Ostap et al. 2001) to 8.3 s-1 (Buss and Kendrick-Jones 2007). KM values of 
~18 µM (De la Cruz et al. 2001) were not reached in this study but it is most probable 
that the kcat of 3.6 s-1  obtained in this study were lower than the published rates, because 
of the lower temperatures used for our assays. All enzymes are sensitive to temperature, 
with different temperature optima. The optimal temperature for myosin VI seems to lie 
well above room temperature (21 °C), as will be shown later in chapter 3.3.7.2. 
 
Myosin VI regulation by folding back the tail 
91 
3.2 The myosin VI tail can fold back on itself as a 
regulative mechanism 
This chapter investigates the ability of the C-terminal tail of myosin VI to fold back onto 
the neck of the protein. Several actin-, lipid- and tag-affinity co-sedimentations show that 
the N-terminal 65 amino acids of the cargo-binding domain interact with the calmodulin 
that is bound to the IQ motifs in the neck. This interaction is not influenced by alterations 
of the calcium concentration. 
3.2.1 Purification and design of myosin VI motor truncations and tail constructs 
The cargo-binding-domain (CBD) of myosin VI is a 198 amino acid globular domain, 
which has been suggested to be involved in the back-folding of the myosin VI tail and 
thus inactivating the protein in its monomeric state (Spink et al. 2008, Spudich and 
Sivaramakrishnan 2010). To dissect the contribution of the CBD to the back folding 
process and to define the interaction site N-terminally of it (in addition to the full-length 
construct) five tail constructs and three motor truncations of different lengths were 
designed (figure 44). These tail constructs (amino acids 814-1258, aa 913-1258, aa 814-
1060, aa 1060-1258 and aa 1125-1258) allowed the flexibility to ex-or include regions 
and domains in experiments and enabled me to screen for interacting regions in a step-by-
step fashion. The motor truncations comprise the motor domain (aa 1-759) and the unique 
insert (Trunc814 aa 1-814), the second IQ-motif and lever arm extension (Trunc913 aa 1-
913) and the predicted coiled coil region (Trunc1060 aa 1-1060) respectively. 
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Figure 44: Schematic representation of myosin VI motor truncation- and tail constructs. Motor truncations: 
Trunc814, Trunc913, Trunc1060; tail constructs: 814 tail, 913 tail, NCBD: Non-cargo-binding domain tail (aa 814-
1060), 1060 tail, 1125 tail and 883∆PIP tail (aa 883 to 1258) which comprises a point mutation in the PIP2 binding site 
and was only used in lipid binding studies.  
The eight different constructs were expressed and purified as specified before (see 2.1.13 
and 2.2.6). Figure 45 shows eluted and concentrated fractions of the various constructs. 
Typically, when expressing the constructs in Sf21 cells, protein concentrations ranged 
between 5 and 15 µM. Variability was much higher when expressions were performed in 
E. coli expression systems and ranged from 5 to 40 µM. The protein fractions were flash 
frozen in liquid nitrogen and stored at -80 °C.  
 
Figure 45: Gel pictures of all myosin VI motor truncations and tail constructs. Purified and concentrated samples 
of all tail constructs with exception of the 883 ∆ PIP are depicted on this gel. The ∆ PIP was left out because of its 
similar size to the 913 tail construct with approx. 48 kDa. 
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3.2.2 Myosin VI tail constructs exhibit unspecific actin-binding 
To test the capability to interact with the actin filament and with other tail constructs, the 
eight different constructs were assayed by an actin-affinity co-sedimentation assay 
(2.3.10). In this assay, actin and the respective construct were mixed and subsequently 
ultra-centrifuged. Thereby, protein constructs that did not bind to the filaments remained 
in the supernatant, while all filament-bound protein was present in the actin pellet. In 
addition to testing the affinity of the single constructs to actin, the eligible constructs were 
tested in combination with each other. Before being able to uncover the detailed 
interactions of the CBD with a region C-terminal of the motor, the binding affinities of 
the single tail and motor constructs to actin had to be assessed. Therefore individual 
constructs were subjected to actin-affinity co-sedimentation before mixing constructs 
together. Co-sedimentation mixes always contained 1-4 µM myosin VI construct and 
5 µM actin. Figure 46 summarises the performed control co-sedimentations. 
 
Figure 46: Control co-sedimentations of myosin VI constructs with actin. First row: motor truncations; second row: 
tail constructs. Due to different running times of gels there is a discrepancy between gels. Therefore the molecular 
weight marker is always pictured. Note that only 814 tail and 1125 tail do not bind actin. Actin is indicated with a. S 
and P stand for supernatant and pellet fraction respectively. All controls were performed at least three times. 
Actin pull-downs with the different constructs revealed that most of the constructs bound 
to actin, not only the motor truncations, but unexpectedly some tail constructs too. The 
1060 tail bound only partly to actin. Only the full length tail (814 tail), the shortest tail 
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construct (1125 tail)  and the 913 tail did not bind actin and could therefore be used in 
actin-based pull-down assays. 
 Myosin VI full-length tail folds back on itself 3.2.2.1
Having identified unspecific actin binding constructs the motor truncations and tails 814, 
913 and 1125 were the only usable constructs for these assays. With those six constructs a 
closer screening of the possible back folding of the myosin VI tail was performed. In 
these co-sedimentations actin was kept at 5 µM and the concentration of the truncations 
usually at 1 µM and the tail construct was added at 2 µM for the 814 and 3 µM for the 
1125 tail to keep one of the binding partners in a slight excess to completely saturate and 
allow for complete binding, if possible. 
 
Figure 47: Actin-affinity co-sedimentations of myosin VI motor constructs with 814 tail. Motor truncations with 
the longest tail construct 814 (A: Trunc1060+ 814 tail+ actin, B: Trunc913+ 814 tail+ actin, C: Trunc814+ 814 tail+ 
actin); + and – indicate if 814 tail is pulled over into the pellet fraction, a (+) means only a little amount is pulled over. 
S and P stand for supernatant and pellet fraction respectively. All experiments were performed twice. 
When the different motor truncations and the longest tail (814 tail) were subjected to 
actin-affinity co-sedimentations, most of the 814 tail remained unbound and therefore in 
the supernatant fraction (figure 47: A, B, C).  
When the 1125 tail was added to the different truncations, it became apparent that this tail 
construct showed no interaction with any of the presented motor truncations (figure 48 D, 
E, F). However, the binding behaviour of the shortest motor truncation was clearly altered 
by adding the 1125 tail construct to the pull-down as figure 48 F shows. Without the tail, 
this motor truncation bound 100% to actin, whilst with the 1125 tail, this complete 
binding seemed to be interrupted and the truncation was found in the pellet and 
supernatant fraction (figure 48 F, inset).  
Myosin VI regulation by folding back the tail 
95 
 
Figure 48: Actin-affinity co-sedimentations of myosin VI motor constructs with 1125 tail. Motor truncations with 
the shortest tail construct 1125 (D: Trunc1060+1125+actin, E: Trunc913+1125+actin, F: Trunc814+1125+actin). inset: 
shows the co-sedimentation behaviour of the Trunc814 construct when pulled down with actin. When the same co-
sedimentation was performed with the 1125 tail construct, this truncation shows an ambiguous binding behaviour, i.e. it 
is found in both supernatant and pellet. Due to different running times of gels there is a discrepancy between gels. 
Therefore the molecular weight marker is always pictured and actin is indicated with a as a size reference (42 kDa). S 
and P stand for supernatant and pellet fraction respectively. All experiments were performed four times. 
To determine the actual interaction of the 814 tail with a construct comprising the motor 
and neck domain, 814 tail was added in different concentrations (3-10 µM) to myosin 
full-length (FL) (2 µM) and actin (10 µM). As figure 49 displays, the full-length protein 
did not bind completely to actin at these concentrations, but it was verified that this 
preparation of protein did at lower concentrations (see figure 49 inset). And most notably, 
that the 814 tail construct does not alter binding behaviour even when added in a great 
excess to the assay. The amount of protein in the pellet, as measured with densitometry 
(see section 2.3.12), did not increase with rising amounts of total protein in the pellet. 
Small changes in the amounts in the pellet might be due to variations in the gels. 
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Figure 49: Densitometry of 814 tail binding to myosin VI full-length protein. Gel shows pull-down experiment with 
full-length myosin VI and a range of 814 tail construct concentrations pulled down by actin. A miniscule amount of the 
tail is pulled over into the pellet fraction by binding to the full-length protein without showing concentration 
dependence. Note that at these concentrations not all of the myosin VI is binding to actin but were chosen for better 
visibility of the proteins and their interactions. Inset: myosin VI (0.6 µM) binding completely to actin (5 µM) at lower 
concentrations. Graph displays amount of 814 tail in the pellet fraction. The intensity of the tail band in the pellet was 
divided by the total intensity (pellet + supernatant) for each sample to determine the percent of protein in the pellet. 
Error bars show standard deviation (n = 4). 
 
3.2.3 Lipid-affinity co-sedimentation with Myosin VI tail constructs 
Since some of the constructs did not have the capability to bind to actin because the actin-
binding site was missing, and some constructs showed unspecific actin binding, vesicles 
consisting of folch were used as pull-down agent. The protocol followed the actin-affinity 
co-sedimentations. All constructs where subjected to these pull-downs. But since 
interactions between motor truncations and tail constructs were of interest here, only 
those tail constructs that did not bind to folch vesicles could be further used in the co-
sedimentations. 
 Unspecific binding to folch liposomes 3.2.3.1
In the same manner as for the actin affinity a liposome affinity-check was performed. 
Since the motor truncations all bound actin and most of the tail constructs as well, a 
different pull-down system had to be found to assess interactions of constructs with each 
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other. In liposome affinity co-sedimentations 1-4 µM of construct were mixed with 
0.2 mg/ml of folch liposomes (see 2.3.4). Figure 50 shows details of all tail and motor 
constructs in interplay with the aforementioned liposomes. 
 
Figure 50: Control co-sedimentations of myosin VI constructs with folch liposomes. First row: motor truncations; 
second row: tail constructs. Note that only 814 tail did not bind folch vesicles. S and P stand for supernatant and pellet 
fraction respectively. All experiments were performed two to six times. Due to differences in gels a molecular marker is 
always depicted but sizes can be seen in figure 45. 
All motor truncations showed binding capability to folch vesicles. The shortest motor 
truncation (Trunc814) exhibited partial binding to folch (marked by (+) in figure 50). A 
similar result was observed for the tail constructs NCBD and 1125. Most notably, the 814 
tail did not bind to the provided pull-down substrate, whilst all other tail constructs bound 
liposomes, and was therefore the only tail construct that could be utilized in further pull-
down experiments with folch vesicles (figure 50). 
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3.2.4 The first 65 amino acids of the Cargo-binding domain interact with the neck 
 His/ GST-tag affinity co-sedimentations with Myosin VI tail constructs 3.2.4.1
For a closer screening for the actual back-folding site C-terminal of the motor domain, a 
different approach had to be used. Some constructs showed unexpected affinity for actin 
and had to be excluded from actin containing assays. To test these constructs for binding 
to other constructs, magnetic bead pull-down systems were utilised. Magnetic beads 
coated with a resin that exhibited high affinity for either His-or GST-tags were used to 
pull down one construct together with an untagged or differently tagged construct 
(see 2.3.11). 
After having exhausted the possibilities with actin-affinity binding, and finding that the 
1125 tail construct did not interact with the motor truncations and that the 814 tail did 
only to a very small extent, the 1060 tail construct in a pGex-6P-1 vector was designed 
and expressed to attach a gluthathione-S-transferase (GST)-tag to the tail (see section 
2.1.3). Since this construct bound to actin and liposomes on its own (see figures 46 and 
50), a GST-affinity pull-down system was utilized (see section 2.3.11) which 
circumvented the necessity for either actin or liposomes as pull-down agents. The GST-
tagged protein was bound to the magnetic beads (MagneGST®, promega), which 
exhibited a very high affinity for GST tags. From Spink et al. (2008) it was known that 
the flexibility for the back folding must lie “[…] somewhere N-terminal of the lever arm 
[…]”. Therefore the shorter motor truncations Trunc913 and Trunc814 were used to 
combine with the 1060 tail. 
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Figure 51: The 1060 tail construct binds to Truncations 913 and 814. Gel (A) first lane: molecular marker, second 
and third lane: truncation 913 was pulled down with the bead-bound 1060 GST construct; lanes 4 and 5: Trunc913 is 
not pulled down with pure GST, indicated by arrows; lanes 6 and 7: pure proteins as reference. Gel (B) first lane: 
molecular marker; second and third lane: Trunc814 is pulled down with the GST tagged 1060 tail construct; lanes 4 to 
6: pure proteins as reference, lane 7: trunc814 is not pulled down with pure GST. Note the additional band at 72 kDa 
(indicated with asterisks), which is an additional band from the GST. Experiment performed three times. 
As shown in figure 51, the 1060 tail interacted with the motor truncations 913 and 814. 
Controls revealed that the Trunc913 was not pulled down with pure GST. Therefore these 
two gels display clear interactions between Trunc913 and Trunc814 and the cargo-
binding domain (1060 tail). The 1125 tail construct on the other hand did not show any 
interaction with the longer motor truncation Trunc913 (figure 52). This indicated an 
involvement of the first N-terminal 65 amino acids of the cargo-binding domain in the 
back folding process (aa 1060-1125). 
 
Figure 52: The 1125 tail construct does not bind to Trunc913. All of the 1125 tail construct stays in the supernatant 
whilst most of the motor truncation is binding to the actin and pellets (n = 3). 
 
 
 
 
Myosin VI regulation by folding back the tail 
100 
3.2.5 Calmodulin- a regulator of back folding? 
The experiments discussed above located which C-terminal part of myosin VI (aa 1060-
1125) folded back onto which N-terminal region of the protein (aa 814- 913). Since the 
folded back tail seemed to bind back on to the neck region (which contains the IQ-
motifs), the next set of experiments were designed to see if the bound calmodulin light 
chain had an influence on this back folding process. 
 Calmodulin affinity titrations 3.2.5.1
For a closer look at the involvement of the IQ-motifs and the Calmodulin (CaM) bound to 
them in the back folding of the tail, small peptides that comprised only the IQ-motifs 
were designed (figure 53). These peptides were procured from Genscript. To improve 
stability the peptides were acetylated at the N-terminal and amidated at the C-terminus. 
 
Figure 53: Amino acid sequence of IQ moitfs 1 and 2 of myosin VI. Blue underlined the additional amino acids 
which were attached for more stability. Additional modifications of the peptides: acetylated N-terminus and amidation 
at the C-terminus. 
The sequences of IQ1 peptide ranged from aa 788-810 and IQ 2 from aa 812-834. 
Calmodulin affinity titrations as described in chapter 2.3.13 were performed to be sure 
that all subsequently used complexes of an IQ-motif peptide and variable CaM 
preparations were stable and saturated. These titrations showed that in a 1 mM calcium 
supplemented buffer IQ1 saturated at a ratio of 1:1 (one CaM:peptide) whereas IQ2 was 
saturated at a 1:2 ratio which equalled one calmodulin per two peptides (see figure 54). 
This 1:2 ratio suggests a lack of coordination between the N- and C- terminus of 
calmodulin. 
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Figure 54: Example calmodulin affinity titration to two different IQ-motifs. IQ1 is the unique insert of myosin VI 
and IQ2 the first IQ-motif. Titrations were performed by adding 0.1 µM CaM to 2 µM peptide. Titrations were 
performed four times. 
 
 Dot Far-western blots  3.2.5.2
For detection of interactions of small, non-labelled IQ peptides, with the 1060 tail 
construct dot far-western blots were used. For this assay the unlabelled protein was 
spotted onto the nitrocellulose membrane and then washed in buffer containing the target 
tail construct. Subsequently the membrane was washed with an antibody against that 
particular tail. A more detailed protocol can be found in chapter 2.3.3. 
To identify the role of CaM in this folding mechanism, dot far-western blots were 
performed with calmodulin and the IQ-motifs 1 and 2 as prey and the GST tagged human 
1060 tail construct as bait. The tail was added in concentrations in the range of 5-10 nM.  
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Figure 55: Dot Far-western blots reveal interaction of the 1060 tail with calmodulin. (A): Calmodulin, the peptides 
of the first (IQ1) and the second (IQ2) IQ-motif with bound calmodulin were spotted on the surface, subsequently 
washed with 1060 GST tail which was then detected by anti-GST antibody reaction. Each experiment conducted as 
duplicate (B): negative control of A; membrane was treated as in A, but without 1060 GST tail. This way unspecific 
antibody-reaction could be ruled out. (C): 1060 GST tail and the IQ1 peptide were spotted on the nitrocellulose 
membrane, washed with 1060 GST tail and subsequently with anti-GST antibody. The 1060 GST tail was spotted on as 
quality control for antibody-reaction. (D): same as C but with IQ2 peptide. Calcium concentration in buffers was 1 mM. 
The 1060 tail bound to calmodulin in the absence or presence of either IQ1 or IQ2 
peptides (figure 55 A and B). However, the 1060 tail did not bind to the IQ peptides in the 
absence of calmodulin (figure 55 C and D). This strongly supports the hypothesis that the 
C-terminal tail folds back onto the calmodulin which emerged from the performed pull-
down experiments in section 3.2.4. The question now is, as we know that calmodulin is a 
calcium sensitive protein, will the holo- or apo-calmodulin have a different affinity for the 
1060 tail? 
 
3.2.6 Influence of calcium on the back folding process 
Since CaM changed conformation upon calcium binding it was interesting to see if this 
interaction influenced the back folding of myosin VI. As a first check the GST-affinity 
co-sedimentation with 1060 GST tail as prey and the truncations Trunc913 and Trunc814 
as bait (see figure 52) were performed with added calcium (1 mM) (figure 56). 
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Figure 56: The 1060 tail construct binds to Truncations 913 and 814 with high calcium (1 mM). (A)The 1060 GST 
tail binds to both truncations although with higher affinity to Trunc913. Concentrations of truncations were the same 
(1 µM). (B) Inset shows binding behaviour of 1060 tail to truncations with no calcium in buffer. Experiments were at 
least conducted three times. 
There was no significant difference to the calcium-free assay. It is worth noting that one 
could see that with the 1060 tail bound, more of the Trunc913 was pulled down with the 
beads than Trunc814.  
A dot far-western with apo-calmodulin that was purified and kept in a calcium-free buffer 
with the added chelator EDTA (CaM·EDTA, pCa 7), showed that binding of the 1060 tail 
to this calmodulin occurred (figure 57). Levels of free ionic calcium were calculated 
using WEBMAXC, Stanford, USA. They are given as the negative decadic logarithm of 
their concentration (pCa).  
 
Figure 57: The 1060 tail binds to calcium free CaM (Cam·EDTA, apo-CaM). (A): Cam EDTA was spotted on the 
surface, subsequently washed with 1060GST tail (5-10 nM) which was then detected by anti-GST antibody reaction. 
(B): negative control of (A); membrane was treated as in (A) but without 1060GST.  
 
Myosin VI IQ1 did not bind apo-calmodulin, IQ2 did bind apo-calmodulin and the ratio 
changed from 1:2 to 1:1, suggesting that the coordination of binding was restored in the 
calcium-free state. The steps of a titration of CaM·EDTA to IQ2 peptide, up to the 
saturation of the peptide, were used as prey on an additional dot far-western blot with 
1060GST tail as bait (figure 58). For this 0.4 µM of the CaM·EDTA was titrated to the IQ 
peptide per step.  
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Figure 58: Dot Far-western blot reveals interaction of the 1060 tail with CaM·calcium bound to IQ2 and 
CaM·EDTA bound to IQ2, respectively. (A): Equal concentrations of CaM·calcium of each titration step (0.4 µM) 
were spotted on nitrocellulose and subsequently washed with 1060GST tail, which was then detected by anti-GST 
antibody; performed at pCa 4 (B): Equal concentrations of CaM·EDTA of each titration step were spotted on and 
subsequently washed with h1060GST tail, which was then detected by anti-GST antibody; performed at pCa 7. (C): 
The graph shows the corresponding intensities of a densitometry of the blot in (B). The first titration step is defined by 
the first addition of CaM to the IQ-motif. The graph represents an example of two titrations. control: negative control 
of (A) and (B) were CaM·calcium and CaM·EDTA were spotted on without washing step with 1060GST. 
 
The interaction between the 1060 tail and the CaM·EDTA was not interrupted by the 
absence of calcium. As figure 58 (B, C) shows, the binding of the tail increased with 
increasing CaM·EDTA:IQ2. Since figure 56 showed that the 1060 tail did not bind to IQ2 
alone it was not surprising to see a stronger interaction towards saturation of the IQ2 
motif with CaM with therefore decreasing levels of free IQ2 in the mixture. On the other 
hand shows figure 58 (A) a similar treated dot-far western with calcium saturated CaM 
(CaM·calcium, holo-CaM) where low to no interaction with the 1060GST tail was 
detected. 
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3.2.7 Discussion 
 The first 65 amino acids of the cargo-binding domain are involved in the back 3.2.7.1
folding 
The 814 tail did not interact with the motor truncations 814 and 913. This finding 
corresponded to a model developed by Spink et al. (2008), which claimed that myosin VI 
folds back its C-terminal tail onto the N-terminal part of the protein which then 
inactivated the protein and prevented dimerisation. Not until cargo is bound would this 
protein unfold, possibly dimerise and move cargo processively along actin tracks. This 
model was supported by Spudich and Sivaramakrishnan (2010), who added a possible 
cargo transportation mode of clustering on the cargo surface to this model. 
The pull-down experiments performed in this study revealed that the tail folds back onto 
itself and that, of the screened cargo-binding constructs, only the 1060 tail interacted with 
the truncations 814 and 913. This pointed towards the explanation that only the first N-
terminal 65 amino acids of the cargo-binding domain were involved in the back folding 
process. 
 Back folding is only possible with calmodulin 3.2.7.2
In protein:protein interaction studies with the 1060 tail and peptides of the IQ-motifs one 
and two it was possible to show that this tail did not interact with ‘naked’ IQ-motifs but 
only with the bound calmodulin. Since calmodulin is a calcium regulated protein, this 
could point towards a regulative mechanism of calcium onto the back folding of myosin 
VI. 
 Calcium regulates back folding of the myosin VI tail 3.2.7.3
With the aforementioned theory in mind, binding studies with the 1060 tail and 
calmodulin in its apo-(calcium free) and holo-(calcium-bound) state with the calmodulin 
bound to the IQ-motif peptides were performed. Since the 1060 tail only interacted with 
the apo-CaM and showed low to no interaction with the holo-CaM this suggests that the 
back folding of myosin VI onto itself is regulated by calcium. Changes in intracellular 
calcium concentrations could contribute to the folding and unfolding and thus inactivation 
and activation of this molecular transporter. 
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3.3 Lipid binding in the myosin VI molecule occurs 
along the entire tail 
Myosin VI is a cellular motor that has the ability to interact directly with lipids in 
membranes. In the subsequent experiments it is shown that lipid binding in this motor 
protein is restricted neither to a particular sequence motif in the C-terminal tail nor to a 
particular phosphatidylinositolphosphate (PIP), but that it shows lipid binding propensity 
along the length of its tail. Since calcium influences the interactions of the tail constructs 
with lipids and their affinities for different lipids, the lipid binding abilities of calmodulin 
are investigated as well. In vitro motility assays on lipid surfaces reveal that myosin VI 
shows the highest affinity for the mono-phosphate PI(4)P. Different tail constructs are 
used to gather detailed information about lipid binding and lipid affinities. 
3.3.1 Myosin VI exhibits lipid binding propensity along the whole tail 
The myosin VI cargo-binding domain (CBD) (see section 4.1.1) has previously been 
shown to bind to lipids, and to phosphatidylinositols in particular. Spudich et al. (2007) 
defined a PI(4,5)P2-specific binding site by whole plasmid site-directed mutagenesis (see 
2.1.11) in the CBD, comprising the amino acids 1115 to 1122 with the sequence 
WSKNKKR. For a close meshed screening for further lipid binding abilities and 
propensities along the whole tail, a sequence analysis was performed to identify any 
known lipid binding domains. The different expressed tail constructs introduced in 
section 3.2.1 (figure 44) were used. Liposomes of different composition were utilised 
under different conditions (i.e. added calcium) in affinity co-sedimentations as well as 
protein-lipid overlays (PLO) (see 2.3.5).  
 Sequence analysis 3.3.1.1
Since defined protein domains that specifically bind membrane lipids (e.g. PH, PX, 
FERM, ENTH, see appendix 5.8) could not be found along the myosin VI tail, a 
computer based search for unstructured membrane-binding sites after Brzeska et al. 
(2010) was performed. This BH-plot searches for basic-hydrophobic regions which are 
potential membrane-binding sites known to often bind to acidic phospholipids. By 
modification of the hydrophobicity scale which then gives Arg- and Lys-positive, rather 
than negative values, the authors were capable of successfully identifying phospholipid-
binding sites in 16 tested proteins. Beginning with the first amino acid in the protein 
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sequence, the program averages the values for each amino acid (see table 10, appendix) in 
a defined window (segment of selected length) and gives a score for the middle residue in 
the segment. Hence for a window size of 19, the first score is an average of the values for 
residues 1-19 and is assigned to residue 10. Then the values for residues 2-20 are 
averaged and the score is given to residue 11. This is continued to the end of the sequence 
with the last residue scored being 10 residues away from the C-terminus. If amino acids 
closer to the N- and C-termini had to be scored, a smaller window size must be used. A 
threshold of 0.6 gave the best results for their tested 16 proteins but the program 
optimises this threshold, giving the optimal signal to noise ratio. The authors developed 
an online based calculator for performing BH-searches which can be openly used at 
http://helixweb.nih.gov/bhsearch/. 
 
Figure 59: Plot of basic-hydrophobic (BH) residue patches of chicken FL (LI) construct. Threshold given at 0.8, 
running window size was 19. Detailed explanation given in text. Cartoon depicts FL myosin protein. Two possible 
membrane-binding regions are indicated. Region indicated by (1) are the unique insert and the second IQ-motif, which 
is a yet unknown possible lipid binding site and (2) indicates the already defined PI(4,5)P2 binding motif KSKNKKR. 
BH-plot was performed on http://helixweb.nih.gov/bhsearch/ 
The BH plot gave two over-threshold proportions. As indicated in figure 59, the second 
(2) showed the known binding site for PI(4,5)P2 at residues 1115 to 1122. The first 
pulled-out possible lipid-binding site (figure 59 (1)) comprised of the unique insert and 
the second IQ-motif, which both have previously not been discussed as potential lipid 
binding regions of myosin VI. 
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 Lipid-affinity co-sedimentations 3.3.1.2
To test the capability of the tail constructs to interact with different lipids, lipid-affinity 
co-sedimentations were performed (see section 2.3.7). The liposomes where produced by 
sonication. Following the protocol of Spudich et al. (2007), the final mixture for PIP-
containing liposomes consisted of 40% PE, 40% PC, 10% Cholesterol and 10% of a 
varying PIP, all kept in a physiological salt buffer (Lipidbuffer, 150 mM NaCl). 
Furthermore vesicles consisting of pure PE, PC, Cholesterol, a mixture of PC and PE and 
a mixture of PC, PE and Cholesterol were produced and assayed to see if binding to the 
PIP-containing vesicles was due to any of these components. Additionally controls for 
self-pelleting of the constructs were performed without added liposomes. The protein 
constructs and the appropriate liposomes were mixed, incubated for 10 min at room 
temperature and subsequently ultra-centrifuged. Thereby, protein constructs that did not 
bind to the vesicles remained in the supernatant fraction whereas all lipid-bound protein 
was present in the pellet. To allocate the protein fraction to either pellet or supernatant 
fraction a SDS-PAGE was performed for every sample. 
 
Figure 60: Control co-sedimentations with Lipidbuffer. Top row: VI FL (149 kDa), Trunc1060 (124 kDa), 
Trunc913 (108 kDa), Trunc814 (97 kDa), 814 tail (56 kDa), 913 tail (45 kDa); Bottom row: NCBD tail (34 kDa), 
human 1060 tail, chicken 1060 tail (29 kDa), 1125 tail (22 kDa) and 883 ∆ PIP tail (49 kDa). S and P stand for 
supernatant and pellet fraction respectively. The concentrations of protein ranged from 1-3 µM. None of the constructs 
pelleted on its own. All experiments performed at least three times.  
To uncover the lipid-binding capacities of the different tail constructs, the binding to 
folch liposomes by quantifying the protein in the pellet fraction and therefore bound to 
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the vesicles (figure 60) was assessed. The construct concentration varied from 1-3 µM 
whilst the liposome concentration was kept at 0.2 mg/ml. 
 
Figure 61: Lipid-affinity co-sedimentations with folch vesicles. (A): Top row: VI FL (149 kDa), Trunc1060 (124 
kDa), Trunc913 (108 kDa), Trunc814 (97 kDa). Bottom row: 814 tail (56 kDa), 913 tail (45 kDa), NCBD tail (34 kDa), 
1060 tail (29 kDa) 1125 tail (22 kDa) and 883 ∆ PIP tail (49 kDa). S and P stand for supernatant and pellet fraction 
respectively. The concentrations of protein ranged from 1-3 µM. All constructs despite the 1125 tail bound to folch 
liposomes. Gel pictures of Trunc1060 and 814 tail are silver stained and therefore gray. Gel pictures differ because 
differences in construct sizes make different gel densities (10-15%) and running times necessary; therefore no 
molecular weight is marked on the pictures but given in the text. (B): Densitometry of shown co-sedimentations. The 
percentage of protein in the pellet fraction is shown. The intensity of the tail or full-length band in the pellet was 
divided by the total intensity (pellet + supernatant) for each sample to determine the percentage of protein in the pellet. 
All experiments performed four times. Error bars show standard deviation. 
All constructs, apart from the shortest tail construct 1125, bound to the provided 
liposomes (figure 61, A). Truncations 1060 and 913 as well as the 913 and the 1060 tail 
constructs bound at 100% of the liposomes. Densitometry revealed that the FL construct 
as well as Trunc814 and the NCBD tail were only bound at 50% to the folch vesicles. The 
883∆ PIP construct showed even less binding (20%) similar to the 814 tail (25%) (figure 
61, B). 
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Since folch is a mixture of membrane lipids with varying amounts of 
phosphatidylinositols (PIPs) and other phospholipids, co-sedimentations with defined 
amounts of PIPs in the liposomes were performed. Concentrations of constructs ranged 
between 1 and 3 µM, the concentration of liposomes was kept at 0.2 mg/ml which 
equalled 0.02 mg/ml PIP per pull-down. The motor truncations as well as the NCBD tail 
construct could not be included in the PIP-affinity co-sedimentations because they all 
readily bound to the other components of the liposomes PC, PE and/ or Cholesterol (see 
appendix, figure 106-108). Liposomes contained 40% PE, 40% PC. 10% Cholesterol and 
10% of a variable PIP. 
 
Figure 62: Binding of myosin VI FL and tail constructs to Phosphatidylinositol-4-mono-phosphate (PI(4)P). (A): 
VI FL construct and tail constructs. Sizes see figure 46. All experiments conducted four times. (B): Densitometry of 
constructs binding to PI(4)P liposomes. All truncations and the NCBD construct bound to the components PC, PE and/ 
or Cholesterol, therefore they had to be excluded from the assays. Bars represent average of four co-sedimentations. All 
experiments conducted four times. Error bars show standard deviation. 
Figure 63 shows the binding of the single constructs to PI(4)P containing liposomes. The 
tails mostly stayed in the supernatant but a closer densitometrical inspection (figure 62, 
B) revealed that the full-length construct and the 913 tail bound completely to the added 
liposomes, which meant a 2-fold increase in binding for myosin VI FL in comparison to 
binding to folch vesicles. In contrast to the pull-down with the folch vesicles, the cargo-
binding domain construct 1060 did not bind to the PI(4)P vesicles. The 1125 construct 
behaved the same as with folch vesicles. The 883∆ PIP construct showed more binding 
than to the folch vesicles (~ 45% against 20% on folch; p = 0.018) whilst the 814 tail 
bound similarly to the PI(4)P vesicles as to folch. 
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A co-sedimentation with PI(3,5)P2 containing liposomes showed a different picture from 
PI(4)P binding.  
 
Figure 63: Binding of myosin VI FL and tail constructs to Phosphatidylinositol-3,5-di-phosphate (PI(3,5)P2). (A): 
VI FL construct and tail constructs. Sizes see figure 46. S and P stand for supernatant and pellet fraction respectively. 
Asterisks indicate faint bands in pellet fraction. All experiments conducted four times. (B): Densitometry of constructs 
binding to PI(3,5)P2 liposomes. All truncations and the NCBD construct bound to the components PC, PE and/ or 
Cholesterol, therefore they had to be excluded from the assays. Bars represent average of four co-sedimentations. Error 
bars show standard deviation.  
Full-length protein bound to PI(3,5)P2 vesicles to only about 50% which marked a 
decrease in comparison to PI(4) and a similar binding behaviour as with folch vesicles. 
The 913 tail bound to about 90% to these liposomes. Even though the 1060 and 1125 tails 
both did not bind to PI(4)P there was a weak interaction detected for both with PI(3,5)P2 
(see figure 63). The interaction of the 883 ∆ PIP mutant and the 814 tail with these two 
different phosphatidylinositols was in comparison the same. 
The affinity co-sedimentation with PI(4,5)P2 (PIP2) containing liposomes showed a very 
similar picture to the assay performed with PI(4)P in terms of binders and non-binders. 
Again no binding of the shorter tail constructs 1060 and 1125 could be observed while the 
interaction of the constructs in general was again weaker than with the mono-phosphate. 
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Figure 64: Binding of myosin VI FL and tail constructs to Phosphatidylinositol-4,5-di-phosphate (PI(4,5)P2). (A): 
VI FL construct and tail constructs. Sizes see figure 46. S and P stand for supernatant and pellet fraction respectively. 
Asterisks indicate faint bands in pellet fraction. All experiments conducted four times. (B): Densitometry of constructs 
binding to PI(4,5)P2 liposomes. All truncations and the NCBD construct bound to the components PC, PE and/ or 
Cholesterol, therefore they had to be excluded from the assays. Bars represent average of four co-sedimentations. Error 
bars show standard deviation. 
Densitometry (figure 64, B) revealed that about 65% of the myosin VI FL and 
approximately 30% of the 913 tail were interacting with PI(4,5)P2. Which was less than 
observed with the PI(3,5)P2-containing vesicles for the 913 tail, with a significant 
difference (p ≤ 0.001) of about 60% . Although the interactions of the 883 ∆ PIP mutant 
and the 814 tail were similar with PI(3,5)P2 and the PI(4)P containing vesicles, the 883 ∆ 
PIP mutant did not bind to the PI(4,5)P2 whereas the 814 tail showed about 16% binding 
(figure 64). 
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3.3.2 Calcium has an effect on lipid binding of the myosin VI full-length protein 
Since calcium plays a pivotal role in the cell, and is known to be one of many regulators 
of myosin, it was decided to test the binding of myosin VI FL to all aforementioned lipid 
mixes with addition of calcium in form of CaCl2. Without calcium, myosin VI full-length 
bound to folch liposomes only in a 50:50 fashion upon calcium addition (standard 
concentration 50 µM CaCl2), this behaviour shifted towards 100% binding to folch 
vesicles (figure 65, A) (p ≤ 0.001).  
 
Figure 65: Densitometry of myosin VI FL binding to different lipid vesicles with and without the addition of 
CaCl2. (A): myosin VI FL binding to folch vesicles +/-calcium; (B): VI FL binding to PI(4)P containing liposomes 
with and without the addition of 50 µM calcium; (C) VI FL binding to PI(3.5)P2 containing liposomes +/-calcium and 
(D): VI FL binding to PI(4,5)P2 containing liposomes with and without the addition of 50 µM calcium. The inset 
pictures are representative examples for experiments. Bars represent average of four to six co-sedimentations. Error 
bars show standard deviation.  
The effect of calcium upon on the interaction of myosin VI FL to PI(4)P containing 
vesicles was noticeably smaller. Whilst the interaction between folch liposomes and 
myosin VI FL was increased with the addition of CaCl2, it reduced the binding of myosin 
VI FL to PI(4)P by 30% from fully bound protein to 70% bound protein (figure 65, B). 
Binding to PI(3,5)P2 containing vesicles was reduced from 50% without calcium to 
around 20% with added CaCl2 ( p = 0.01) (see figure 65, C). 
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The interaction between PI(4,5)P2 and myosin VI FL (50:50 binding) upon addition of 
50 µM CaCl2 was disrupted completely (p ≤ 0.001) (figure 65, D). 
 
3.3.3 Myosin VI’s lipid binding might be tightly regulated 
After having seen the effects of Ca2+ on the lipid binding abilities of myosin VI FL 
protein, it was tested if different concentrations of CaCl2 had varied effects on the 
protein:liposome interaction. Since the disruption of binding to PI(4,5)P2 was the most 
striking result, the interaction between this lipid and myosin VI FL was tested. To the 
normal assay as described above, CaCl2 was added in different concentrations (5 µM, 
10 µM, 25 µM and 50 µM). 
 
Figure 66: Densitometry of myosin VI FL binding to PI(4,5)P2 vesicles with different CaCl2 concentrations. The 
inset pictures are representative examples for experiments. Bars represent mean value of four experiments. Error bars 
show standard deviation. 
As figure 66 shows, low concentrations of an effect on binding. About 10% of the protein 
bound with additions of 5 and 10 µM CaCl2, respectively. The most striking effect was 
that at 25 µM added CaCl2 around 45% binding could be observed whereas 50 µM CaCl2 
was enough to completely stop any interaction of myosin VI FL to PI(4,5)P2 containing 
liposomes (p ≤ 0.001). 
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3.3.4 Myosin VI 1125 tail construct shows Calcium dependent lipid binding 
Most of the tail constructs did not show any significant change in binding behaviour when 
CaCl2 was added to the assay. But strikingly the shortest tail, 1125 changed its behaviour 
from not binding to the vesicles towards binding to around 50% (p ≤ 0.001) and the 814 
tail changed from 25% binding to around 90% binding (p = 0.001) (figure 67). 
 
Figure 67: Densitometry of myosin VI constructs binding to folch vesicles with and without CaCl2 additions. The 
inset pictures show effect of CaCl2 on 1125 tail binding to folch vesicles. Left panel: binding to folch without Calcium, 
right panel: binding to folch with 50 µM CaCl2. Bars represent average of at least four co-sedimentations. Error bars 
represent standard deviation. 
 
3.3.5 Almost all myosin VI constructs bind to folch on nitrocellulose 
A different approach for examining lipid binding of the protein constructs is the protein-
lipid overlay assay (PLO) (Dowler et al. 2002), which presents defined lipid components 
or mixtures on a nitrocellulose surface (see 2.3.5). In short, lipids were spotted on a 
nitrocellulose surface, allowed to dry and then incubated with the target protein, which 
was subsequently detected by an appropriate antibody. Three slightly different methods 
were used here: (1) as a first and crude check, PC, PE and folch fraction were spotted on 
the membrane; (2) commercial pre-spotted Membrane Lipid Strips® and (3) PIP Strips® 
(echelon, see section 2.3.6) were purchased. On the latter two, very distinct and pure 
lipids were spotted, so that a more defined classification of lipid binding was made 
possible for each construct. 
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On protein-lipid-overlay blots (PLO) the protein of choice was presented with surface 
bound lipid mixtures or pure lipids (see 2.3.5). As figure 68 shows, almost all constructs 
bound to the presented folch on nitrocellulose. Only the NCBD construct ranging from 
amino acids 814-1060 and the 883∆ PIP showed low to no binding to the lipids. The 1125 
tail gave a very low signal which indicated weak binding. None of the constructs 
interacted with the control lipids PC and PE although the truncations as well as the 
NCBD tail showed binding to these phospholipids when presented as liposomes (see 
appendix figure 108). 
 
Figure 68: PLO blots for all myosin VI constructs. First row on each blot: pure PC in different amounts (from left to 
right: 500 pmol, 350 pmol and 200 pmol). Second row: pure PE, third row: folch. The control consisted of the 
respective target construct as check for antibody performance. A black dot indicates a positive reaction with the 
antibody and therefore binding of the protein construct to the particular lipid/ lipid-mix. NCBD tail (814-1060). All 
experiments were performed at least three times.  
 
3.3.6 Calcium has effect on full-length myosin VI on nitrocellulose 
After having seen the effect of calcium onto the binding behaviour of myosin VI FL (see 
section 5.1.2), it was tested whether this effect was also present on PLO blots. For this, 
PLOs as above were performed but with the addition of 1 mM CaCl2 in the buffer. 
 
Figure 69: Calcium effect on myosin VI FL on PLO blots First row on each blot: pure PC in different amounts (from 
left to right: 500 pmol, 350 pmol and 200 pmol). Second row: pure PE, third row: folch. The control consisted of the 
respective target construct as check for antibody performance. A black dot indicates a positive reaction with the 
Myosin VI binds lipids along entire tail 
117 
antibody and therefore binding of the protein construct to the particular lipid/ lipid-mix. Left blot myosin VI FL without 
addition of Calcium, right blot with addition of 1 mM CaCl2. (n = 3) 
Figure 69 shows that myosin VI FL bound to folch on nitrocellulose only weakly. When 
the same experiment was done with the addition of calcium however, the binding 
increased significantly. 
3.3.7 Calcium changes lipid affinities of myosin VI FL protein 
An even more obvious effect was seen when Membrane and PIP Strips were performed 
with and without the addition of Calcium. 
 
Figure 70: Calcium effect on myosin VI FL on Membrane Lipid Strips® ®. A black dot indicates a positive 
reaction with the antibody and therefore binding of the protein construct to the particular lipid. Membrane Strips with 
myosin VI FL. Blot on the left without Calcium, on the right with addition of 1 mM CaCl2 in all buffers (n = 2). 
Figure 70 illustrates a shift of lipid binding affinities of the full-length protein. Without 
calcium it bound strongly to PI(4)P and Cardiolipin. Weaker binding was detected to 
sulfatide and even weaker to PA and PI(4,5)P2. When the same experiment was 
performed in a 1 mM CaCl2-supplemented Blocking-buffer, binding to PA, PI(4,5)P2 and 
sulfatide increased substantially (indicated by coloured circles).  
3.3.8 Myosin VI constructs show different membrane lipid affinities 
Since almost all constructs were capable of interacting with nitrocellulose-bound mixed 
lipids (i.e. folch) (figure 68), a more detailed view of membrane lipid binding was sought. 
As figure 71 shows, myosin VI bound to a limited number of lipid components. 
Strikingly all of the interacting lipids were negatively charged whereas no binding to the 
available neutral lipids was observed. 
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Figure 71: Membrane Lipid Strips® for myosin VI constructs. A black dot indicates a positive reaction with the 
antibody and therefore binding of the protein construct to the particular lipid. Trunc1060 was left out to avoid 
redundancies. All experiments were performed at least twice. Those lipids where reactions could be found are indicated 
with names, for full layout of strips see 2.3.6. 
Between the FL construct and the truncations only the loss of binding to PI could be 
detected, but between the tail constructs, more apparent differences were noticed. The 
814 tail did not interact specifically but showed more or less only background or 
nonspecific binding, which was indicated by the “coffee-ring stains” on the blots. Repeats 
and adjustments in exposure time or incubation lengths did not enhance the signal either. 
But a weak signal for PI(4)P binding as well as PI(4,5)P2 and PI(3,5)P2 was detectable. 
On the other hand all shorter tails interacted with the same range of membrane lipids, but 
showed differences in binding preferences. The 913 tail bound in exactly the same 
manner as the truncations, but the NCBD construct lost the ability to bind to PS and PG 
completely whereas binding to PI, PI(4,5)P2, PI(3,5)P2, sulfatide and Cardiolipin was 
considerably reduced. Remarkably the cargo-binding domain (1060 tail) bound almost 
identically as the 913 tail to PI(4)P, PI(4,5)P2, PI(3,5)P2, sulfatide and Cardiolipin as well 
as PS and PA but did not bind to PG. For the shortest tail construct, 1125 tail, attachment 
to PI(4)P remained strong but was noticeably lower for PA, PS, Cardiolipin and 
PI(3,5)P2. It was entirely disrupted for PG, sulfatide, PI and PI(4,5)P2. 
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3.3.9 Myosin VI constructs show differences in Phosphatidylinositol (PIP) binding 
An even more detailed look into binding affinities was feasible by using PIP Strips® as 
PLO substrate (figure 72). Again it was seen that only a range of lipids were bound to by 
the myosin VI constructs and that there was variability in binding affinities.  
 
Figure 72: PIP Strips® for myosin VI constructs. A black dot indicates a positive reaction with the antibody and 
therefore binding of the protein construct to the particular lipid. Trunc1060 was left out to avoid redundancies. 1125 
tail: the signal for PI(3)P to PI(5)P had such high intensity, leaving only white spots. All experiments were performed at 
least twice. Lipids where reactions could be detected are indicated. For full layout of strip, see chapter 2.3.6. 
The FL construct bound to the three mono-phosphates PI(3)P, PI(4)P and PI(5)P as well 
as the di-phosphates, PI(3,4)P2, PI(3,5)P2 and PI(4,5)P2. Additionally binding to the tri-
phosphate PI(3,4,5)P3 and the phospholipids PA and PS was detectable (figure 72). The 
most remarkable aspect was that binding to the three mono-phosphates was strong 
throughout the constructs. Binding to PI(3,5)P2 changed from a weaker signal in the FL 
protein to strong binding in Trunc913 and the tail constructs. The 814 tail again showed 
in total a weak binding behaviour expressed by very low signal detection. However, a 
binding reaction to the mono-phosphates and PI(3,5)P2, PI(4,5)P2 and PI(3,4,5)P3 was 
identified. The 1125 tail additionally showed a higher affinity for PA than the other 
constructs including the FL protein. This effect was not seen on the Membrane Lipid 
Strips where PA was spotted on as well (figure 71). This might be due to the availability 
of better binding partners than PA on the PIP Strips. 
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3.3.10 Myosin VI cargo-binding domain constructs reveal differences in lipid 
binding 
 Sequence alignment 3.3.10.1
An alignment of the amino acid sequences of human and chicken derived myosin VI 
cargo-binding domain (CBD) revealed that the major known motifs for interaction with 
binding partners (i.e. RRL and WWY) as well as the PI(4,5)P2 binding sequence exist in 
both constructs. Though slight differences in the amino acid sequence were noticed 
(figure 73, yellow marking). 
 
Figure 73: Sequence alignment for human 1060 tail (h) and chicken 1060 tail (c). The sequences show a 98.7% 
similarity. Purple: known motifs (RRL: NDP52 binding, WWY: Dab2 binding and KSKNKKR: PI(4,5)P2 binding). 
Yellow marks show dissimilarities in sequences. 
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 Co-sedimentation reveals differences in cargo-binding domain lipid-3.3.10.2
binding affinities between chicken (LI) and human (NI) tail constructs 
 
Although the sequences of human 1060 (h1060) and chicken 1060 (c1060) tail showed 
98.7% similarity, they exhibited distinct discrepancies regarding lipid binding.  
 
Figure 74: Co-sedimentations of myosin VI human 1060 tail construct vs. chicken 1060 tail construct. Upper 
panels show exemplary SDS-PAGE of co-sedimentations with the particular liposomes. Upper left: human 1060 tail co-
sedimentations; a: with folch vesicles, b: PI(4)P, c: PI(4,5)P2, d: PI(3,5)P2. Upper right panel: chicken 1060 tail with e: 
folch, f: PI(4)P, g: PI(4,5)P2, h: PI(3,5)P2. S and P stand for supernatant and pellet fraction, respectively. Graph shows 
densitometry of upper gels; first column “buffer” shows that none of the constructs pelleted on its own without 
liposome addition. All experiments conducted at least four times. Bars represent average of four co-sedimentations. 
Error bars show standard deviation. 
 
As figure 74 shows 100% of the h1060 tail bound to folch vesicles but the chicken 
construct bound to only 30% (p ≤ 0.001). Whilst both tail constructs did not bind to either 
PI(4)P or PI(4,5)P2, only the human cargo-binding domain construct showed capacity to 
bind PI(3,5)P2 with a low affinity of ~35% (p ≤ 0.001). 
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 Cargo-binding domain constructs show different lipid affinities 3.3.10.3
When added to nitrocellulose-bound lipids, there was a clear difference detectable 
between the two cargo-binding domain constructs. The human construct bound to folch 
spotted on nitrocellulose, as would be predicted from the co-sedimentation (figure75), 
and the chicken tail did not bind at all to the PLO even though it bound to the liposomes 
(figure 75). 
 
Figure 75: PLO for myosin VI h1060 tail vs. c1060 tail. A black dot indicates a positive reaction with the antibody 
and therefore binding of the protein construct to the particular lipid. Upper row: PLO with PC, PE and folch spotted on 
in three different concentrations and control (see figure 68). a: PIP strip of h1060 tail, b: Membrane Lipid Strip h1060 
tail, c: PIP Strip c1060 tail, d: Membrane Strip c1060 tail. All experiments were performed at least twice. For full 
layout of strip, see chapter 2.3.6. 
A more refined look using the PIP and Membrane Strips® revealed that more binding-
preference differences existed. On the PIP strips binding to the mono-phosphates PI(3)P, 
PI(4)P and PI(5)P was seen for both constructs. But binding to PI(3,5)P2, being noticeable 
for the human construct, was very feeble with the chicken tail construct. On the 
membrane Strips on the other hand a different effect was noticed. While h1060 tail bound 
predominantly to PI(4)P and Cardiolipin and only weakly to sulfatide. This last 
interaction was strongly enhanced in the c1060 construct.  
Both constructs showed high affinity to PI(4)P when presented on nitrocellulose but did 
not bind to it as soon as it was incorporated in liposomes. Additionally none of the cargo-
binding domain constructs interacted with PI(4,5)P2. 
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3.3.11 Myosin VI motility on lipid monolayers 
 In vitro Gliding-filament assay 3.3.11.1
After dissecting the lipid binding capabilities of the myosin VI tail (section 5.1.1) it was 
intriguing to see whether lipid binding had an effect on the functionality of myosin VI as 
well as being a possible regulative mechanism. Therefore a typical in vitro gliding-
filament assay was altered (see section 2.3.1) and non-fluid lipid-monolayers as substrate 
were used instead of nitrocellulose. These were tested with fluorescence recovery after 
photobleaching (FRAP) for their non-fluidity before use (figure 76). 
 
Figure 76: FRAP test for immobile lipid surfaces. (A): shows typical lipid surface in flow-cell, to test the surfaces 
they were stained using Rhodamine labelled PE in the mixture which was exchanged for non-fluorescent PE in the 
actual assays. (B): surface after 10 s photobleaching with 405 nm laser and 2 min recovery time, recorded with a 488 
nm laser. As (C) shows, no recovery of fluorescence was achieved over time. 
In figure 76 a typical FRAP experiment can be seen. It depicts the fluorescently labelled 
lipid layer before (A) and after photobleaching (B). The graph (C) shows that in this 
experiment no recoveries of the fluorophores in the bleached region of interest occurred 
over time. This was done for several flow-cells and proved that with this preparation 
method (section 2.3.8) only static lipid monolayers were produced. 
 
 Myosin VI shows higher gliding-velocity and functional affinity for lipid 3.3.11.2
surfaces 
Myosin VI is known to be a relatively slow motor protein with published velocities of up 
to 71 nm/s (Lister et al. 2004). As a comparison in vitro experiments of myosin V provide 
a mean velocity in the range of 200-450 nm/s (Mehta et al. 1999). From our experience 
we knew that myosin VI did not move on nitrocellulose directly like most other myosins, 
but needed the support of an antibody or another substrate (figure 77). The antibody that 
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was used here was a myosin VI tail-specific antibody (from J. Kendrick-Jones, MRC, 
Cambridge, UK) which was raised against the entire tail of myosin VI. 
 
Figure 77: Setting of in vitro gliding-filament assays for myosin VI. (A): shows typical motility assay for myosin VI, 
using anti-tail antibody (light green) on the nitrocellulose surface and the possible resulting positioning of the myosin 
VI molecule. (B): unordered phospholipid surface (yellow: phospholipid) instead of antibody and the possible resulting 
positioning of myosin VI on the surface.  
All filaments that showed continuous motility for ≥ 3 frames were tracked by hand using 
the GMimPro software (see chapter 2.4). Motility assays were performed with protein 
from at least three different preparations and per setting at least four flowcells. 
 
Figure 78: Bar chart for two different motility assay substrates with myosin VI at a motor concentration of 
420 nM at different temperatures. RT: 23 °C. Temperature was changed to and kept at 37 °C with a standard 
temperature controller (TC200, Thorlabs) custom fitted to microscopic slides. Error bars show standard deviation. (n= 
656 filaments). 
For one chosen intermediate motor concentration of 420 nM on the surface, it was 
possible to see two major changes in velocity (figure 78). For antibody-bound myosin VI, 
the change of temperature from RT (23 °C) to 37 °C enhanced the velocity from 27 nm/s 
(± 6.8 nm/s) to 37 nm/s (± 5.4 nm/s) which marked an increase of 27%. When the 
substrate, to which the myosin was bound, was exchanged for folch, the speed increased 
from 37 nm/s to 55 nm/s (± 7.1 nm/s), which corresponded to an increase of 104% when 
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compared to antibody bound at RT (p ≤ 0.001). Figure 79 displays the effects on antibody 
and folch bound myosin VI at 37 °C for different motor concentrations. 
 
Figure 79: Velocities of myosin VI at 37 °C on anti-tail antibody versus folch. Error bars mark standard deviation. 
Myosin VI concentrations in the flow cells were: 42 nM, 84 nM, 168 nM, 280 nM and 420 nM; no motility was 
traceable at higher or lower concentrations. (n= 606 filaments) 
According to figure 79, three main effects could be noticed. First, there seemed to be a 
motor density on the surface of the flow-cell around 280 nM where the filament gliding 
speed was almost equal (~ 60 nm/s) for both substrates. Second, it was obvious that with 
higher motor density the speed decreased from the maximum of 70 nm/s (± 12 nm/s) for 
folch bound myosin VI (52 nm/ s (± 14 nm/s) antibody bound) to 55 nm/s (± 7.1 nm/s)  
and 37 nm/s (± 5.8 nm/s) respectively. This equals a decrease in velocity of 21% for folch 
bound and 26% for antibody bound myosin VI. At even higher concentrations this effect 
seemed to level off for folch bound myosin VI but on nitrocellulose a further decrease 
was noted. And third, the lowest concentration at which uninterrupted motility was 
obtainable (here termed ‘affinity’) for both substrates were different. On folch surfaces 
motility was obtained at 42 nM whilst on antibody motility stopped at 84 nM. 
 
 Myosin VI exhibits different behaviour on various lipid surfaces 3.3.11.3
After having seen the effect of the lipid mixture folch upon the motility of myosin VI, it 
was important to see whether the three different phosphatidylinositolphosphates (PIPs) 
PI(4)P, PI(3,5)P2 and PI(4,5)P2 had distinct impacts on the activity of this motor protein 
as well. 
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Figure 80: Bar chart for five different motility assay substrates with myosin VI at a motor concentration of 
420 nM (37 °C). Error bars show standard deviation. (n = 3315 filaments) 
Figure 80 compiles the effects of five different substrates on filament gliding speed 
driven by myosin VI at a motor concentration of 420 nM. It shows that not only folch 
surfaces improved the velocity but the aforementioned PIPs had an influence upon it too. 
At this particular motor concentration the fastest gliding speed was measured for a 
surface containing PI(4)P at 66 nm/s (± 8.9 nm/s). Motors on surfaces containing 
PI(3,5)P2 exhibited a velocity of 62 nm/s (± 7.2 nm/s) followed by motors on PI(4,5)P2-
containing surfaces with 57 nm/s (± 5.7 nm/s) which was similar to folch surfaces where 
the tracked filament gliding speed was 55 nm/s (± 7.1 nm/s). Although the differences 
between the various PIPs were not as big as the initially observed changes in figure 79, at 
different concentrations they became more apparent.  
Figure 81 A gives an indication that different species of lipids had different impacts upon 
the gliding speed of myosin VI. The comparison with folch as substrate revealed that 
PI(4)P, PI(4,5)P2 and folch showed very similar velocities at a motor concentration of 
84 nM (60-70 nm/s). This was similar to the abovementioned situation where myosin VI 
on folch and antibody showed an almost identical speed at 280 nM (see figure 79). 
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Figure 81: Velocities of myosin VI at 37 °C on different PIPs and folch surfaces. Myosin VI concentrations in the 
flow cells were: (A) 21 nM, 42 nM, 84 nM, 168 nM, 280 nM and 420 nM. For the PIPs additionally 1680 nM myosin 
VI were possible. At this concentration no motility was detected on folch surfaces. (n=3028) (B) Same graph as above 
without folch for emphasis of effect of PIPs on myosin VI motility. (n= 2946 filaments). Error bars mark standard 
deviation, logarithmic scale on x-axis. 
Additionally myosin VI was capable of performing motility on all three PIPs at much 
higher concentrations (up to 1680 nM) than on folch surfaces where no motility was 
detected above a protein concentration of 420 nM (figure 81, A, blue squares). A closer 
look on the interactions with the PIP-containing surfaces (figure 81, B) revealed that the 
gliding velocity on PI(3,5)P2 surfaces was the slowest at low motor densities up to 
420 nM myosin VI where it showed an intermediate velocity of 62 nm/s (± 7.2 nm/s) (see 
figure 80). Furthermore it was noticed that myosin VI had the lowest affinity for PI(3,5)P2 
containing surfaces. On this particular surface it stopped moving at motor concentrations 
of 84 nM whereas the protein was still bound to and moving on PI(4,5)P2  (42 nM) and 
PI(4)P (21 nM) at considerably lower concentrations. Therefore the highest affinity in this 
assay was attributable to PI(4)P containing surfaces. 
Myosin VI motility on lipid monolayers 
128 
3.3.11.3.1 Myosin VI full-length ∆ PIP mutant binds to and moves on lipid surfaces with 
different affinities 
The ∆ PIP mutant bound to the folch surfaces as well as to the other lipid surfaces. As 
figure 82 shows, only slight differences in filament gliding speed could be detected at a 
myosin VI concentration of 220 nM. The speed on folch surfaces was in total slightly 
higher (68 nm/s ± 10.2 nm/s) than with the formerly analysed wild-type FL. In total 
differences were not as distinct as with the wild type FL VI (figure 81). 
 
Figure 82: Bar chart for four different motility assay substrates with myosin VI ∆ PIP at a motor concentration 
of 220 nM (37 °C). Error bars show standard deviation. (n= 3769 filaments) 
 
Figure 83 depicts the filament gliding velocities on PIP surfaces in comparison with folch 
surfaces at different motor concentrations. As it can be seen in figure 83 A, the affinity to 
folch surfaces was highest with detectable motility down to a motor concentration of 
11 nM. This was significantly lower than with the wild-type protein where motility 
ceased at a concentration of 42 nM. Amongst PIPs (figure 83, B) an equal affinity for 
PI(4)P and PI(3,5)P2 could be measured. No motility could be detected below 88 nM 
myosin VI concentration. The lowest affinity was found for PI(4,5)P2. With this lipid on 
the surface movement ceased already at a higher concentration of motors (146 nM). 
Above all a decrease in speed was detectable at concentrations higher than 88 nM. The 
velocity was not further decreasing between 146 nM and 880 nM but plateaued around 
80 nm/s. 
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Figure 83: Velocities of myosin VI ∆ PIP at 37 °C on different PIP and folch containing surfaces. (A): Myosin 
VI ∆ PIP on different lipid surfaces.(n= 3769 filaments) (B) Same graph as above without folch for emphasis of effect 
of PIPs on myosin VI motility. Myosin VI ∆ PIP concentrations in the flow cells were: 11 nM, 22 nM, 44 nM, 88 nM, 
146 nM, 220 nM and 880 nM. (n=2382). Error bars mark standard deviation, logarithmic scale on x-axis. 
 
To investigate further whether these phenomena were only due to better positioning on 
the lipid surface in comparison to the antibody, biotinylated myosin VI FL with a C-
terminal biotin recognition site (BRS) was expressed, (see 2.2.9) and the in vitro gliding 
filament assay on Biotin-BSA with Neutravidin surfaces were performed as a control. 
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Figure 84: Motility of biotinylated VI FL BRS on Biotin BSA. (A): Myosin VI BRS in the flow cells were 1 µM, 
500 nM, 250 nM, 100 nM, 50 nM, 25 nM, 12.5 nM, 8.3 nM and 6.25 nM. (B): combination graph of motility on PIPs 
and of myosin VI BRS on biotinylated BSA. Error bars mark standard deviation, logarithmic scale on x-axis (n=1512 
filaments). 
As figure 84 shows, the myosin VI FL BRS (VI BRS) was comparable in velocity to the 
former preparation used with the lipid layers. The maximum gliding speed was 66 nm/s 
(± 12.4 nm/s). Motility was obtainable to a motor concentration as low as 6.25 nM, which 
was significantly lower than on the lipid surfaces. 
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3.4 Calmodulin and lipid binding 
After interrogating the lipid-binding abilities of the myosin VI tail (see 3.3), the back 
folding abilities of the cargo-binding domain and the role of CaM in this mechanism, a 
closer look at the lipid-binding capacity of CaM had to be taken. The already introduced 
techniques of Protein-Lipid overlay assays (PLO, see 2.3.5) and lipid-affinity co-
sedimentations (see 2.3.7) were used to deepen the understanding of the role CaM plays 
in the regulation of myosin VI. 
3.4.1 Calmodulin affinity titration 
It was of interest to establish whether CaM binds lipids and if so, whether there was a 
difference between free CaM and CaM bound to an IQ-peptide. As described in chapter 
3.2.6, CaM was titrated to target peptide sequences (IQ1 and IQ2) in either Ca2+ or EDTA 
buffer. Approximately 0.1 µM CaM was added per injection to a total concentration of 
2 µM peptide (figure 85). 
 
Figure 85: Calmodulin binds to IQ-motif peptide. Peak at ~358 nm shows the tryptophane fluorescence of IQ 
peptide alone. Shift to the left implicates change in tryptophane fluorescence and thus binding of CaM.  
CaM was titrated to the particular IQ-motif peptide until its saturation (see section 4.3.1). 
As figure 85 shows an obvious shift in tryptophan (Trp) fluorescence was detected upon 
CaM addition to the peptide. This happened due to changes on the local tryptophan 
environment which was caused by the binding of CaM to the IQ peptide (Bahloul et al. 
2004). 
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3.4.2 Calmodulin binds lipids in a Calcium-dependent manner 
Figure 86 details the lipid binding of CaM to folch lipiosomes as well as the three 
phosphatidylinositolphosphates PI(4)P, PI(3,5)P2 and PI(4,5)P2. In a calcium-free buffer, 
binding to folch liposomes was minimal (~ 5% of protein in pellet). Whilst CaM bound to 
PI(3,5)P2 and PI(4,5)P2 equally well (~25% of protein in pellet), no binding could be 
detected for the mono-phosphate PI(4)P.  
 
Figure 86: Calcium-dependent lipid binding of Calmodulin. (A): top row: lipid-affinity co-sedimentations with 
CaM and folch, PI(4)P, PI(3,5)P2, PI(4,5) P2 in Calcium-free buffer. Second row: same co-sedimentations as in A, but 
with 50 µM CaCl2 in the buffer. (B): Densitometry of both sets of co-sedimentations. Bars show mean value of four 
independent experiments. Size CaM: 24 kDa. Given is the percentage of protein in the pellet fraction. The intensity of 
the tail or full-length band in the pellet was divided by the total intensity (pellet + supernatant) for each sample to 
determine the percent of protein in the pellet. Error bars show standard deviation. (n = 4) 
This behaviour changed as soon as the identical co-sedimentation was performed with 
1 mM CaCl2 in the assay buffer. It was seen that calcium affected the binding of CaM to 
folch and the di-phosphates PI(3,5)P2 and PI(4,5)P2 only a little. The amount of protein in 
the pellet increased by approximately 6%. The effect of calcium on the interaction of 
CaM with PI(4)P on the other hand was substantial. Without calcium in the buffer, no 
interaction was measurable whereas with added Calcium around 10% of the total protein 
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was bound to the PI(4)P liposomes (p = 0.008) (figure 86, B). Binding to the lipid 
components PC, PE and Cholesterol was not detected. 
 
 Calmodulin binds IQ-motifs and lipids in a competitive manner 3.4.2.1
CaM on its own bound to folch, as can be seen in figure 87 A. But as soon as CaM was 
bound to the IQ-motifs 1 or 2, binding to lipids was abolished. The binding to either IQ 
peptide or lipids seemed to be mutually exclusive (figure 87, B and C). 
 
Figure 87: Calmodulin binds either lipids or IQ-motifs. Protein-lipid overlay assay (PLO) with CaM. On each blot: 
top row PC, second row PE and third row: folch is spotted on in serial dilutions (see 2.3.5). Only with folch a reaction is 
seen. PLO with IQ1 saturated with CaM shows no binding to any of the offered lipids. Only the antibody control spot at 
the bottom were the IQ1:CaM was spotted on is visible. Same as for IQ2:CaM which did not show an interaction with 
the lipids. For all three blots buffer was supplemented with 1 mM CaCl2. Blots at least conducted twice. 
 
 Calmodulin exhibits calcium-dependent lipid affinities 3.4.2.2
As seen in section 3.4.2, binding to folch, PI(3,5)P2 and PI(4,5)P2 was increased only 
slightly with the addition of calcium. Since calcium had such an impact on binding to 
PI(4)P, it was of interest to elucidate this calcium-dependent change in lipid affinities 
even further. For this purpose the PIP® and Membrane Strips®, introduced in section 
2.3.6, were used for a more detailed look into lipid affinity changes of CaM. Figure 88 
depicts the influence of calcium onto binding of CaM to the different offered lipids. 
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Figure 88: Calmodulin changes lipid affinities under changing calcium conditions. (A): PIP Strips of CaM without 
and with added 1 mM calcium (indicated above Strip). (B): Membrane Strips of CaM without and with added calcium 
show clear differences in lipid binding. (C): Whereas binding to folch on PLO was not altered by calcium addition. All 
blots were at least conducted twice. For blotted lipids see 2.3.6.  
Figure 88 C presents that calcium had no influence on the binding behaviour of CaM to 
folch when the lipid was presented on nitrocellulose. On the PIP Strips CaM 
demonstrated interaction with the mono-phosphates PI(3)P, PI(4)P and PI(5)P as well as 
weak interaction with the di-phosphate PI(3,5)P2. This binding pattern was not changed 
by addition of 1 mM calcium to the assay (figure 88, A). On the membrane strips on the 
other hand calcium had an influence on the binding of CaM to the lipids. In a Ca2+ -free 
buffer, CaM bound to Cardiolipin, PI(4)P and weakly to sulfatide. The interaction with 
sulfatide was highly increased when the assay was performed in a calcium supplemented 
buffer. In Ca2+-free buffer a very weak interaction between CaM and phosphatidic acid as 
well as phosphatidylserine was detected, which was almost completely abolished in 
1 mM calcium buffer. Interestingly binding to PI(4)P and Cardiolipin was not calcium-
dependent (figure 88). 
 
 IQ-motif-Calmodulin complex shows reduced lipid affinities 3.4.2.3
The interaction of the (Cam:IQ1) and (Cam:IQ2) complexes with lipids on the PIP Strips 
in figure 89 A and B were very weak. It was reproducible and proved to be only non-
specific antibody-reaction. Therefore a binding of this complex to any of the offered PIPs 
was not detected. All interactions which CaM alone showed as seen in figure 89 c 
encircled in red, were lost. 
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Figure 89: Calmodulin changes lipid affinities when bound to IQ peptides. (A): PIP Strip (see chapter 2.3.6) of 
IQ1:CaM. The reaction is non-specific. (B): PIP Strip (see 2.3.6) of IQ2:CaM. The reaction is non-specific as well. (c): 
PIP Strip of CaM under same buffer conditions as (A) and (B). (D): Membrane Strip (see 2.3.6) of IQ1:CaM. (E): 
Membrane Strip of IQ2:CaM. (f): Membrane Strip of CaM under the same buffer condition as (D) and (E). A reaction 
with sulfatide was maintained with and without bound peptide. Red circles indicate reaction of CaM with the Strips that 
is lost in the peptide-bound state. Buffer contained 1 mM CaCl2 for all experiments. Blots performed at least twice. 
Although CaM on its own (figure 89, f) bound to PI(4)P, Cardiolipin and Sulfatide on the 
membrane strips, the peptide-bound CaM showed a different behaviour. Binding to 
PI(4)P and Cardiolipin was lost and only a slight interaction with PI(4)P was traceable 
(figure 89 D and E, dotted circle). 
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3.4.3 Discussion 
 Lipid binding is not restricted to lever arm extension (LAE) or cargo-binding 3.4.3.1
domain (CBD) 
The BH-plot of myosin VI FL revealed two possible lipid-binding sites along the protein, 
one around the unique insert and the second IQ-motif and a second one in the CBD (see 
figure 59). This second possible binding site corresponded to the binding site published 
by Spudich et al. (2007), where it was found to specifically bind to PI(4,5)P2. Yu et al. 
(2012) described lipid binding in the LAE, which they found to bind to folch vesicles. In 
the course of this work it was found that in myosin VI lipid binding was not limited to 
these two structures but was found along the whole tail. All constructs, with the exception 
of the shortest tail (1125 tail), bound to folch liposomes. This special case will be 
discussed in a following section. 
Subtly different binding patterns of the tail constructs in binding studies with defined 
lipid compositions (PI(4)P, PI(3,5)P2, PI(4,5)P2) suggested different lipid affinities along 
the protein. FL VI, 913 tail and 814 tail bound to all three different PIPs whereas 1060 
and 1125 tail only bound PI(3,5)P2. Since the PIP Strips showed a slightly different 
picture with all constructs binding PI(3)P, PI(4)P, PI(5)P and PI(3,5)P2 and a very weak 
interaction with PI(4,5)P2 this pointed towards two main explanations: 
First, PIP-binding was not restricted to the CBD. Binding to PI(4)P and PI(4,5)P2 seemed 
to be present N-terminal of amino acid 1060 although described differently by Spudich et 
al. (2007) where they identified an amino acid sequence (WSKNKKR), by mutating it 
(→WASANNNR), as PI(4,5)P2 binding sequence. The ∆ PIP 883 tail construct was a 
kind gift from the Spudich lab and served here as a control. It was possible to repeat their 
findings (Spudich et al. 2007) with this construct, although the construct they used in the 
aforementioned publication was slightly longer (from aa 1017 to the end) than the one 
used in this project (aa 1060 to the end). This could mean that PI(4,5)P2-binding might 
not be limited to the abovementioned sequence motif. They never tested the mutated tail 
in a PI(4,5)P2-affinity co-sedimentation assay but only in immunofluorescence studies 
which could involve other, not yet defined binding partners linking myosin VI to the 
PI(4,5)P2.  
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Therefore it is claimed here, that myosin VI has a much weaker affinity for PI(4,5)P2 in 
calcium-free in vitro studies than thought until now and that all evidence points towards a 
much higher affinity for the precursor lipids PI(3)P, PI(4)P and PI(5)P as well as 
PI(3,5)P2 along the whole protein. All these findings allude to the assumption that 
membrane binding of myosin VI might not necessarily be mediated in a stereospecific 
fashion but via more unspecific electrostatic interactions with a variety of charged 
phospholipids. A possible regulative mechanism for PI(4,5)P2-binding will be discussed 
in the next section. These phosphatidylinositolphosphates are all involved, amongst 
others, in endocytosis, maintaining Golgi apparatus structure and autophagy and are 
therefore covering all fields of function of myosin VI.  
 
Second, the CBD constructs (1060 and 1125 tail) did not interact with PI(4)P and 
PI(4,5)P2 when presented as liposomes, but bound to these lipids when bound to a 
nitrocellulose surface. This might mean that additional mechanisms like curvature sensing 
(DiNitto et al. 2003, Hurley 2006, Lemmon 2008, Morton et al. 2012), electrostatic 
sensing (Rizo and Sudhof 1998, Sutton and Sprang 1998) or other mechanisms could 
account for this behaviour. Since lipids dried on nitrocellulose may in proportions expose 
parts of their molecules they would not when fitted into a liposome conformation, the 
nitrocellulose based assays may only give additional information about lipid binding 
affinities and should not stand alone. However they are highly repeatable and reliable and 
as shown in the myosin XXI mutant studies highly specific (see 3.5.3). 
 
 Calcium is a regulator of lipid binding 3.4.3.2
Calcium plays a pivotal role in the cell, especially in signal transduction pathways where 
it, amongst others, acts as secondary messenger. Its cytosolic concentration ranges from 
0.1 to 0.2 µM (pCa 7 to pCa 6.7) but can locally and temporarily change to considerably 
higher concentrations, depending on cell type, by released Ca2+ for example from the ER, 
the SR or introduced from the extracellular space. Here it is noticeable that the addition of 
higher amounts of CaCl2 to assays resulted in a change in lipid binding behaviour as well 
as lipid affinities. The addition of CaCl2 (pCa 4.3) increased the binding of FL VI to folch 
vesicles and switched the binding of the 1125 tail from no interaction to 50% bound 
protein and it influenced the binding behaviour to PIPs as well. Binding of the full-length 
protein to PI(4)P was slightly reduced by addition of CaCl2 (pCa 4.3), interaction with 
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PI(3,5)P2 was reduced by 10 fold and binding to PI(4.5)P2 was abolished completely. 
With PI(4,5)P2 however it was possible to show that calcium in lower concentrations 
(ranging from pCa 5.3 to pCa 4.6, calculated with WEBMAXC, Stanford, USA) did not 
abolish binding of myosin VI FL to it. This indicates a regulative mechanism where 
changes in intracellular calcium levels may help regulate binding to vesicles and therefore 
make cargo-exchange easier and more effective. The 1125 tail, as mentioned above, 
bound only by addition of calcium (pCa4.3) to folch vesicles. This construct bound 
additionally to vesicles with a 10% PIP content. The 814 tail bound only to 20% to folch 
vesicles but with added Calcium (pCa 4.3) to around 87%. Since calcium is meant to 
cluster PIPs in vesicles (Czech 2000, McLaughlin et al. 2002, Mak 2013), this could be 
an additional effect, which affected the binding of these two constructs to the folch 
vesicles. It possibly made the PIP more available to these otherwise weak binders. 
Additionally calcium changed the lipid affinities of the FL protein considerably. Where it 
did not bind to PA and PI(4,5)P2 on the membrane strips this binding was increased by 
addition of CaCl2 (pCa 4.3), whereas binding to PI(3,5)P2 was reduced after CaCl2 
addition. This can be explained by possible effects upon calmodulin conformational 
change  or the folding of the protein (Payrastre et al. 2001). 
 Different roles in different species for myosin VI? 3.4.3.3
The direct comparison of the cargo-binding domains (CBD) of chicken and human 
myosin VI revealed only slight differences in the sequence but major differences in lipid 
binding ability and affinity as well. The human CBD showed a much higher affinity to 
bind to folch vesicles and on nitrocellulose than the c1060 construct. And although both 
constructs bound to Cardiolipin, a main component of the inner mitochondrial membrane 
and other bacterial membranes, only the chicken CBD interacted strongly with sulfatide. 
Sulfatide is a major constituent of brain myelin where it is found exclusively on the 
extracellular membrane of the myelin sheath. It can be found in the islet of Langerhans 
and in other cells where it is involved in the activation of ion channels (1.8.2.1). This 
might point towards a different set of functions for avian myosin VI in comparison to 
mammalian myosin VI. 
 Motility on lipids is improved by better positioning 3.4.3.4
Although other myosins, for example myosin V and myosin XXI (see 1.5), are capable of 
smooth motility on nitrocellulose surfaces, myosin VI was not. A tail specific anti-body 
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had to be used to obtain motility. Motility on unordered non-fluid lipid surfaces was 
much better in comparison to motility on antibody covered surfaces. These two facts 
allude to the possible explanation that both systems may offer a better positioning for the 
motor on the surface than nitrocellulose. And that myosin VI was in an improved 
configuration to support motility as soon as it was bound to lipid surfaces. This was 
additionally supported by the fact that motility of a C-terminally biotinylated myosin VI 
FL construct on a biotinylated BSA substrate was equally good as on lipid surfaces. 
 
Figure 90: Possible configuration of myosin VI on different substrates. (A): motors on nitrocellulose may stick in 
all ways to the surface, (B): tail-specific antibody sticks different parts of the tail down (aa 846-1274) C: possible 
positioning of myosin VI on phospholipid containing non-fluid lipid surface and (D): optimal positioning of the myosin 
VI by biotinylation of the C-terminus and binding to biotinylated BSA. Arrow indicates largest possible lever arm of 
the protein in the gliding filament assay. 
As the cartoon in figure 90 depicts, different conformational settings for myosin VI on the 
surface are imaginable. On nitrocellulose, where no motility was measured, the motor 
might stick in unfavourable ways to the surface (A), whereas in a more ordered way with 
the polyclonal anti-tail antibody which was raised against the amino acids 846 to 1274 
and can bind to diverse parts in that amino acid range, resulting in an unordered mixture 
of positions of the VI FL (B) and in (C) possibly in the best configuration for motility 
which supports the highest measured velocities for this set-up, supported by (D) which 
depicts the optimal configuration of the myosin VI on the surface. An additional effect 
was the temperature dependence of myosin VI, where higher temperatures (37 °C) 
improved motility and accelerated the motion of the motor. Most intriguing was the 
finding of different affinities for substrates containing different types of PIPs. This might 
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be a regulative mechanism for different transport settings. The highest affinity for PI(4)P, 
which was only outperformed by the VI BRS, possibly stands for a long-range transport 
system in which myosin VI might be involved. PI(4)P is prevalent at the Golgi-apparatus 
and vesicles pinched off here need to be transported to various sites in the cell for 
example to the cell membrane, or the ER. This affinity will be discussed in detail in 
chapter 4 (general discussion). 
  Calmodulin binds directly to lipids 3.4.3.5
Calmodulin (CaM), the ubiquitous Ca2+ sensor of eukaryotic cells is involved in a wide 
variety of signalling events, regulating numerous proteins, including phosphatases, 
kinases, ion channels and pumps and myosins. As it was possible to show here, 
calmodulin bound to folch lipids on its own, but as soon as an IQ-peptide was bound to it, 
binding was disrupted. This may be a regulative mechanism with CaM binding 
exclusively either protein or lipid. Such was confirmed on the PIP strips, where no 
interaction with the lipids was detected as soon as calmodulin was bound to peptide. As a 
single protein CaM readily bound PI(3)P, PI(4)P and PI(5)P. On the membrane strips it 
was striking that binding to sulfatide was maintained or even improved throughout IQ-
peptide binding, whereas binding to Cardiolipin and PI(4)P was abolished. Kovacs, 
Harmat et al. (2010) found that CaM bound to sphingosylphosphorylcholine (SPC), a 
precursor to 3-Sulfogalactosylceramide (Sulfatide) in the sphingomyelin cycle. CaM 
bound to SPC in the presence and absence of Ca2+. In my experiments binding to 
Sulfatide improved with the addition of calcium. As soon as the IQ peptides were bound 
to CaM all other lipid binding abilities were lost, but the interaction to sulfatide persisted. 
That CaM still bound to sulfatide, even in the peptide-bound state, hints to the possibility 
that calmodulin might have a specific lipid binding site for sphingomyelin and its 
derivates which could still be exposed when CaM is wrapped around a target peptide. But 
this lipid binding ability might only be measurable in assays with peptides and not be 
commensurable in a properly folded full-length protein. 
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3.5 Myosin XXI, a novel molecular motor from 
Leishmania exhibits lipid binding abilities 
3.5.1 Lipid binding in Myosin XXI 
This chapter introduces myosin XXI, a novel molecular motor with similarities to myosin 
VI in terms of multifunctionality, which binds directly to lipids with most parts of its tail. 
Lipid binding and dimerisation in this motor seem to be mutually exclusive. It has protein 
has a phox homology (PX) domain in the converter region which is specifically 
interacting with PI(3,5)P2. In vitro filament gliding assays prove a higher affinity and 
faster actin translocation of myosin XXI on lipid surfaces than on nitrocellulose.  
 Designing of myosin XXI tail constructs 3.5.1.1
Myosin XXI is a motor that has only recently been expressed and characterised (Batters et 
al. 2012). Therefore it was relevant to design various constructs in the style of myosin VI, 
which allowed scrutinisation of various aspects of this protein (e.g. dimerisation, lipid 
binding, motility, cellular localisation etc.). This study is focussed, following the pattern 
of myosin VI, upon lipid-binding abilities of the tail and the identification of lipid-binding 
motifs or regions as well as motility on lipids. Therefore the full length protein as well as 
tail constructs of myosin XXI were designed and expressed (figure 91). The full-length 
protein and the truncation were expressed in a baculovirus system (2.1.12) whereas the 
tail constructs were expressed in an E. coli based expression system (2.2.4). 
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Figure 91: Schematic representation of myosin XXI motor truncation- and tail constructs. Full-length protein (aa 
1-1051), Motor truncation TruncXXI (aa 1-800). Tail constructs: 730 tail (aa 730-1051) 830 tail (aa 830-1051), 930 tail 
(aa 930-1051), 730-930 tail, 730-830 tail, 830-930 tail. Red dot represents Red-fluorescent protein (RFP) with which 
these constructs was expressed as well. 
 
3.5.2 Myosin XXI Lipid-binding capabilities bestride the entire tail 
As described for myosin VI in chapter 3.3.1.2, lipid-affinity co-sedimentations were 
performed to test lipid-binding competence of different tail-constructs. Initially the focus 
was set on the question does myosin XXI bind to lipids? And if it does, which parts of the 
protein were responsible for this interaction? To uncover the lipid-binding capacities of 
the different tail constructs, the binding to folch liposomes was assessed by quantifying 
the protein in the pellet fraction and therefore bound to the vesicles. The construct 
concentration varied from 1-4 µM whilst the liposome concentration was kept at 
0.2 mg/ml. 
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Figure 92: Control co-sedimentations of myosin XXI constructs. Full-length protein (123 kDa), Motor truncation 
XXI-T (95 kDa). Tail constructs: 730 tail (42 kDa), 830 tail (31 kDa), 930 tail, 730-930 tail (29 kDa). Controls were 
performed without the addition of liposomes. 
Because the tails 730-830 and 830-930 also pelleted in the control co-sedimentations 
(figure 92), they were excluded from the lipid-affinity co-sedimentations. 
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Figure 93: Co-sedimentations of myosin XXI constructs with folch liposomes. (A): Full-length protein (123 kDa), 
Motor truncation XXI-T (95 kDa). Tail constructs: 730 tail (42 kDa), 830 tail (31 kDa), 930 tail, 730-930 tail (29 kDa). 
The other tail constructs 730-830 and 830-930 pelleted without addition of liposomes and were therefore excluded from 
the assay (see control co-sedimentations figure 92). (B): Densitometry of the above co-sedimentations. Error bars 
represent standard deviation. Experiments were performed at least thrice. Given is the percentage of protein in the pellet 
fraction. The intensity of the construct band was divided by the total intensity (pellet+supernatant) for each sample to 
determine the percentage of protein in the pellet. 
 
All tested constructs bound to folch liposomes. All other constructs bound to more than 
50% of the offered liposomes. Only the longest tail (730 tail) bound to only 11% (figure 
93, B). The only tail binding completely to the liposomes was the 830 tail. 
 
 Almost all myosin XXI constructs bind to folch on nitrocellulose 3.5.2.1
Following the protocol of Dowler et al. (2002), protein-lipid overlay assays were 
performed as described in chapter 2.3.5.       
 As figure 94 shows, almost all constructs bound to the presented folch on 
nitrocellulose. Only the 730 tail construct ranging from amino acids 730 to 1051 did not 
bind to the lipids although it bound to liposomes of the same composition. The RFP 730-
830 and RFP 830-930 tail gave a very low signal, which indicated weak binding. For both 
tail constructs it looked as if there might be a concentration dependent binding with 
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stronger signal on the highest concentrated lipid spot and weakest signal on the lower 
lipid concentrations. 
 
Figure 94: PLO blots for all myosin XXI constructs. First row on each blot: pure PC in different amounts (from left 
to right: 500 pmol, 350 pmol and 200 pmol). Second row: pure PE, third row: folch. The control consisted of the 
respective target protein as check for antibody performance. A black dot indicates a positive reaction with the antibody 
and therefore binding of the protein construct to the particular lipid/ lipid-mix. All blots performed two to three times. 
None of the constructs interacted with the control lipids PC and PE. Since the RFP-tagged 
constructs were not available as untagged versions at the time of the assays, a test blot 
with pure RFP was performed as well, which did not bind to lipids (figure 94).  
 
 Myosin XXI tail constructs reveal only marginal membrane lipid binding-3.5.2.2
affinities 
Since almost all constructs were capable of interacting with nitrocellulose-bound mixed 
lipids (i.e. folch) (figure 94), a more detailed view of membrane lipid binding-affinities in 
this protein was to be obtained. As figure 95 shows, myosin XXI bound to a limited 
number of membrane components. Strikingly, as with myosin VI, all of the interacting 
lipids were negatively charged. 
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Figure 95: Membrane Lipid Strips® for myosin XXI constructs. A black dot indicates a positive reaction with the 
antibody and thus binding of the protein to the particular lipid. All experiments were at least performed twice. Lipids 
where reactions could be detected are indicated, for full layout of strips, see chapter 2.3.6. 
Between the FL construct and the tails no obvious change in binding-affinity could be 
detected. Only binding to Cardiolipin was slightly weaker in the 830 and the RFP730-830 
tail. The interaction with PA and PS was very weak throughout the tail constructs and the 
RFP730-930 tail did not interact with PA at all. 
 
 Myosin XXI constructs show only slight differences in Phosphatidylinositol (PIP) 3.5.2.3
binding 
An even more detailed look into lipid binding affinities was performed using PIP Strips® 
as PLO substrates. It was seen that only a range of lipids was bound to by myosin XXI 
constructs and that a variability of binding affinities was observable. 
The FL construct bound to the three mono-phosphates PI(3)P, PI(4)P and PI(5)P as well 
as the di-phosphate PI(3,5)P2 and the tri-phosphate PI(3,4,5)P3. Additionally binding to 
the di-phosphates PI(4,5)P2 and PI(3,4)P2 was detectable. Interaction with the 
phospholipids PA and PS was only seen in the tail constructs whereas the full-length 
protein did not interact. Binding to PS was pronounced only in the 830 tail construct, 
whereas it was more or less weak in all other tails (figure 96, blue circle). 
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Figure 96: PIP Strips® for myosin XXI constructs. A black dot indicates a positive reaction with the antibody and 
thus binding of the protein to the particular lipid. All experiments were at least performed twice. Lipids where reactions 
could be detected are indicated, for full layout of strips, see chapter 2.3.6. 
Binding to the three mono-phosphates was retained throughout the constructs and thus 
along the whole tail. Binding to PI(3,5)P2 was altered towards weaker interaction only in 
the tail constructs 730-930 (figure 95, green circle) and 830-930 (figure 96, green circle). 
A larger effect was seen on binding to PI(3,4,5)P3, which was strong with the full-length 
myosin XXI, weaker with the truncation and almost non-existent throughout the tail 
(figure 96, red circle). Therefore it can be summarised that binding to triphosphates was 
found only N-terminally of amino acid 830. 
 Sequence analysis 3.5.2.4
Since a BH plot (see chapter 5.1.1.1) showed one possible lipid binding site (figure 97), 
additionally to the experiments for lipid binding, a detailed search for known membrane 
interacting sequence motifs in the myosin XXI sequence was performed. A perfectly 
spaced Phox-Homology (PX) consensus sequence [R (Y/F) x23-30 K x13-23 R] (Teasdale 
and Collins 2012) was found in the converter domain. This domain type is a protein-lipid 
interaction motif which is thought to form an electro-positive patch to bind to negatively 
charged phosphate groups of phosphoinositides (Kurten et al. 2001) (see appendix 5.8).  
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Figure 97: BH plot of myosin XXI FL protein. Threshold given at 0.8, running window size was 19. A detailed 
explanation is given in chapter 3.3.1.1. Cartoon depicts FL myosin protein. One possible membrane-binding region is 
indicated in the converter region. BH-plot was performed on http://helixweb.nih.gov/bhsearch/ 
 
3.5.3 Phox-homology (PX) domain in the myosin XXI converter domain 
 Site-directed mutagenesis of PX-domain mutant 3.5.3.1
To prove the actual functionality of this motif, a PX-domain mutant was designed and 
expressed. The resulting construct ranged from amino acid 600 to 758 (see figure 98) and 
had two amino acids exchanged. The initial RY of the PX-motif was exchanged into LS 
in a two-step site-directed mutagenesis (see chapter 2.1.12). From CGG (R) to CTG (L) 
only one single base-exchange had to be performed, same as for TAC (Y) to TCC (S). 
The exchange of a strongly bound G to a weaker bound T (and a weaker bound A to 
stronger bound C) ensured additionally the reduction of reading errors of the DNA-
Polymerase during PCR reactions. Additionally amino acids with different characteristics 
were chosen to guarantee a diverging behaviour.  
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Figure 98: Amino acid sequence of myosin XXI converter domain and site-directed mutagenesis PX-mutant. (A): 
amino acid sequence of the construct comprising the converter domain and parts of the motor (aa 600-758, green) with 
flanking amino acids. (B): PX-domain official consensus sequence (Teasdale and Collins 2012), myosin XXI wild-type 
(WT) sequence and generated PX-mutant.  
Since different types of PX domains specifically bind PI(3)P, PI(3,4)P2, PI(4,5)P2, PS 
and/or PA it was necessary to perform protein-lipid overlay assays with PIP Strips® in 
order to see a difference in the behaviour between the wild-type and the mutant construct 
(see section 2.3.6). 
The wild-type (WT) not only bound PI(3)P, which is a PX-domain specific 
monophosphate, but PI(4)P and PI(5)P as well as the diphosphate PI(3,5)P2 (see figure 
99).  
 
Figure 99: PIP Strip® for myosin XXI PX-mutant construct. A black dot indicates a positive reaction with the 
antibody and thus binding of the protein to the particular lipid. Experiments were at least performed twice. Lipids where 
reactions could be detected are indicated, for full layout of strips, see chapter 2.3.6. 
A very weak interaction for other anionic lipids such as phosphatidylserine (PS, figure 99, 
blue circle) was found as well. The interaction with PI(3,5)P2 (figure 99, red circle) 
disappeared almost entirely in the mutant construct, whilst binding to the 
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monophosphates was retained. The weak interaction with PS, as seen in the WT construct 
was not detectable in the PX-mutant. This strongly supported the idea that the PX domain 
in the converter is involved in lipid binding. 
The sequence of the converter domain of a scallop muscle myosin II was replaced with 
the sequence of the L. donovani converter (see figure 100) and found that the amino acids 
of the PX domain form a patch on the surface of the converter domain consistent with 
these residues interacting with membranes without interfering with the general structure 
and function of the converter of this myosin motor (Batters et al. 2014). 
 
Figure 100: Crystal structure of scallop muscle myosin II. The sequence in the converter domain was replaced by 
the sequence of L. donovani. The amino acids specific to the PX domain (green) form a patch on the surface of the 
converter (red).  
 
3.5.4 Myosin XXI dimerisation and phospholipid-binding domains overlap  
In size exclusion chromatography (SEC) studies, it was shown that the distal 800-, 830- 
and 930-tail constructs were monomeric (Batters et al. 2014), but that all tail constructs, 
with exception of 830-930 tail, adopted mixed monomeric and dimeric populations in the 
presence of an N-terminal RFP tag (figure 101).  
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Figure 101: Lipid binding and dimerisation of myosin XXI tails are mutually exclusive. Membrane strips of 
RFP 730-830 tail fractions from SEC experiments. (A): PIP Strips of fractions 2 and 7 in comparison. Blue circle 
indicates binding to PI(4)P by fraction 7. (B): SEC curve of RFP 730-830 tail shows mixture of dimeric (fraction 2) and 
dimeric (fraction 7) conformation. Inset: silver-stained SDS PAGE of the obtained fractions from the SEC run, which 
shows that all fractions contain the same protein.  
Comparing the phospholipid binding of a monomeric and a dimeric fraction of the 
RFP 730-830 tail construct revealed that the monomeric form of the RFP 730-830 (see 
figure 101, fraction 7) bound to the phospholipid PI(4)P whereas the formed dimer of this 
tail (figure 101, fraction 2) did not bind to it. 
 
3.5.5 Myosin XXI shows higher gliding-velocity and functional affinity for lipid 
surfaces in in vitro motility assays  
After the examination of lipid-binding propensities in the myosin XXI protein, it was 
interesting to see whether a lipid substrate would alter myosin XXI motility in a similar 
way than it did for the myosin VI. This study was focussed only on motility on folch 
surfaces. These were prepared as described for myosin VI in chapter 3.3.11. 
Myosin XXI showed relatively slow motility when directly attached to nitrocellulose 
surfaces (figure 102) with velocities around 18 nm/s. Interestingly, velocity was about 
four times higher (66 nm/s) when the motor was bound to immobile folch membranes 
(figure 102) (Batters et al. 2014). Velocities were measured by tracking of actin filaments 
from 10 s-time-lapse movies by hand. 
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Figure 102: Bar chart for two different motility assay substrates with myosin XXI at a motor concentration of 
250 nM. Error bars show standard deviation; (p ≤ 0.001). (n = 653 filaments).  
According to figure 103 two major effects were noticed. First, the velocities for the two 
substrates were, as described for figure 102, significantly different (p ≤ 0.001). The 
highest velocity for motors on folch surfaces was 66 nm/s (± 8.8 nm/s) at a motor 
concentration of 12 nM. In contrast, the highest velocity on nitrocellulose was 18 nm/s 
(± 5 nm/s) at motor concentrations from 170 to 250 nM. 
 
Figure 103: Graph for two different motility assay substrates with myosin XXI at different motor 
concentrations. Error bars show standard deviation. (n = 653 filaments) 
The second effect was that the necessary motor density for uninterrupted filament motility 
was much lower on folch surfaces than on nitrocellulose surfaces. Motility on 
nitrocellulose ceased at a concentration of 160 nM whilst smooth motility on folch was 
obtainable down to a concentration of 8 nM, which equalled a 20-fold reduction.  
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3.5.6 Discussion 
Lipid binding was found along the entire tail of myosin XXI including the converter 
domain in the neck of this motor. Therefore it can be said that in myosin XXI the 
predicted coiled-coil regions overlap with lipid binding regions and thus dimerisation and 
lipid binding might be influenced or regulated by each other. In a recent study connected 
to this thesis (Batters et al. 2014) we found that dimerisation and lipid binding were 
mutually exclusive. Size exclusion chromatography of the 730-830 tail revealed that this 
motor seemed to be able to adopt dimeric and monomeric states. The dimer could 
possibly play a role in the cytosol since it did not bind to lipids. The monomer on the 
other hand bound lipids and lipid binding along the neck and tail might target this fraction 
to specific membrane compartments. As found with myosin VI, most of the membrane 
binding of myosin XXI was not mediated in a stereospecific way but relied on unspecific 
electrostatic interactions to various phospholipids. The newly described PX domain in the 
converter region was not highly specific for PI(3)P, as they reportedly are (Lemmon 
2008), but bound to all three monophosphates, PI(3,5)P2 and PS. In the mutant construct 
binding to the latter two was completely abolished. The higher velocity and better 
motility of myosin XXI on lipid surfaces might be the result of an improved configuration 
of the motor on the surface. 
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4.1 Myosin VI back folds its tail to change into an 
inactive conformation 
The inability of the full-length myosin VI to dimerise spontaneously even though it has a 
predicted coiled-coil structure with a high score in its C-terminal tail, brought forth a 
model that predicted the myosin VI tail folds back onto itself (Spink et al. 2008, Spudich 
and Sivaramakrishnan 2010). In this study it was possible to show that the entire tail folds 
back onto itself and also which regions interact with each other (Chapter 3.2). The 814 
tail showed low binding to lipid vesicles and no interaction with the motor truncation 
constructs. This is because the tail is folded back and thus inactive. The 1060 tail was 
shown to interact with the calmodulin bound to the IQ-motifs one and two but not to the 
free IQ-motif peptides. This interaction was disrupted by the addition of calcium. Taken 
together this points to a regulative mechanism that a bound calmodulin is needed for the 
back folding, and that as soon as this calmodulin changes its conformation into the holo-
state upon calcium binding it disrupts the interaction of the C-terminal tail and the neck. 
Yet, no unfolding events of the tail were measured in any assay upon the change of the 
calcium concentration. This might be due to the fact that the folding back of the tail is not 
an exclusive interaction between the calmodulin and the first 65 amino acids of the cargo-
binding domain but electrostatic interactions along the entire tail (figure 104).  
4.2 Myosin VI interacts directly with membrane lipids 
Lipid binding in myosin VI is not restricted to formerly described binding sites in the 
cargo-binding domain and lever arm extension (Spudich et al. 2007, Yu et al. 2012) but is 
present along the entire tail (Chapter 3.3) which could be deduced from the differences in 
binding patterns of the different tail constructs. The phosphatidylinositolphosphates 
PI(4)P, PI(3,5)P2 and PI(4,5)P2, when presented as vesicles, were bound to by all 
constructs apart from the 1060 and 1125 tail which only bound to PI(3,5)P2. On the 
protein-lipid-overlay blots all constructs bound to PI(3)P, PI(4)P, PI(5)P, PI(3,5)P2 and 
only weakly to PI(4,5)P2. As mentioned before, the cargo-binding domain constructs 
1060 and 1125 tail did not interact with PI(4)P and PI(4,5)P2 in vesicles but they did on 
the nitrocellulose strips (table 6). 
General Discussion 
156 
 
Table 6: Lipid binding in myosin VI to vesicles and on Protein-lipid-overlay assays (PLOs). Green filled cells 
indicate binding, red no binding. A complete table with controls can be found in the appendix. 
 
When bound to lipid surfaces in an in vitro motility assay myosin VI seemed to be 
favourably positioned on PI(4)P surfaces where the highest affinity and velocity was 
seen. Slightly weaker binding to PI(3,5)P2 and PI(4,5)P2 might result in a more instable 
positioning on the surface. Although most of the motors might be in a favourable 
position, those that are not may disrupt motility at higher concentrations accounting for 
the lower affinities. The 1125 tail did not bind to PI(4)P without calcium but bound in a 
calcium-supplemented buffer. Motility was, as said before, best on PI(4)P surfaces and a 
control with myosin VI BRS showed optimal C-terminal positioning and comparable 
velocities. Therefore one could argue that the myosin VI is, under low calcium conditions 
not ‘standing on tip-toe’ but binding to the surface with the entire CBD. This could 
change slightly with the change of calcium concentration and thus myosin VI would have 
the complete tail as lever arm for motility. 
These findings lead to the following conclusions: (1) binding to lipids in the myosin VI 
tail might well be stereospecific in some places but relies on unspecific electrostatic 
interactions to various phospholipids in other places. (2) Binding to lipids on a surface 
varies from binding to lipids in a physiological vesicle conformation. This indicates that 
other binding mechanisms like curvature sensing (DiNitto et al. 2003, Hurley 2006, 
Lemmon 2008) and electrostatic sensing (Rizo and Sudhof 1998, Sutton and Sprang 
1998) might play a role in the interaction of myosin VI to lipids as well. (3) The 
differences in velocity and affinity for different phospholipid surfaces point towards a 
possible explanation for the involvement and regulation of myosin VI in its diverse tasks 
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in the cell. The high affinity for PI(4)P might be due to a ‘long-range’ transport system 
between Golgi and ER with PI(4)P being the most important lipid in exocytosis not only 
as precursor for other PIPs but also for membrane targeting and activation of regulatory 
proteins (Johansen et al. 2012). This could explain the higher affinity of myosin VI for 
this lipid. The lower affinities for PI(3,5)P2 and PI(4,5)P2 might be connected to their 
occurrence in the cell as well. PI(3,5)P2 for example is prevalent in the endosomal 
pathway in which myosin VI is only partly involved (e.g. early endosome transport). 
PI(4,5)P2, being the major polyphosphoinositide in mammalian cells is enriched in the 
plasma membrane and is involved in exo- and endocytosis as well as membrane 
trafficking. Here, the interaction between myosin VI, which is involved in most of these 
processes, might not only be a direct one but could involve several regulatory binding 
partners (see next section). 
 
4.3 Calcium as co-regulator of myosin VI back folding 
and lipid binding  
Myosin VI’s lipid binding seems to be regulated or at least co-regulated by calcium 
(Chapter 3.3.2). Under high calcium conditions the full-length protein bound to folch 
vesicles much better than without calcium. The 1125 tail did not bind to folch vesicles 
until calcium was added. The finding that the binding behaviour of the FL protein to the 
PIPs was differently influenced by calcium depending on whether the lipid was presented 
in a spherical vesicle or on nitrocellulose membranes, together with the findings of the 
formerly described influence of calcium onto the back folding of myosin VI, led to the 
idea that a much more complicated regulative mechanism than mere calcium regulation is 
involved in lipid binding. It is very likely that a whole range of effectors regulate myosin 
VI in the cell, therefore the analysis of binding partners is of interest. An important 
binding partner is the autophagy receptor NDP52 which binds directly to myosin VI via 
the RRL motif in the cargo-binding domain (Tumbarello et al. 2013) which is then 
specifically bound by Galectin-8 (Kim et al. 2013) which targets it to membranes 
(Thurston et al. 2012). Another example is the monomeric yeast myosin IV which builds 
a heterotrimer with the dimeric binding partner She3p which then recruits a mRNA 
zipcode and an additional partner She2p and this complex then binds to another myosin 
IV molecule to form a processive dimer.  
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This leads to the model where a multi-step regulatory mechanism with calcium unfolding 
the protein partially, thus exposing formerly hidden binding sites for binding partners or 
lipids which then starts a cascade during which myosin VI is bound to cargo and 
transports it to its destination (figure 104). 
 
Figure 104: Possible folding of the C-terminal myosin VI tail onto the IQ-bound Calmodulins. (A): back folded, 
monomeric and mechanically inactive myosin VI, (B): with high calcium concentrations the tail partly unfolds and the 
lever arm may be destabilised. (C): active state of myosin VI. At low calcium concentration it may first unfold and thus 
bind to binding partners or cargo, can dimerise and is mechanically active when bound to cargo. If no binding to either 
cargo or binding partner occurs it goes back in the inactive state as seen in (A). 
 
4.4 Myosin XXI binds lipids along the tail and has a 
specific PX-domain 
Myosin XXI exhibits lipid binding along the entire tail, as seen with myosin VI (Chapter 
3.5). Although it is the only expressed myosin in Leishmania sp. and must therefore be a 
multifunctional motor protein, it has a PI(3,5)P2 specific phox-homology (PX) domain in 
the converter region in the neck of the motor. PI(3,5)P2 is concentrated mainly in the late 
compartments of the endosomal pathway and plays important functions in multivesicular 
body sorting, endosomal dynamics and autophagy (Shaw et al. 2003). This might point 
towards the performance of very specific transport functions in the endosomal pathway 
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and autophagy. In Leishmania, two distinct myosin XXI populations were described, one 
motile cytosomal fraction and one immotile membrane bound fraction (Batters et al. 
2014). Since this is a very newly described motor, not much is known about regulatory 
mechanisms and possible differences between these two populations. Considering the tail 
of myosin XXI, it comprises several coiled-coil regions, most of which bind lipids. In this 
study it was possible to show with SEC measurements, that lipid binding and 
dimerisation are mutually exclusive. Myosin XXI may, as myosin VI, be part of a very 
complicated and diverse regulatory system, including regulatory proteins, binding 
partners, ions and lipids.  
 
4.5 Calmodulin exhibits lipid binding on its own 
Calmodulin, the ubiquitous calcium sensor of eukaryotic cells binds to lipids (Chapter 
3.4). This in itself is not a new finding (Kovacs et al. 2010), but in this present study it 
was shown that binding to lipids depends on the binding state of calmodulin to its target 
peptide. Calmodulin exclusively bound either protein or lipid. It was found to bind 
especially to 3-galactosylceramide (sulfatide), a descendant of sphingosyl-
phosphorylcholine (SPC) in the sphingomyelin cycle which was already published by 
Kovacs et al. (2010). This binding persisted throughout IQ-peptide binding and therefore 
this points towards the possibility that calmodulin might have a specific binding site for 
spingomyelin and its derivates which could, upon binding to a target sequence still be 
exposed.  
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4.6 Conclusions 
Both myosin VI and XXI were found to have the ability to bind to lipids at multiple sites 
along the entire length of the tail. This protein-lipid interaction was shown to be calcium 
dependent in myosin VI, suggesting that calcium regulates the tertiary structure of the 
protein and thus might play a pivotal role for the regulation of myosin VI in the cell. 
Despite having a large predicted coiled-coil region myosin VI did not show any 
dimerisation in this study. Using protein co-sedimentation experiments it was shown that 
the formerly proposed back folded state occurs due to an interaction between the first 65 
amino acids of the C-terminal cargo-binding domain and the calmodulin bound to the IQ- 
motifs in the N-terminal neck region. As already known, the calcium-sensing protein 
calmodulin changes its conformation depending on whether it is in the calcium free (apo)- 
or the calcium bound (holo)-state. This led to the hypothesis that the backfolding of 
myosin VI could be regulated by the ability of the C-terminal tail of myosin VI to 
distinguish between these two conformations. Using Dot Far-western blots and 
tryptophan titrations experiments it was shown that this was the ‘switch’ for myosin VI to 
unfold. 
Similar to myosin VI, lipid binding in myosin XXI occurs along the length of the entire 
tail, although with different affinities for different tested lipids. Myosin XXI is capable of 
dimerisation and it was shown that lipid binding and dimerisation are mutually exclusive. 
Additionally, a PI(3,5)P2 sensitive PX (phox homology)-domain was found in the 
converter region of this motor which capacitates it to bind this lipid specifically. 
 
4.7 Outlook 
The effect on myosin VI binding to liposome cargoes and how this affects the 
dimerisation tendencies of myosin VI, with bound partner proteins, and in turn changes in 
the translocation abilities of vesicle cargo in in vitro assays are the major aspects of this 
work. In terms of cargo-binding, single-particle work with vesicle-laden myosin VI 
would be of interest to measure the actual strength of the direct binding to diverse lipids 
in contrast to binding to liposomes via cargo-adaptor proteins. This could either be done 
utilizing optical tweezers with an actin filament suspended between two polystyrene 
beads or magnetic tweezers where one end could be tethered to the glass surface by e.g. 
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polyethyleneglycol (PEG) or an antibody and the other on a magnetic bead. With these 
mechanical experiments it would be possible to actually measure a myosin VI carrying 
cargo on actin filaments and measure step-length, displacement and processivity. To 
assess how myosin VI carries its cargoes a motility assay with fascin-actin bundles on the 
surface could show if the motor does side-stepping movements and thus does possibly not 
need to dimerise.  
Since binding partners play a pivotal role in the regulation of myosin VI, it is therefore of 
great interest to investigate the direct interaction between myosin VI and its diverse 
binding partners. Analytical ultracentrifugation (AUC) could be used to scrutinize these 
interactions in more detail. In this context the direct interactions of myosin VI with 
ubiquitin via its MIU (motif interacting with ubiquitin) in the C-terminal tail are of 
interest to investigate further roles in the autophagic process.          
Live cell imaging with cells transfected with myosin VI can reveal not only where 
myosin VI is localised in the cell, as has been done before, but to see it moving along 
actin. Photo bleaching experiments could provide us with further insights as to how many 
myosin VI motors are bound to a vesicle and thus help to answer the question how 
myosin VI transports vesicles. Additionally, different point mutations and leucine-
zippered constructs could help to show how and if myosin VI is dimerising. 
Myosin XXI is a very intriguing motor since it seems to fulfil a multitude of tasks in 
Leishmania. Therefore further characterisation and localisation studies in living cells can 
yield new information about this newly described versatile motor. Its interactions with 
calmodulin-like (CaM-like) proteins need to be established further as well as its direct 
interaction with ubiquitin via its C-terminal ubiquitin-associated domain (UBA). These 
interactions can give better insight to myosin XXI’s role in Leishmania. Its mechanical 
properties such as displacement, processivity and step-length should be measured 
according to other myosins to further characterise this motor protein. 
If we gain an in-depth understanding of myosins, their transport and binding behaviour in 
cells, organelle-specific targeting of drugs and thus new ways of therapy will come into 
reach. 
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5.1 Plasmids 
pEt-28a (novagen®) 
 
 
 
 
 
 
 
 
 
 
 
 
 
pGex 6P-1 (GE healthcare) 
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pFastBac HTB (Invitrogen®) 
 
 
 
 
 
 
 
 
 
 
 
 
 
pFastBac 1 (Invitrogen®) 
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pColaDuet (Novagen) 
 
 
 
 
 
 
 
 
 
 
 
 
 
pAC4 (Avidity) 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
v 
Champion pET SUMO (life technologies) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 105: Vectormaps of plasmids used in this study. Vectormaps created with SnapGene software. 
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5.2 Oligonucleotides 
5.2.1 Oligonucleotides Myosin VI 
Internal Primer ID Primer Sequence Rest. site 
 
Chick VI SalI F 
Chick VI XhoI RP 
 
c FL VI 
AAAGTCGACAATGGAGGACGGGAAGCCCGTTTG 
ACTCGAGCTATTTCAACAGGTTCTGCAGC 
 
SalI  
XhoI 
 c FL ∆ PIP 
construct gift from F. Buss‘ lab. 
 
 
CVI Trunc814-SalI-FP 
CVI Trunc814-XhoI-RP 
c Trunc 814 
AAAAAAGTCGACAATGGAGGACGGGAAGCCCGTTTG 
AAAAAACTCGAGCTAGTATTTTGATGCAGGCACT 
 
SalI  
XhoI 
 
Chick VI SalI F 
Chick_trun913_XhoI_R 
c Trunc 913 
AAAGTCGACAATGGAGGACGGGAAGCCCGTTTG 
ACTCGAGCTACCTCTTGCTGTTTTTTCTTTTG 
 
SalI  
XhoI 
 
Chick VI SalI F 
Chick_trun1060_XhoI_R 
c Trunc 1060 
AAAGTCGACAATGGAGGACGGGAAGCCCGTTTG 
ACTCGAGCTAGTAGCTTGAACTGCAGGACC 
 
SalI  
XhoI 
 
NCB_NotI_For 
NCB_XhoI_Rev 
h 814-1060 
AGAGGCGGCCGCATGGAAGCCTGCATTAAAATGC 
AAAAAACTCGAGCTAGGTGGCTAGTACAGCAGGACC 
 
NotI  
XhoI 
 
CT814FPNOT1 
CTRPXHOI 
h 814 
AGAGGCGGCCGCCAGTGCCTGCATCAAAATAC 
ACTCGAGTTATTTCAACAGGTTCTGCAGC 
 
NotI  
XhoI 
 
CT913FPNOTI 
CTRPXHOI 
h 913 
AGAGGCGGCCGCCCAAAAGAAAAAACAGCAAGAGG 
ACTCGAGTTATTTCAACAGGTTCTGCAGC 
 
NotI  
XhoI 
 
CT1060FPNOTI 
CTRPXHOI 
h 1060 
AGAGGCGGCCGCCGGTCCTGCAGTTCAAGCTAC 
ACTCGAGTTATTTCAACAGGTTCTGCAGC 
 
NotI  
XhoI 
 
hVI-1060FPBamHI 
hVI-ENDRP-XhoI 
h 1060 
AAAAAAGGATCCGCAGAACTACGTGATACC 
ACTCGAGTTATTTCAACAGGTTCTGCAGC 
 
BamHI  
XhoI 
 
CT1060FPNOTI 
ChickenVI 1060-XhoI-
RP 
c 1060 
AGAGGCGGCCGCCGGTCCTGCAGTTCAAGCTAC 
AAAAAACTCGAGCTAACCTCTAGACAACATTTCTGAC
ATTTCTTTGGCCATTT 
 
NotI  
XhoI 
 
Human_VI1125_NotI_F 
Human_VI1125_XhoI_R 
h 1125 
AGAGGCGGCCGCATGACTGATTATCCTCAGCAAAAC 
ACTCGAGCTATTATTTCAACAGGTTCTGCAGC 
 
NotI  
XhoI 
 
Chick VI 883-NotIF 
CTRPXHOI 
h 883 ∆ PIP 
AGAGGCGGCCGCATGACCAAAATTAAGACTACG 
ACTCGAGTTATTTCAACAGGTTCTGCAGC 
 
NotI  
XhoI 
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 Sequencing primers 5.2.1.1
primer ID primer vector 
T7 
pRSET-RPnew 
TAATACGACTCACTATAGGG 
GGGTTATGCTAGTTATTGC 
pET28 
pGex5-FP 
pGex3-RP 
AACGTATTGAAGCTATCCC 
TCAAGAATTATACACTCCG 
pGex 
pBakPac-FP 
pEGFP_C2-RP 
TAAAATGATAACCATCTCGC 
TTTAAAGCAAGTAAAACCTC 
pFastBac 
 
Table 7: List of oligonucleotides used for myosin VI constructs design. All primers procured from Sigma. 
 
5.2.2 Oligonucleotides myosin XXI 
Primer ID Primer Sequence Rest. site 
 
XXIFP6BamHI 
XXIRP4 
FL XXI 
AGGATCCATGCCGGAGCGTGTGTCTGTG 
AAAAGCGGCCGCCTAGCTCACCTTGAACAGCATCTTAACGG 
 
BamHI 
NotI 
 
XXIFP6BamHI 
MYOXXTR6 
1-800 
AGGATCCATGCCGGAGCGTGTGTCTGTG 
AAAAGCGGCCGCCTATTTCTCCGCCGGCACACC 
 
BamHI 
NotI 
 
XXI730FP-
MAM 
XXI-ENDRP-
MAM 
730 
GGGAAGCTTGGCAAGACGAAGGTGTTCCTCC 
AAAAAAGGATCCCTAGCTCACCTTGAACAGC 
 
HindIII 
BamHI 
 
XXI800FPNONF 
XXI-ENDRP-
MAM 
800 
GGGAAGCTTTAGACGCCGCCAATGGTGTGC 
AAAAAAGGATCCCTAGCTCACCTTGAACAGC 
 
HindIII 
BamHI 
 
XXI830FP-
MAM 
XXI-ENDRP-
MAM 
830 
GGGAAGCTTGCCGTCGAGGCGGACACGCGCG 
AAAAAAGGATCCCTAGCTCACCTTGAACAGC 
 
HindIII 
BamHI 
 
XXI930FP-
MAM 
XXI-ENDRP-
MAM 
930 
GGGAAGCTTGGCACGGACAGCGAATATGCC 
AAAAAAGGATCCCTAGCTCACCTTGAACAGC 
 
HindIII 
BamHI 
 
XXI730FP-
MAM 
XXI830RP-
MAM 
730-836 
GGGAAGCTTGGCAAGACGAAGGTGTTCCTCC 
AAAAAAGGATCCCTAGCGCGTGTCCGCCTCGACGGC 
 
HindIII 
BamHI 
 
XXI830FP-
MAM 
830-930 
GGGAAGCTTGCCGTCGAGGCGGACACGCGCG 
AAAAAAGGATCCCTAGGCATATTCGCTGTCCGTGCC 
 
HindIII 
BamHI 
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XXI930RP-
MAM 
 
XXI730FP-
MAM 
XXI930RP-
MAM 
730-930 
GGGAAGCTTGGCAAGACGAAGGTGTTCCTCC 
AAAAAAGGATCCCTAGGCATATTCGCTGTCCGTGCC 
 
HindIII 
BamHI 
 
XXI-658-
SUMO-FP 
XXI-760-RP-
SUMO 
SUMO 650-758 
TACTTCCAATCCAATGCATCGCAGCTTGAGTCCGCTGG 
TTATCCACTTCCAATGTTATTAGCAGCGGTGCAGCAGCTGCGC
GCGGCGACGAA 
 
SspI 
 
 
XXI-600-
SUMO-FP 
XXI-760-RP-
SUMO 
SUMO 600-758 (PX mutant) 
TACTTCCAATCCAATGCATCTCTCGACGGAGAAGAGCGAGGCA
CGCCGCAAGCAGA 
TTATCCACTTCCAATGTTATTAGCAGCGGTGCAGCAGCTGCGC
GCGGCGACGAA 
 
SspI 
 
 
Table 8: List of oligonucleotides used for myosin XXI construct design in this study. All primers procured from 
Sigma. 
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5.3 Sequences Myosin VI 
5.3.1 Myosin VI (NI) 
Sequence obtained by sequencing the pFastBacHTB_EGFP_MyosinVI_NI_hum  
ATGGAGGATGGAAAGCCCGTTTGGGCGCCACACCCTACAGATGGATTTCAGATGGGCAAT
ATTGTGGATATTGGCCCCGACAGCTTAACAATTGAACCCTTGAATCAGAAAGGCAAGACA
TTTTTGGCTCTCATAAACCAAGTGTTTCCTGCAGAAGAGGACAGTAAAAAAGATGTGGAA
GATAACTGTTCACTAATGTATTTAAATGAAGCCACACTGCTCCATAATATCAAAGTTCGA
TATAGTAAAGACAGAATTTATACATATGTCGCCAACATTCTGATTGCAGTGAATCCATAC
TTTGACATACCTAAAATATATTCTTCAGAAGCAATAAAGTCATATCAAGGAAAATCTCTT
GGGACAAGACCACCTCATGTCTTTGCAATTGCTGATAAAGCTTTTCGAGACATGAAGGTG
CTCAAGATGAGTCAGTCTATCATTGTATCTGGAGAATCAGGAGCCGGCAAAACAGAAAAT
ACAAAATTTGTTCTAAGATACCTGACTGAATCCTATGGAACAGGTCAAGATATTGATGAC
AGAATTGTTGAAGCTAACCCACTCCTAGAAGCCTTTGGAAATGCGAAGACTGTTCGCAAC
AATAATAGCAGTCGATTTGGGAAATTTGTAGAAATACATTTTAATGAAAAGAGCTCAGTT
GTTGGAGGATTTGTTTCACATTATCTCCTAGAGAAATCTAGGATCTGTGTTCAAGGCAAA
GAGGAAAGAAATTATCATATCTTTTATAGGTTGTGTGCTGGTGCTTCTGAAGATATTAGA
GAAAAACTTCATTTGAGTTCACCAGATAATTTTCGGTATTTAAACCGAGGCTGCACTAGA
TACTTTGCTAACAAAGAAACTGACAAACAGATTTTACAGAACCGCAAAAGTCCTGAGTAC
CTTAAGGCAGGTTCTATGAAAGATCCTCTGCTAGATGACCATGGTGATTTTATTAGAATG
TGCACGGCTATGAAAAAAATTGGTTTGGATGATGAAGAAAAGCTTGATCTCTTCCGGGTA
GTAGCTGGCGTCCTGCACCTTGGAAATATTGATTTTGAGGAAGCTGGCAGCACTTCAGGT
GGTTGTAATCTGAAGAATAAATCTGCTCAGTCTTTGGAATATTGTGCTGAATTACTGGGT
TTGGACCAAGATGATCTTCGAGTAAGTTTGACCACAAGAGTCATGCTAACAACAGCAGGG
GGCACCAAAGGAACAGTTATAAAGGTACCTCTGAAAGTGGAGCAAGCAAACAATGCTCGT
GATGCCCTGGCAAAGACAGTGTATAGCCATCTTTTTGATCATGTGGTAAACAGAGTAAAT
CAGTGTTTTCCTTTTGAAACATCATCCTATTTTATTGGAGTCCTAGATATTGCTGGTTTT
GAGTACTTTGAGCATAACAGTTTTGAACAATTTTGCATCAACTATTGCAATGAAAAACTT
CAACAATTTTTTAATGAAAGGATTCTGAAGGAGGAACAAGAACTCTATCAAAAAGAAGGT
TTAGGTGTTAATGAAGTGCATTATGTGGATAATCAGGACTGTATAGATTTAATTGAAGCC
AAATTAGTGGGAATACTGGATATTTTGGATGAAGAAAATCGCCTTCCCCAGCCAAGTGAT
CAACACTTTACATCTGCAGTTCACCAAAAGCACAAGGATCATTTTCGACTCACTATTCCC
AGAAAATCTAAGCTGGCAGTTCATAGGAATATCAGAGACGACGAAGGCTTCATTATCAGG
CATTTTGCGGGGGCAGTGTGCTATGAAACAACCCAGTTTGTGGAGAAAAATAATGATGCT
TTACATATGTCTCTTGAATCCTTAATATGTGAATCCAGAGATAAGTTTATACGGGAATTA
TTTGAATCATCCACAAATAACAACAAAGATACTAAACAAAAAGCAGGAAAACTTAGCTTC
ATCAGCGTGGGAAACAAGTTTAAGACACAGTTAAATTTGCTTCTGGATAAACTTCGAAGT
ACTGGAGCAAGCTTTATTCGTTGCATCAAACCTAACTTAAAGATGACAAGCCACCACTTT
GAAGGTGCTCAAATTCTGTCTCAGCTTCAGTGTTCAGGGATGGTGTCTGTTTTGGACTTG
ATGCAGGGTGGTTACCCATCACGAGCTTCATTTCATGAACTCTACAACATGTACAAAAAG
TATATGCCAGATAAACTTGCAAGATTGGATCCAAGACTATTTTGTAAGGCTTTGTTTAAA
GCTTTGGGCTTAAATGAAAATGACTACAAGTTTGGGTTAACCAAAGTATTTTTTAGACCT
GGCAAGTTTGCAGAATTTGATCAGATCATGAAGTCTGACCCTGACCACTTAGCAGAGTTG
GTTAAAAGAGTCAATCACTGGCTCACATGCAGTCGCTGGAAGAAAGTTCAGTGGTGCTCA
CTCTCAGTCATCAAATTGAAAAACAAAATAAAATATCGAGCTGAAGCCTGCATTAAAATG
CAAAAAACTATTCGAATGTGGCTTTGCAAGAGGAGACACAAACCTCGCATTGATGGTCTG
GTTAAGGTGGGCACACTGAAAAAACGACTTGATAAATTTAATGAGGTAGTCAGTGTGTTG
AAAGATGGAAAACCCGAGATGAATAAACAGATCAAGAATCTGGAAATTTCTATTGATACT
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TTGATGGCCAAAATTAAGTCCACTATGATGACGCAGGAACAAATCCAGAAAGAATATGAT
GCACTGGTTAAAAGCTCAGAGGAACTCCTCAGTGCATTACAGAAAAAAAAACAGCAGGAA
GAGGAAGCAGAAAGGCTGAGGCGTATTCAAGAAGAAATGGAAAAGGAAAGAAAAAGACGT
GAAGAAGACGAAAAACGTCGAAGAAAGGAAGAGGAGGAAAGGCGGATGAAACTTGAGATG
GAAGCAAAGAGAAAACAAGAAGAAGAAGAGAGAAAGAAAAGGGAAGATGATGAAAAACGC
ATTCAAGCTGAAGTGGAGGCACAGCTGGCCCGACAGAAGGAGGAGGAATCCCAACAGCAA
GCAGTTCTGGAGCAGGAGCGCAGGGACCGGGAGCTGGCCCTGAGGATTGCCCAGAGTGAA
GCCGAGCTCATCAGTGATGAGGCCCAGGCCGACCTGGCGCTGCGGAGAGGTCCTGCTGTA
CTAGCCACCAAAGCAGCTGCTGGTACTAAGAAATATGATCTTAGTAAATGGAAATATGCA
GAACTACGTGATACCATCAATACTTCTTGTGATATTGAGCTCCTGGCAGCTTGCAGAGAA
GAATTTCATAGGAGACTAAAAGTGTATCATGCTTGGAAATCTAAGAACAAGAAGAGAAAT
ACTGAAACAGAGCAACGTGCTCCAAAGTCTGTTACTGATTATCCTCAGCAAAACCCAGCA
GCTCAGATTCCTGCCAGGCAGCGGGAGATTGAAATGAACCGACAGCAACGCTTCTTCCGC
ATCCCATTCATCCGCCCTGCCGACCAGTACAAAGACCCTCAGAGTAAGAAAAAAGGCTGG
TGGTATGCCCATTTTGATGGACCATGGATTGCCCGGCAAATGGAACTCCATCCTGACAAG
CCACCCATCCTACTTGTGGCTGGTAAGGACGACATGGAGATGTGTGAGCTGAATCTTGAG
GAGACTGGCCTGACTCGGAAGCGTGGTGCTGAGATCTTGCCAAGACAGTTTGAAGAAATC
TGGGAACGCTGTGGAGGCATCCAGTACCTTCAGAATGCGATTGAGAGCAGACAGGCTCGG
CCCACCTATGCAACAGCCATGCTGCAGAACCTGTTGAAATAA 
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5.3.2 MyoVI(LI)_Chick Sequence 
(3831 ntds, gallus gallus, GenBank: AJ278608.1) 
ATGGAGGACGGGAAGCCCGTTTGGGCTCCACACCCAACTGATGGGTTTCAGATGGGCATG
ATTGTGGACATTGGTACCGACTACTTAACTATTGAACCTTTGAATCAGAAAGGCAAGACT
TTCCAGGCTGCCATCAATCAAGTGTTTCCTGCCGAAGAGGACAGCAAAAAAGATGTGGAA
GATAATTGTTCCCTTATGTATTTAAATGAAGCCACTCTCCTCCACAATATCAAAGTTCGG
TACAGTAAGGACAGAATTTACACATATGTAGCCAACATTCTTATTGCAGTGAATCCATAT
TTTGATATACCTAAGTTCTATTCTTCAGATGCTATTAAAAAGTACCAGGGTAGATCACTT
GGGACGTTGCCACCACATGTCTTTGCTATTGCTGATAAAGCATACCGTGATATGAAAGTA
CTCAAAATGAGTCAGTCCATCATAGTTTCTGGAGAATCCGGAGCTGGCAAGACAGAAAAC
ACTAAATTTGTTTTGAGATATTTGACCGAGTCCTATGGTACTGGCCAAGATATTGATGAT
AGAATTGTAGAAGCAAATCCATTATTGGAAGCCTTTGGAAATGCAAAGACTATTCGTAAC
AACAATAGCAGTCGTTTTGGGAAATTTGTGGAAATTCACTTCAATGAAAAGAACTCGGTG
GTTGGTGGATTTGTATCACATTACCTTCTGGAGAAATCTCGCATCTGTGTGCAAGGCAAA
GAAGAGAGGAATTATCATATCTTTTACAGGCTTTGTGCCGGTGCTCCAGAAGACATTAGA
GAAAAACTGTACCTAAGCTCTCCTGACAGCTTCAGATATTTAAATCGAGGCTGTACGAGG
TACTTTGCTACCAAAGAAACAGACAAGCAGATCTTGCAAAATCGCAAGAGTCCTGAGTAT
CTTAAGGCAGGTTCCTTGAAGGATCCACTCTTAGATGATCATGGAGACTTCAACAGAATG
TGCACAGCAATGAAAAAGATTGGACTGGATGATGCAGAAAAACTTGACCTTTTTCGAGTA
GTGGCTGGTGTCCTTCACCTTGGAAATATTGATTTTGAGGAAGCTGGGAGCACTTCAGGG
GGCTGCACGCTGAAGGCGCAGAGCCAGCCGGCGCTGGAGTGCTGCGCGGCGCTGCTGGGG
CTGGACGAGGAGGACCTGCGAGTCAGCCTGACCACGCGCGTCATGCTCACCACGGCAGGG
GGCGCCAAAGGAACGGTCATTAAGGTACCCTTGAAGGTGGAACAAGCAAACAATGCTCGT
GATGCCTTGGCTAAAACGGTGTATAGTCATCTCTTTGACCATGTGGTGAACAGGGTGAAC
CAGTGTTTTCCATTTGAGACTTCTTCTTTCTTCATTGGAGTTCTAGATATAGCTGGTTTT
GAATACTTTGAACACAACAGTTTTGAGCAATTTTGTATCAACTATTGTAATGAAAAACTG
CAGCAATTTTTTAATGAAAGGATTCTGAAAGAGGAACAAGAACTTTACCAAAAAGAAGGC
CTGGGGGTTAATGAAGTACGCTATGTAGATAATCAGGACTGTATAGATTTGATTGAAGCA
AAGTTAATAGGTGTGCTGGATATTTTGGATGAAGAAAATCGTCTTCCTCAACCAAGTGAC
CAGCATTTCACTTCAGTTGTACACCAAAAACACAAGGACCATTTCAGACTCTCTATCCCT
AGGAAGTCTAAACTGGCTGTTCACAGAAATGTCAGAGATGATGAAGGCTTTATTATCCGG
CATTTTGCAGGAGCAGTGTGCTACGAGACGACACAATTTGTGGAAAAAAATAATGATGCT
TTACACATGTCACTTGAATCTCTTATATGTGAATCCAAGGACAAGTTTGTTCGGCAGCTG
TTTGAATCTAACACTAATAACAACAAGGATCCCAAACAAAAAGCTGGGAAACTTAGTTTC
ATCAGTGTGGGAAACAAATTCAAGACTCAGTTAAATTTGCTTCTTGAGAAGCTTCACAGT
ACTGGATCTAGCTTTATTCGCTGCATCAAACCTAATTTAAAGATGACAAGTCACCATTTT
GAAGGAGGACAGATCCTCTCCCAGCTTCAGTGTTCAGGAATGGTGTCTGTTCTGGATTTG
ATGCAAGGTGGCTTCCCTTCACGAGCTTCATTTCATGAACTATATAATATGTACAAGAAA
TATTTGCCTGAAAAATTGGCACGACTGGATCCCAGACTCTTTTGCAAGGCACTATTTAAA
GCTTTGGGACTGAATGAAATTGATTACAAATTTGGGTTAACCAAGGTGTTTTTTAGACCT
GGCAAGTTTGCAGAGTTTGATCAGATAATGAAGTCTGATCCGGATCACTTAGCAGAGCTA
GTTAAAAGGGTGAATCACTGGCTCATCTGCAGTCGCTGGAAAAAAGTTCAATGGTGTTCT
CTCTCAGTGATTAAATTGAAAAATAAGATAAAATACCGAGCTAGTGCCTGCATCAAAATA
CAAAAGACTATTCGTATGTGGCTTTGCAAGAGAAAACACAAACCACGCATCGATGGTCTG
ATAAAGGTCCGTACACTGAAAAAGAGACTTGATAAGTTTAATGAAGTGGTAAGTGCTCTG
AAGGAGGGGAAGGCAGAGACAAGCAAGCAGATCAAGGAGCTGGAGTATTCAATTGATGCT
TCAATGACCAAAATTAAGACTACGATGATGACTAGAGAACAGATAATGAAAGAATATGAT
GCTCTAGTTAGAAGCTCAGAGCAGCTTCTGAGTGCATTGCAAAAGAAAAAACAGCAAGAG
GAAGAAGCAGAGAGGTTACGACGCATCCAGGAGGAAATGGAAAAAGAAAGAAAGAGACGT
Appendix 
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GAAGAGGAAGAGAAACGGCGAAGGAAGGAAGAGGAAGAAAGGCGCCTGAAATCTGAGATT
GAGGCAAAGAGAAAACAGGAAGAAGAAGAAAGGAAAAAGAGGGAAGAGGAAGAAAAGCGT
ATTCAGGCTGAAATTGAAGCTCAGCTAGCTAGAGAACGAGAAGAGGAAACCCAGCACCAG
GCAATTCTTGAACAGGAACGTCGTGATCGTGAACTTGCGATGAGAATTGCCCAAACTGGG
GCAGAACTCAGCACTGAAGAGACAAAGCTTGATGTAGGATTATGCAGAGCCAATGGAACA
AAGCTGCAAATGACTGCGGAACAAATGGCCAAAGAAATGTCAGAAATGTTGTCTAGAGGT
CCTGCAGTTCAAGCTACAAAAGCTGCTGCTGGTGCTAAGAAGCATGATCTGAGTAAATGG
AAATATGCAGAGCTTCGTGATACCATCAACACATCGTGTGATATTGAACTATTGGCGGCT
TGCAGAGAAGAGTTTCACAGAAGGCTAAAGGTGTATCATGCTTGGAAATCCAAGAACAAG
AAACGCAATGCAGAAACAGAACAGCGTGCTCCCAAATCAGTCACAGACTATGCTCAACAG
AACCCAACAGCTCAGCTACCAATGAGGCAGCAGGAGATTGAAATAAATAGACAACAGCGT
TACTTCCGCATTCCCTTCATCCGTCCCATGGACCAATATAAAGATCCACAGAACAAGAAG
AAGGGTTGGTGGTATGCACATTTTGATGGGCCATGGATTGCTCGACAGATGGAGCTTCAT
CCTGACAAGGCACCCATTCTCCTTGTAGCTGGTAAGGATGACATGGATATGTGTGAGCTT
AATCTTGAAGAGACTGGCTTAACTCGAAAGCGTGGTGCTGAAATTTTGCCGAGACAGTTT
GAAGAAATTTGGGAGCGCTGTGGAGGTATCCAGTACCTTCAAAATGCAATTGAAAGCAGA
CAAGCTCGTCCTACGTATGCTACAGCTATGCTGCAGAACCTGTTGAAATAA 
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5.4 Myosin XXI sequence 
Leishmania donovani 
ATGCCGGAGCGTGTGTCTGTGAATCAGGAGGTGTACTACTTCGACACCAAGAGCGGGTGG
CTGCGTGGCACCGTGAAGGAGGTCGATGGCGCCAAGGTGACGGTAGAGGACAATGCCTCG
CAGAGTGCCGTGAAAGTGGCGGCCGATAATGTGCACGGCTACATGTCGGAGAGCTACGAT
ATCGAGGACGCGGACCTCTTCCACGTGAGCGATCTGCACGTGGCCACTCTCTTGCACTGC
GTCAAGGACCGTTTTGAGAAGCTGCACAAGCAGTACTCGCTCATGGGGGAGATGGTGCTC
TCCGTCAACCCATTTCGCCTCATGCCCTTCAACAGCGAAGAGGAGCGTAAAGAGTATCTG
GCCCTGCCGGACCCCCGCATGCTGCCCCCGCACATCTGGCAGGTGGCGCACAAGGCCTTC
AACGCGGTCTTCGTTCAGGGTCAGGGCAACCAGTCCATCGTCATCTCCGGCGAGTCCGGT
TCCGGAAAAACCGAGAACGCCAAGATGCTCATCGCGTACCTGGGCCAACTCAGCTACATG
CACAGCAAGAACACCTCGCAGCGCAGCATCGCGGACAAGATCGACGAGAACCTAACCTGG
AGCAACCCCGTCATGGAGTCGTTCGGCAACGCCCGCACCGTGCGCAACGACAACTCTTCG
CGCTTCGGCAAGTACATCAAGCTCTACTTTGATCCTGTATCTGGCGTCATGGTGGGGGGC
CAGACCGTCACCTACTTGCTGGAGAGGAGCCGCATCATCATGCAGTCTCCTGGCGAGCGC
AACTACCACATCTTCTACGAGATGCTGGCGGGCCTGTCGCCGACAGAGAAGCAGCAGCTT
GGCGGGCTCAAGACTGCCCAGGACTACAAGTGCCTGAACGGCGGTAACACCTTCATCCGC
CGCGGCGTGGATGGCAAGCCGCTCGACGACGCGCACGAGTTTCAGATGGTGCGCCGCGCG
CTTTCCATGATCGGTGTGCCGCTGGAGACGCAGAACTGCATGTTGCGCGTGCTGGCGGCC
ATCCTGCACCTGATGGAGGTCGAGTTCGAGCCCGACAACAACGACAAGGCACAGATCGCA
AACGGGACACCGCTCGCGACGGCCTGCGCGCTGCTCTGCCTGGATGAGGCCAAGGTGCGC
GAGTGCTTTCTCGTGAGGAGCAAGACGTCGCTTGTCACGATCCTCGCCTCCAAGACGGAG
GCGGAGGGCCTGCGCAACGCCTTCTGCAAGGGACTTTACGTTGGCATGTTCGACCGGCTG
GTCGAGTTTGTGAACGCCGCCATTCAGCCCCGGGTGGACTGCAGCGACTGCAAGTACGTC
GGCCTGCTCGATATTTTCGGCTTTGAAAACTTCACGCGCAACAGCTTCGAGCAGATCTGC
ATCAATTACGCGAACGAGTCGCTGCAAAACCACTACAACAAGTACACGTTCATCAACGAC
GAAGAGGAGTGCCGCCGCGAGGGTATCCAGACCCCGAATATCGAGTTCCCAGACAACTCC
GAGTGCGTCAACATGCTCGATGCGAAGCGCGTCGGCATCTTCTCGATGCTGGATGAGGAG
TGCAACTTCAAGGGCGGCAACACAGACCGCTTCACCACGAACCTTTGGGAGGAGTGGGCT
GGCAGGAACCCGTACTTTGTGAAGCCGAAGAGCACGATCCCGAACCAGTTCGGCGTGAAC
CACTACGCTGCCTTCGTCAACTACAACACGGCGGACTGGTTGGAGAAGAACACGGACGCA
CTCAAGGAAGACATGTATGAGTGCGTGAGTGAGTCCACCGACGAGTTCATTCGGACCCTT
CTCTCGACGGAGAAGAGCGAGGCACGCCGCAAGCAGACCGTTGCCATCCGCTTCCAGCGC
CAGCTCACGGACCTGCGCTCCGAGCTGGAGTCCACCGAGACACGGTTCATTCGCTGCATC
AAGCCAAATATGGAGGCAAGCCCCTCGTTCCTCGAAAACCTTCTCGTCGGCTCGCAGCTT
GAGTCCGCTGGTGTGCTGCAGACCATCTCCCTCAAGCGTCAGGGCTACCCGGTGCGCCGT
CCGCTGGAGCAGTTTTGCAGGTACTTCTACCTTGTCATGTCCCGCACCACCGCCTCCTTG
TTCAAGCAAGGGCGGTACAGCGACGCGTCCCAGGACTTTCTGCAGCGACACCAGCGCCTC
TACAGCTGGGCGGAGCCCAACTACGCCGTTGGCAAGACGAAGGTGTTCCTCCGGGCTGAG
GTGTGGTCGGCGCTGGAGCGGCTGGTGCTTCGTCGCCGCGCGCAGCTGCTGCACCGCTGC
AAGCCCTACCTGCGCCGCTGGATCGACGAGCTCCGCGAGCGCAGGCGTATCGAGGAGCAG
AAGCGGCTGGAGGCAGCGCGCAAGCTGCGCGAGGCGCGGGAGGCCAAGGCCGCCGACGCC
GCCAATGGTGTGCCGGCGGAGAAACTGCAGTGGGTGGAGGAGGCGTCGAACATGTTCCCA
GACTTCGACACGGACACGCTGCTCGACGTTGCCGTCGAGGCGGACACGCGCGAGGAGGCT
CTCAGCGCCATCCTTGCCATCCAGGCTGACCGCCTTGACAAGCAGACAGCCTCTGGATTC
ATGGAAGTGATGGCGGCTGCGAACGTGCGCCGTGGCGTCATCAACAACTTTATCTCGGCG
GACATCAAGACGGTGTCGGCGCTGTCGAGGCTGCAGCCGGAGGATATGAAGAGCCTCGGC
GCCAGTGAGATGGAGGTGGTGGCGATCACGAAGAAGCTGGCGGAGCAGCAGGGGCAGCGC
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GTCAAGTACCAGCGCCTCGCCGAGGCCATCGGCACGGACAGCGAATATGCCGCCGCTGGC
GCCGTCCAACGCGCCGAGGTGGCTCGCCACCAGGAAGACTTCGACGCCAAAGTGCAGACC
CTTGCCAGCATGGGCTTTGATGAGCCCACCGGCCGCCTCGTGCTGGCGCACTACAACGGC
GACGTGCAGCGCACGGCGGCGCGCCTGCTTTATGGCGTGGACAGCCGGAAGATGAGGAAC
AACGCGCGCAAGCACAAGAACTTCAACACAACGGACCCCAACGTGCAGCAGCTCATCTCT
CTCGGTGCGACGAAGCAGGATGCAAAGATGGCACTACGTCGCAACAACGGAGACGCGAAC
GCCGCCGTTAAGATGCTGTTCAAGGTGAGCTAG 
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5.5 Complete lipid binding tables Myosin VI and XXI 
 
 
Table 9: Table of all investigated protein:lipid interactions of myosin VI constructs. Green filled cells indicate 
binding, red no binding. 
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Table 10: Table of all investigated protein:lipid interactions of myosin XXI constructs. Green filled cells indicate 
binding, red no binding. 
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5.6 Lipid-affinity co-sedimentations of myosin VI 
constructs
Figure 106: Lipid affinity control co-sedimentations of myosin VI FL, Trunc814 and Trunc913. 
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Figure 107: Lipid affinity control co-sedimentations of myosin VI 814, 913 and 1060 tails. 
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Figure 108: Lipid affinity control co-sedimentations of myosin VI 1125, NCB and 883 delta PIP tails. 
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5.7 BH plot scales used for computer searches 
Table 11: BH plot scales used for computer search. From Brzeska et al. (2010) 
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5.8 Membrane binding domains 
Domain Target Consensus 
sequence/motif/ 
structure 
Binding 
mechanism 
References 
C1 DAG, phorbol 
ester 
PX(F/W/Y)CX2CX2Hy3
GX0-1 HyX2QG (X: any 
aa; Hy: any hydrophobic 
residue) 
 Hurley and Misra (2000) 
C2 PS, anionic 
membranes, 
neutral 
membranes 
two, four stranded β-
sheets creating three 
loops at the top of the 
domain and four at the 
bottom; 5 conserved D 
residues and one S in up-
per loops 1 and 3 binding 
of 3 Ca2+ ions necessary 
for phospholipid binding 
coincidence 
detection, 
electrostatic 
switch 
Sutton and Sprang 
(1998), Rizo and Sudhof 
(1998) 
PH PI(3)P, PI(4)P, 
PI(3,4)P2, 
PI(3,5)P2, 
PI(4,5)P2, 
PI(3,4,5)P3 
K-Xm-(R/K)-X-R-Xn-
(Y/N) 
K-Xn-(K/R)-X-R 
 
K-Xaa-Sma-Xaa 6-11-
R/K-Xaa-R-Hyd-Hyd 
(Xaa: any aa, Sma: small 
aa, Hyd: hydrophobic aa) 
coincidence 
detection, HIS 
protonation 
DiNitto et al. (2003), 
Stahelin (2009), 
Dowler et al. (2000) 
FYVE PI(3)P Zn2+ fingers with an N-
terminal WXXD motif, a 
central R(R/K)HHCR 
motif, and a C-terminal 
RXC motif 
(R/K)(R/K)HHCR 
HIS-protonation, 
use their turret 
loops to penetrate 
the membrane 
DiNitto et al. (2003), 
Stenmark and Aasland 
(1999), 
Balla (2005), 
Hurley and Misra (2000), 
Hurley (2006) 
PX PI(3)P, 
PI(3,4)P2, 
PI(4,5)P2, PS, 
PA 
R(Y/F) X23-30 K X13-23 R, 
N-terminal 3-stranded β-
sheet followed by helical 
subdomain (4 α-helices) 
coincidence 
detection 
Teasdale and Collins 
(2012), Balla (2005) 
ENTH PI(3,5)P2, 
PI(4,5)P2, 
PI(3,4,5)P3 
DP(W/F) repeats, α-
helical solenoid 
HIS-protonation;  
membrane 
curvature 
detection 
DiNitto et al. (2003), 
De Camilli et al. (2002), 
Rozovsky et al. (2012) 
ANTH phosphoinositi
des, little 
specificity 
α-helical solenoid  Lemmon (2008) 
BAR acidic 
phospholipid 
membranes 
dimer, banana shaped 
extended α-helical 
bundle 
curvature sensing/ 
inducing, electro-
static interactions 
Hurley (2006), Lemmon 
(2008) 
FERM PI(4,5)P2 subdomains A, B and  C  DiNitto et al. (2003) 
tubby PI(3,4)P2, 
PI(4,5)P2 
  DiNitto et al. (2003) 
PHD PI(3)P, PI(5)P C4HC3-type zinc finger  Bienz (2006) 
MARCK
S 
PI(4,5)P2  curvature sensing DiNitto et al. (2003), 
Morton et al. (2012) 
Table 12: List of membrane binding domains and their targets. 
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6 Publication list 
Ellrich, H., Batters, C., Brack, D., Averbeck, B., Veigel, C. “Myosin VI unfolding is 
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Published abstracts and Posters 
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